data_2lq1_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2lq1 _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.546 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.0 OUTLIER . . . . . 0 C--O 1.232 0.136 0 CA-C-O 121.677 0.751 . . . . 74.549999999999997 110.845 . . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . 0.546 ' HD2' ' N ' ' A' ' 7' ' ' SER . 54.4 Cg_endo -69.69 -4.89 14.89 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.678 2.252 . . . . 75.010000000000005 112.341 179.959 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -111.07 -26.33 4.7 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.72 -0.753 . . . . 65.299999999999997 112.503 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.4 tt -77.93 -40.96 37.92 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.856 0.36 . . . . 71.209999999999994 110.943 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 10.4 t -79.05 -19.41 51.46 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.17 -0.468 . . . . 62.020000000000003 110.898 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 96.9 m -86.87 -22.16 25.92 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.128 -0.487 . . . . 73.409999999999997 111.173 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.497 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -92.36 -35.29 13.8 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.214 -0.448 . . . . 63.549999999999997 111.094 179.876 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -76.07 -12.03 60.05 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.224 -0.444 . . . . 73.019999999999996 110.924 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 97.1 m -98.61 -35.26 10.27 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.158 -0.473 . . . . 71.150000000000006 111.175 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.51 ' O ' ' C ' ' A' ' 17' ' ' PHE . . . -103.89 -7.5 41.35 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.778 -0.725 . . . . 65.140000000000001 112.46 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.51 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.58 -54.36 0.15 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.943 0.401 . . . . 74.329999999999998 110.877 -179.859 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.445 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.4 m -115.92 -14.39 11.28 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.126 -0.488 . . . . 73.310000000000002 111.17 -179.916 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -82.46 -14.57 54.84 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.206 -0.452 . . . . 73.010000000000005 110.955 179.91 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.579 ' N ' ' HD2' ' A' ' 21' ' ' PRO . 16.5 t -75.7 -55.03 2.1 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.612 0.72 . . . . 73.319999999999993 111.166 179.818 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . 0.579 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 54.1 Cg_endo -69.79 -21.17 33.7 Favored 'Trans proline' 0 C--O 1.232 0.194 0 C-N-CA 122.695 2.264 . . . . 75.329999999999998 112.362 179.92 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 44.4 t -99.29 -11.73 8.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.261 -0.427 . . . . 74.340000000000003 111.149 179.91 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.33 -0.246 0 CA-C-N 116.156 -0.474 . . . . 72.329999999999998 110.859 -179.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.544 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.0 OUTLIER . . . . . 0 C--O 1.232 0.142 0 CA-C-O 121.707 0.765 . . . . 74.549999999999997 110.861 . . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . 0.544 ' HD2' ' N ' ' A' ' 7' ' ' SER . 53.3 Cg_endo -69.74 -4.76 14.66 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.693 2.262 . . . . 75.109999999999999 112.319 -179.978 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -111.24 -26.01 4.78 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.783 -0.722 . . . . 74.430000000000007 112.539 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 3.6 tt -78.17 -41.07 35.86 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.819 0.343 . . . . 72.019999999999996 110.891 -179.888 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 4.9 t -79.2 -19.27 51.22 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.193 -0.458 . . . . 74.310000000000002 110.866 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 97.1 m -86.93 -22.25 25.75 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.133 -0.485 . . . . 71.409999999999997 111.11 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.497 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -92.33 -35.32 13.8 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.217 -0.447 . . . . 71.129999999999995 111.087 179.88 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -76.07 -11.89 60.02 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.219 -0.446 . . . . 70.430000000000007 110.941 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 98.4 m -98.59 -35.33 10.25 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.161 -0.472 . . . . 74.420000000000002 111.174 179.897 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.511 ' O ' ' C ' ' A' ' 17' ' ' PHE . . . -103.91 -7.42 41.45 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.739 -0.744 . . . . 62.530000000000001 112.536 179.938 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.511 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.59 -54.22 0.15 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.926 0.393 . . . . 73.25 110.889 -179.911 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.44 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.3 m -116.08 -14.58 11.18 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.132 -0.485 . . . . 71.040000000000006 111.129 -179.886 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -82.36 -14.57 55.04 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.237 -0.438 . . . . 73.519999999999996 110.96 179.946 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.578 ' N ' ' HD2' ' A' ' 21' ' ' PRO . 14.3 t -75.76 -55.16 2.04 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-O 121.64 0.734 . . . . 60.210000000000001 111.099 179.843 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . 0.578 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.7 Cg_endo -69.73 -21.1 34.09 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.692 2.261 . . . . 72.400000000000006 112.326 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 45.3 t -99.37 -11.74 8.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.186 -0.461 . . . . 75.219999999999999 111.163 179.906 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.329 -0.284 0 CA-C-N 116.177 -0.465 . . . . 75.120000000000005 110.921 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.545 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.094 0 CA-C-O 121.639 0.733 . . . . 64.450000000000003 110.869 . . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . 0.545 ' HD2' ' N ' ' A' ' 7' ' ' SER . 54.1 Cg_endo -69.75 -4.94 15.04 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.671 2.248 . . . . 64.310000000000002 112.324 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -111.0 -26.09 4.82 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.765 -0.731 . . . . 71.150000000000006 112.469 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -78.04 -41.35 35.92 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.797 0.332 . . . . 74.019999999999996 110.945 -179.938 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -78.64 -19.67 52.08 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.197 -0.456 . . . . 74.420000000000002 110.861 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 97.4 m -86.55 -22.44 26.31 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.084 -0.507 . . . . 74.040000000000006 111.167 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.495 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -92.18 -35.29 13.92 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.185 -0.461 . . . . 60.310000000000002 111.088 179.914 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -76.02 -11.96 60.04 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.201 -0.454 . . . . 73.519999999999996 110.921 -179.967 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 98.8 m -98.66 -35.24 10.25 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.152 -0.476 . . . . 74.230000000000004 111.115 179.942 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.51 ' O ' ' C ' ' A' ' 17' ' ' PHE . . . -103.92 -7.5 41.28 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.746 -0.74 . . . . 74.439999999999998 112.466 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.51 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.6 -54.31 0.15 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.885 0.374 . . . . 72.030000000000001 110.894 -179.852 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.442 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.5 m -115.91 -14.43 11.28 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.166 -0.47 . . . . 73.219999999999999 111.14 -179.931 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -82.55 -14.39 54.97 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.232 -0.44 . . . . 72.230000000000004 110.889 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.58 ' N ' ' HD2' ' A' ' 21' ' ' PRO . 15.2 t -75.95 -55.06 1.96 Allowed Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.607 0.717 . . . . 73.099999999999994 111.113 179.87 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . 0.58 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 54.1 Cg_endo -69.72 -21.2 34.0 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.708 2.272 . . . . 75.140000000000001 112.374 179.909 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 45.9 t -99.1 -11.98 8.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.24 -0.436 . . . . 74.150000000000006 111.118 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 116.156 -0.475 . . . . 71.329999999999998 110.892 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.547 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.6 OUTLIER . . . . . 0 C--O 1.231 0.126 0 CA-C-O 121.679 0.752 . . . . 74.200000000000003 110.857 . . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . 0.547 ' HD2' ' N ' ' A' ' 7' ' ' SER . 53.9 Cg_endo -69.7 -4.92 14.96 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.714 2.276 . . . . 71.239999999999995 112.358 179.991 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -111.11 -26.03 4.81 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.715 -0.755 . . . . 74.120000000000005 112.448 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -78.16 -41.07 35.96 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.81 0.338 . . . . 74.150000000000006 110.934 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -79.05 -19.48 51.26 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.161 -0.472 . . . . 73.349999999999994 110.861 -179.929 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 97.7 m -86.7 -22.39 26.07 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.175 -0.466 . . . . 73.400000000000006 111.13 -179.953 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.496 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -92.12 -35.43 13.88 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.265 -0.425 . . . . 73.109999999999999 111.147 179.84 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -75.99 -11.88 60.03 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.206 -0.452 . . . . 74.109999999999999 110.938 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 97.6 m -98.69 -35.4 10.19 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.194 -0.457 . . . . 72.439999999999998 111.149 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.51 ' O ' ' C ' ' A' ' 17' ' ' PHE . . . -103.83 -7.35 41.84 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.707 -0.758 . . . . 60.25 112.523 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.51 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.68 -54.24 0.15 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.893 0.378 . . . . 74.439999999999998 110.869 -179.869 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.438 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 20.5 m -116.08 -14.91 11.17 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.17 -0.468 . . . . 72.019999999999996 111.188 -179.936 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 10.5 mp -82.23 -15.02 54.57 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.179 -0.464 . . . . 74.109999999999999 110.937 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.574 ' N ' ' HD2' ' A' ' 21' ' ' PRO . 9.4 t -75.44 -55.35 2.14 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.588 0.709 . . . . 73.019999999999996 111.103 179.839 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . 0.574 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 54.2 Cg_endo -69.71 -20.54 34.94 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.687 2.258 . . . . 70.230000000000004 112.371 179.936 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 45.9 t -100.26 -11.76 8.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.179 -0.464 . . . . 75.420000000000002 111.118 179.919 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.329 -0.289 0 CA-C-N 116.194 -0.457 . . . . 70.040000000000006 110.906 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.542 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.126 0 CA-C-O 121.664 0.745 . . . . 74.400000000000006 110.837 . . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . 0.542 ' HD2' ' N ' ' A' ' 7' ' ' SER . 53.0 Cg_endo -69.81 -4.9 15.0 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.686 2.257 . . . . 75.319999999999993 112.312 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -111.1 -25.99 4.83 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.718 -0.753 . . . . 73.239999999999995 112.467 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -77.87 -41.65 36.08 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.813 0.34 . . . . 73.040000000000006 110.923 -179.947 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -78.5 -19.67 52.5 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.218 -0.446 . . . . 72.310000000000002 110.858 -179.917 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 97.6 m -86.51 -22.41 26.41 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.093 -0.503 . . . . 74.140000000000001 111.161 -179.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.496 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -92.16 -35.35 13.9 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.209 -0.45 . . . . 53.329999999999998 111.092 179.851 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -75.99 -12.08 60.07 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.202 -0.453 . . . . 75.230000000000004 110.887 -179.915 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 98.3 m -98.71 -35.27 10.22 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.218 -0.446 . . . . 72.450000000000003 111.167 179.905 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.507 ' O ' ' C ' ' A' ' 17' ' ' PHE . . . -103.84 -7.35 41.81 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.747 -0.74 . . . . 72.329999999999998 112.442 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.507 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.72 -54.13 0.15 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.966 0.412 . . . . 75.430000000000007 110.937 -179.872 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.44 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 20.5 m -116.24 -14.99 11.07 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.138 -0.483 . . . . 64.299999999999997 111.114 -179.924 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 10.5 mp -82.26 -15.1 54.22 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.261 -0.427 . . . . 75.549999999999997 110.885 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.574 ' N ' ' HD2' ' A' ' 21' ' ' PRO . 7.3 t -75.64 -55.34 2.05 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.644 0.735 . . . . 74.450000000000003 111.134 179.868 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . 0.574 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.5 Cg_endo -69.78 -20.27 34.96 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.699 2.266 . . . . 75.5 112.324 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 47.2 t -100.31 -11.66 8.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.217 -0.447 . . . . 73.439999999999998 111.164 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--N 1.33 -0.25 0 CA-C-N 116.162 -0.472 . . . . 71.200000000000003 110.895 -179.978 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.543 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.5 OUTLIER . . . . . 0 C--O 1.232 0.163 0 CA-C-O 121.668 0.747 . . . . 64.530000000000001 110.844 . . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . 0.543 ' HD2' ' N ' ' A' ' 7' ' ' SER . 53.2 Cg_endo -69.79 -4.87 14.92 Favored 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.676 2.251 . . . . 63.399999999999999 112.351 179.992 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -110.93 -26.22 4.78 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.747 -0.739 . . . . 75.340000000000003 112.486 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 3.0 tm? -78.42 -40.44 35.93 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.808 0.337 . . . . 73.230000000000004 110.916 -179.914 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 5.4 t -79.47 -19.49 49.68 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.258 -0.428 . . . . 75.510000000000005 110.843 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 97.8 m -86.81 -22.27 25.96 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.131 -0.486 . . . . 72.219999999999999 111.149 -179.927 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.495 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -92.15 -35.44 13.86 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.252 -0.431 . . . . 74.400000000000006 111.072 179.883 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -75.83 -12.02 60.09 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.236 -0.438 . . . . 74.400000000000006 110.896 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 97.7 m -98.53 -35.43 10.24 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.21 -0.45 . . . . 75.439999999999998 111.152 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.509 ' O ' ' C ' ' A' ' 17' ' ' PHE . . . -103.85 -7.43 41.61 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.732 -0.747 . . . . 72.409999999999997 112.457 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.509 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.67 -54.22 0.15 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.947 0.403 . . . . 73.519999999999996 110.844 -179.835 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.445 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.3 m -116.01 -14.54 11.22 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.198 -0.456 . . . . 74.120000000000005 111.159 -179.901 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -82.5 -14.52 54.84 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.224 -0.444 . . . . 73.129999999999995 110.945 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.577 ' N ' ' HD2' ' A' ' 21' ' ' PRO . 14.1 t -75.77 -55.11 2.04 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.6 0.714 . . . . 75.439999999999998 111.144 179.799 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . 0.577 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.7 Cg_endo -69.81 -21.08 33.77 Favored 'Trans proline' 0 C--O 1.232 0.18 0 C-N-CA 122.695 2.263 . . . . 75.430000000000007 112.298 179.964 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 44.8 t -99.34 -11.78 8.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.273 -0.422 . . . . 72.200000000000003 111.124 179.934 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--N 1.33 -0.276 0 CA-C-N 116.178 -0.464 . . . . 74.109999999999999 110.914 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.541 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.3 OUTLIER . . . . . 0 C--O 1.231 0.11 0 CA-C-O 121.649 0.738 . . . . 71.420000000000002 110.854 . . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . 0.541 ' HD2' ' N ' ' A' ' 7' ' ' SER . 54.2 Cg_endo -69.75 -4.55 14.25 Favored 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 122.666 2.244 . . . . 75.340000000000003 112.392 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -111.44 -25.93 4.75 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.775 -0.726 . . . . 50.210000000000001 112.442 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 2.5 tt -78.49 -40.82 34.25 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.826 0.346 . . . . 70.329999999999998 110.907 -179.901 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -79.23 -19.5 50.54 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.213 -0.448 . . . . 74.030000000000001 110.867 -179.933 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 94.8 m -86.81 -22.28 25.95 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.134 -0.485 . . . . 72.209999999999994 111.121 -179.924 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.494 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -92.11 -35.44 13.89 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.213 -0.449 . . . . 72.430000000000007 111.055 179.89 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -75.79 -12.06 60.1 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.271 -0.422 . . . . 74.040000000000006 110.889 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 98.9 m -98.6 -35.32 10.25 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.229 -0.441 . . . . 71.430000000000007 111.109 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.508 ' O ' ' C ' ' A' ' 17' ' ' PHE . . . -103.96 -7.32 41.51 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.725 -0.75 . . . . 62.210000000000001 112.487 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.508 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.74 -54.11 0.15 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.953 0.406 . . . . 73.120000000000005 110.885 -179.89 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.442 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.2 m -116.27 -14.65 11.06 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.152 -0.476 . . . . 73.420000000000002 111.127 -179.905 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -82.5 -14.66 54.62 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.25 -0.432 . . . . 75.109999999999999 110.907 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.577 ' N ' ' HD2' ' A' ' 21' ' ' PRO . 10.4 t -76.04 -55.21 1.89 Allowed Pre-proline 0 C--N 1.33 -0.257 0 CA-C-O 121.599 0.714 . . . . 71.310000000000002 111.098 179.819 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . 0.577 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.6 Cg_endo -69.76 -20.33 34.97 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.711 2.274 . . . . 74.409999999999997 112.31 179.994 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 46.9 t -100.07 -11.69 8.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.236 -0.438 . . . . 74.439999999999998 111.131 179.937 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 5.8 tp10 . . . . . 0 C--N 1.329 -0.29 0 CA-C-N 116.16 -0.473 . . . . 74.439999999999998 110.899 179.967 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.54 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.0 OUTLIER . . . . . 0 C--O 1.232 0.136 0 CA-C-O 121.613 0.721 . . . . 61.420000000000002 110.838 . . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . 0.54 ' HD2' ' N ' ' A' ' 7' ' ' SER . 54.4 Cg_endo -69.74 -4.88 14.91 Favored 'Trans proline' 0 C--N 1.341 0.153 0 C-N-CA 122.645 2.23 . . . . 73.140000000000001 112.382 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -111.06 -26.68 4.56 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.767 -0.73 . . . . 72.310000000000002 112.468 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -77.69 -40.59 40.91 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.826 0.346 . . . . 73.030000000000001 110.908 -179.906 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -79.35 -19.44 50.26 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.161 -0.472 . . . . 64.239999999999995 110.825 -179.878 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 92.1 m -87.38 -21.45 25.63 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.141 -0.481 . . . . 62.240000000000002 111.138 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.498 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -92.86 -35.44 13.37 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.181 -0.463 . . . . 72.230000000000004 111.071 179.922 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -76.3 -12.02 60.01 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.255 -0.43 . . . . 74.439999999999998 110.956 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 94.3 m -98.5 -35.37 10.27 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.153 -0.476 . . . . 74.450000000000003 111.152 179.922 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.508 ' O ' ' C ' ' A' ' 17' ' ' PHE . . . -103.83 -7.37 41.8 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.727 -0.749 . . . . 74.120000000000005 112.514 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.508 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.71 -54.24 0.15 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.924 0.392 . . . . 74.450000000000003 110.873 -179.914 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.44 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.2 m -116.01 -14.8 11.22 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.148 -0.478 . . . . 73.120000000000005 111.134 -179.905 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -82.29 -14.6 55.16 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.21 -0.45 . . . . 75.439999999999998 110.909 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.574 ' N ' ' HD2' ' A' ' 21' ' ' PRO . 10.0 t -76.53 -55.39 1.63 Allowed Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.651 0.739 . . . . 71.319999999999993 111.108 179.875 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . 0.574 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.4 Cg_endo -69.75 -19.83 35.64 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.712 2.274 . . . . 75.129999999999995 112.327 179.962 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 41.6 t -102.3 -11.92 8.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.195 -0.457 . . . . 72.5 111.12 179.911 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.9 tp10 . . . . . 0 C--N 1.329 -0.286 0 CA-C-N 116.207 -0.451 . . . . 73.099999999999994 110.897 -179.959 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.547 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.6 OUTLIER . . . . . 0 C--O 1.231 0.095 0 CA-C-O 121.726 0.774 . . . . 73.129999999999995 110.916 . . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . 0.547 ' HD2' ' N ' ' A' ' 7' ' ' SER . 53.7 Cg_endo -69.76 -4.78 14.73 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.704 2.269 . . . . 70.200000000000003 112.359 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -111.23 -25.96 4.81 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.685 -0.769 . . . . 75.430000000000007 112.481 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 6.4 tp -80.15 -37.15 34.06 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.849 0.357 . . . . 75.109999999999999 110.939 -179.962 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -82.52 -19.22 39.1 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.173 -0.467 . . . . 51.130000000000003 110.874 -179.926 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 99.5 m -86.56 -23.19 25.92 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.124 -0.489 . . . . 63.340000000000003 111.123 -179.922 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.505 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -92.62 -34.83 13.84 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.194 -0.457 . . . . 73.140000000000001 111.11 179.895 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -76.65 -11.8 59.91 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.203 -0.453 . . . . 74.540000000000006 110.933 179.987 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 98.9 m -99.14 -34.26 10.45 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.182 -0.463 . . . . 74.150000000000006 111.149 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.509 ' O ' ' C ' ' A' ' 17' ' ' PHE . . . -104.73 -7.77 38.46 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.731 -0.747 . . . . 74.329999999999998 112.537 179.921 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.509 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.5 p90 -29.81 -54.84 0.16 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.9 0.381 . . . . 75.540000000000006 110.887 -179.924 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.435 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 20.0 m -115.57 -14.95 11.48 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.175 -0.466 . . . . 74.120000000000005 111.135 -179.882 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 10.1 mp -82.11 -15.2 54.25 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.204 -0.453 . . . . 73.430000000000007 110.937 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.575 ' N ' ' HD2' ' A' ' 21' ' ' PRO . 8.5 t -75.68 -55.29 2.04 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.6 0.714 . . . . 72.200000000000003 111.162 179.826 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . 0.575 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.4 Cg_endo -69.79 -20.19 35.0 Favored 'Trans proline' 0 C--O 1.231 0.143 0 C-N-CA 122.669 2.246 . . . . 72.040000000000006 112.323 179.934 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 47.4 t -100.41 -11.65 8.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.228 -0.442 . . . . 72.120000000000005 111.142 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 116.14 -0.482 . . . . 70.129999999999995 110.884 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.5 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.086 0 CA-C-O 121.704 0.764 . . . . 72.549999999999997 110.858 . . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . 0.5 ' HD2' ' N ' ' A' ' 7' ' ' SER . 53.3 Cg_endo -69.77 -6.84 19.57 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.704 2.269 . . . . 73.409999999999997 112.351 -179.998 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -107.17 -27.42 5.34 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.696 -0.764 . . . . 65.420000000000002 112.513 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -78.71 -40.01 34.86 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.823 0.344 . . . . 72.409999999999997 110.908 -179.942 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -79.59 -19.22 49.84 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.194 -0.457 . . . . 74.439999999999998 110.875 -179.925 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 47.3 m -86.48 -23.31 26.02 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.117 -0.492 . . . . 73.0 111.148 -179.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.5 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -91.59 -35.5 14.21 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.203 -0.453 . . . . 70.209999999999994 111.094 179.877 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -75.91 -11.8 60.03 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.247 -0.433 . . . . 73.329999999999998 110.909 179.999 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 98.3 m -98.45 -35.57 10.23 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.22 -0.445 . . . . 73.219999999999999 111.146 179.936 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.502 ' O ' ' C ' ' A' ' 17' ' ' PHE . . . -103.95 -7.47 41.26 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.783 -0.722 . . . . 53.409999999999997 112.483 179.98 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.502 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.71 -54.05 0.15 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.877 0.37 . . . . 73.549999999999997 110.878 -179.832 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.444 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.5 m -116.01 -14.62 11.22 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.151 -0.477 . . . . 74.329999999999998 111.133 -179.922 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -82.26 -14.78 54.93 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.19 -0.459 . . . . 72.209999999999994 110.893 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.564 ' N ' ' HD2' ' A' ' 21' ' ' PRO . 13.7 t -75.74 -55.32 2.01 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.625 0.726 . . . . 74.129999999999995 111.112 179.918 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . 0.564 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.6 Cg_endo -69.71 -20.95 34.41 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.735 2.29 . . . . 73.25 112.324 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 45.2 t -99.65 -11.78 8.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.2 -0.454 . . . . 63.140000000000001 111.145 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.329 -0.308 0 CA-C-N 116.172 -0.467 . . . . 72.549999999999997 110.866 -179.989 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.497 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.094 0 CA-C-O 121.668 0.747 . . . . 54.43 110.882 . . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . 0.497 ' HD2' ' N ' ' A' ' 7' ' ' SER . 53.8 Cg_endo -69.73 -5.65 16.69 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.695 2.263 . . . . 72.430000000000007 112.348 179.962 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -109.17 -26.5 5.17 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.724 -0.751 . . . . 73.25 112.501 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 6.5 tt -78.62 -41.68 30.94 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.79 0.329 . . . . 73.450000000000003 110.902 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 2.2 t -77.96 -19.88 53.72 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.211 -0.45 . . . . 75.439999999999998 110.844 -179.91 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 91.8 m -86.74 -22.71 25.81 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.137 -0.483 . . . . 62.420000000000002 111.137 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.492 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -91.65 -34.75 14.56 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.224 -0.444 . . . . 64.219999999999999 111.124 179.835 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -76.44 -11.53 59.9 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.197 -0.456 . . . . 74.209999999999994 110.913 -179.967 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 96.7 m -99.01 -35.44 10.05 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.191 -0.459 . . . . 65.040000000000006 111.117 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.512 ' O ' ' C ' ' A' ' 17' ' ' PHE . . . -103.57 -7.63 42.02 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.714 -0.755 . . . . 54.439999999999998 112.479 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.512 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.57 -54.21 0.15 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.914 0.388 . . . . 73.239999999999995 110.843 -179.87 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.44 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 23.3 m -116.05 -14.75 11.19 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.168 -0.469 . . . . 74.219999999999999 111.159 -179.92 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -82.21 -14.46 55.53 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.229 -0.441 . . . . 73.099999999999994 110.901 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.578 ' N ' ' HD2' ' A' ' 21' ' ' PRO . 14.9 t -75.71 -55.14 2.06 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.603 0.716 . . . . 62.25 111.097 179.839 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . 0.578 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.7 Cg_endo -69.69 -21.18 34.17 Favored 'Trans proline' 0 C--O 1.231 0.15 0 C-N-CA 122.729 2.286 . . . . 74.219999999999999 112.329 179.961 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 44.6 t -99.43 -11.88 8.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.224 -0.444 . . . . 72.150000000000006 111.104 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--N 1.329 -0.313 0 CA-C-N 116.216 -0.447 . . . . 63.200000000000003 110.884 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.509 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.3 OUTLIER . . . . . 0 C--O 1.232 0.16 0 CA-C-O 121.637 0.732 . . . . 61.420000000000002 110.856 . . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . 0.509 ' HD2' ' N ' ' A' ' 7' ' ' SER . 53.3 Cg_endo -69.75 -7.45 21.08 Favored 'Trans proline' 0 C--N 1.341 0.14 0 C-N-CA 122.736 2.291 . . . . 71.349999999999994 112.311 179.984 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -107.2 -26.26 5.79 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.723 -0.751 . . . . 65.319999999999993 112.449 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -78.44 -41.71 32.09 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.832 0.348 . . . . 51.43 110.954 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -77.54 -20.29 54.41 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.171 -0.468 . . . . 73.329999999999998 110.845 -179.917 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 86.1 m -86.67 -22.35 26.16 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.18 -0.464 . . . . 74.329999999999998 111.134 -179.951 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.491 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -91.76 -34.82 14.45 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.189 -0.459 . . . . 70.209999999999994 111.1 179.884 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -76.12 -11.97 60.03 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.182 -0.463 . . . . 75.120000000000005 110.883 -179.951 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 98.4 m -98.6 -35.33 10.24 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.229 -0.441 . . . . 73.5 111.138 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.504 ' O ' ' C ' ' A' ' 17' ' ' PHE . . . -103.87 -7.43 41.56 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.706 -0.759 . . . . 63.219999999999999 112.505 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.504 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.61 -54.28 0.15 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.957 0.408 . . . . 75.239999999999995 110.871 -179.874 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.443 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.4 m -116.01 -14.54 11.22 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.165 -0.471 . . . . 74.310000000000002 111.138 -179.886 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -82.45 -14.52 54.96 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.228 -0.442 . . . . 74.120000000000005 110.948 179.91 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.574 ' N ' ' HD2' ' A' ' 21' ' ' PRO . 14.0 t -75.77 -55.13 2.04 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.623 0.725 . . . . 74.329999999999998 111.149 179.818 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . 0.574 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.5 Cg_endo -69.81 -21.03 33.81 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.647 2.231 . . . . 72.439999999999998 112.375 179.934 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 44.9 t -99.35 -11.77 8.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.187 -0.46 . . . . 65.140000000000001 111.119 179.88 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--N 1.329 -0.308 0 CA-C-N 116.219 -0.446 . . . . 65.439999999999998 110.889 -179.976 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.494 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.123 0 CA-C-O 121.697 0.76 . . . . 75.010000000000005 110.868 . . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . 0.494 ' HD2' ' N ' ' A' ' 7' ' ' SER . 53.7 Cg_endo -69.75 -6.28 18.23 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.708 2.272 . . . . 71.209999999999994 112.337 179.963 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -108.72 -25.82 5.56 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.715 -0.755 . . . . 63.240000000000002 112.45 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.8 tt -79.13 -40.98 29.62 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.88 0.371 . . . . 75.140000000000001 110.955 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 30.0 t -78.7 -19.88 51.42 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.185 -0.461 . . . . 75.230000000000004 110.855 -179.919 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 92.3 m -86.77 -22.34 25.99 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.132 -0.486 . . . . 63.32 111.158 -179.974 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.494 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -91.88 -35.12 14.23 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.21 -0.45 . . . . 62.210000000000001 111.082 179.855 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -75.9 -12.14 60.1 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.236 -0.438 . . . . 74.129999999999995 110.898 -179.955 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 97.9 m -98.43 -35.3 10.32 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.196 -0.456 . . . . 74.040000000000006 111.153 179.96 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.509 ' O ' ' C ' ' A' ' 17' ' ' PHE . . . -103.99 -7.36 41.37 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.732 -0.747 . . . . 41.210000000000001 112.5 179.945 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.509 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.65 -54.2 0.15 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.915 0.388 . . . . 74.010000000000005 110.859 -179.87 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.44 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.2 m -116.15 -14.39 11.14 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.156 -0.475 . . . . 72.239999999999995 111.124 -179.912 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -82.56 -14.59 54.6 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.246 -0.434 . . . . 73.299999999999997 110.913 179.932 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.577 ' N ' ' HD2' ' A' ' 21' ' ' PRO . 13.4 t -75.74 -55.26 2.02 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.631 0.729 . . . . 71.099999999999994 111.11 179.847 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . 0.577 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.1 Cg_endo -69.78 -20.79 34.27 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.7 2.266 . . . . 62.240000000000002 112.316 179.989 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 44.1 t -99.98 -11.7 8.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.231 -0.44 . . . . 74.530000000000001 111.133 179.889 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--N 1.329 -0.306 0 CA-C-N 116.197 -0.456 . . . . 72.25 110.884 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.498 ' H ' ' HD2' ' A' ' 8' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.231 0.131 0 CA-C-O 121.66 0.743 . . . . 74.099999999999994 110.862 . . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . 0.498 ' HD2' ' H ' ' A' ' 7' ' ' SER . 53.3 Cg_endo -69.75 -6.62 19.04 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.649 2.233 . . . . 74.140000000000001 112.333 -179.976 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -108.0 -26.26 5.57 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.725 -0.75 . . . . 70.340000000000003 112.453 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -78.62 -41.81 30.57 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.848 0.356 . . . . 74.430000000000007 110.954 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 7.7 t -77.48 -20.53 54.22 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.157 -0.474 . . . . 70.040000000000006 110.874 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 98.0 m -86.65 -21.96 26.42 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.103 -0.498 . . . . 74.409999999999997 111.173 -179.918 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.488 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -92.06 -34.99 14.17 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.171 -0.468 . . . . 62.530000000000001 111.062 179.911 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -75.99 -11.72 60.01 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.214 -0.448 . . . . 74.540000000000006 110.892 -179.934 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 98.5 m -98.72 -35.38 10.18 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.164 -0.471 . . . . 64.420000000000002 111.162 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.501 ' O ' ' C ' ' A' ' 17' ' ' PHE . . . -103.94 -7.42 41.37 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.779 -0.724 . . . . 64.450000000000003 112.509 179.934 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.501 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.61 -54.27 0.15 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.913 0.387 . . . . 75.530000000000001 110.907 -179.869 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.445 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 20.6 m -115.91 -14.57 11.28 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.105 -0.498 . . . . 75.349999999999994 111.15 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -82.48 -14.33 55.2 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.211 -0.45 . . . . 74.150000000000006 110.933 179.952 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.57 ' N ' ' HD2' ' A' ' 21' ' ' PRO . 14.3 t -75.98 -55.22 1.92 Allowed Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.669 0.747 . . . . 75.409999999999997 111.169 179.789 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . 0.57 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.7 Cg_endo -69.74 -20.91 34.34 Favored 'Trans proline' 0 C--N 1.342 0.22 0 C-N-CA 122.631 2.221 . . . . 75.329999999999998 112.366 179.923 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 46.4 t -99.23 -12.17 8.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.212 -0.449 . . . . 75.310000000000002 111.124 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.178 -0.465 . . . . 73.219999999999999 110.897 -179.936 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.572 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 0.5 OUTLIER . . . . . 0 C--O 1.231 0.094 0 CA-C-O 121.695 0.759 . . . . 70.329999999999998 110.904 . . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . 0.572 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 53.4 Cg_endo -69.75 -7.3 20.69 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.683 2.255 . . . . 73.340000000000003 112.32 -179.993 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -121.32 -15.21 4.67 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.726 -0.75 . . . . 33.340000000000003 112.483 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.1 tp -80.07 -40.72 27.07 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.841 0.353 . . . . 74.209999999999994 110.952 -179.932 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -78.41 -20.1 51.86 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.141 -0.481 . . . . 65.329999999999998 110.881 -179.944 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 87.9 m -86.21 -22.54 26.86 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.145 -0.479 . . . . 51.420000000000002 111.17 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.488 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -91.86 -35.34 14.12 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.19 -0.459 . . . . 73.329999999999998 111.14 179.839 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -75.87 -12.02 60.08 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.187 -0.46 . . . . 74.420000000000002 110.914 -179.972 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 97.7 m -98.64 -35.34 10.23 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.165 -0.47 . . . . 74.230000000000004 111.157 179.932 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.498 ' O ' ' C ' ' A' ' 17' ' ' PHE . . . -103.81 -7.38 41.84 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.711 -0.757 . . . . 73.319999999999993 112.468 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.498 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.7 -54.08 0.15 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.913 0.387 . . . . 72.299999999999997 110.824 -179.849 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.449 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.0 m -116.31 -14.74 11.03 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.194 -0.457 . . . . 74.140000000000001 111.131 -179.869 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -82.39 -14.64 54.87 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.218 -0.446 . . . . 74.230000000000004 110.947 179.938 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.575 ' N ' ' HD2' ' A' ' 21' ' ' PRO . 9.8 t -76.17 -55.31 1.81 Allowed Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.645 0.736 . . . . 72.319999999999993 111.138 179.848 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . 0.575 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 54.1 Cg_endo -69.74 -20.23 35.2 Favored 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 122.715 2.277 . . . . 74.549999999999997 112.364 179.922 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 45.1 t -100.67 -11.71 8.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.207 -0.451 . . . . 72.209999999999994 111.165 179.905 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--N 1.329 -0.286 0 CA-C-N 116.18 -0.464 . . . . 71.420000000000002 110.878 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.574 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 0.5 OUTLIER . . . . . 0 C--O 1.232 0.151 0 CA-C-O 121.618 0.723 . . . . 74.140000000000001 110.855 . . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . 0.574 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 53.7 Cg_endo -69.81 -7.25 20.6 Favored 'Trans proline' 0 N--CA 1.466 -0.115 0 C-N-CA 122.673 2.249 . . . . 72.129999999999995 112.357 179.979 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -121.34 -15.18 4.67 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.685 -0.769 . . . . 71.329999999999998 112.479 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.1 tt -80.0 -40.9 26.91 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.851 0.358 . . . . 64.109999999999999 110.896 -179.902 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -78.24 -20.15 52.29 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.177 -0.465 . . . . 72.150000000000006 110.859 -179.918 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 81.8 m -86.15 -22.55 26.97 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.128 -0.487 . . . . 72.109999999999999 111.162 -179.929 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.494 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -91.91 -35.38 14.06 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.188 -0.46 . . . . 74.120000000000005 111.077 179.882 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -75.87 -11.98 60.07 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.247 -0.433 . . . . 64.340000000000003 110.925 -179.964 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 97.6 m -98.58 -35.39 10.23 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.171 -0.468 . . . . 70.120000000000005 111.163 179.89 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.494 ' O ' ' C ' ' A' ' 17' ' ' PHE . . . -103.8 -7.44 41.73 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.704 -0.76 . . . . 70.519999999999996 112.449 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.494 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.62 -54.23 0.15 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.907 0.384 . . . . 74.5 110.842 -179.846 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.448 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.1 m -116.05 -14.58 11.19 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.172 -0.467 . . . . 75.049999999999997 111.127 -179.864 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -82.46 -14.54 54.91 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.251 -0.431 . . . . 72.5 110.919 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.575 ' N ' ' HD2' ' A' ' 21' ' ' PRO . 13.6 t -75.85 -55.16 1.99 Allowed Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.649 0.738 . . . . 75.140000000000001 111.117 179.834 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . 0.575 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.5 Cg_endo -69.8 -20.82 34.15 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.652 2.235 . . . . 75.400000000000006 112.365 179.976 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 44.3 t -99.88 -11.81 8.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.194 -0.457 . . . . 75.140000000000001 111.116 179.909 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.2 -0.455 . . . . 75.5 110.842 -179.932 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.568 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 0.5 OUTLIER . . . . . 0 C--O 1.232 0.138 0 CA-C-O 121.64 0.733 . . . . 73.329999999999998 110.877 . . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . 0.568 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 53.8 Cg_endo -69.79 -7.26 20.6 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.702 2.268 . . . . 72.030000000000001 112.347 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -121.37 -15.21 4.65 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.696 -0.764 . . . . 71.140000000000001 112.462 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 5.6 tp -80.05 -40.75 27.08 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.792 0.329 . . . . 64.150000000000006 110.911 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.9 t -78.38 -20.12 51.92 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.23 -0.441 . . . . 71.340000000000003 110.836 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 64.1 m -86.24 -22.42 26.89 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.159 -0.473 . . . . 73.049999999999997 111.183 -179.956 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.492 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -92.01 -35.32 14.03 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.18 -0.464 . . . . 71.340000000000003 111.073 179.876 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -75.87 -12.06 60.09 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.235 -0.439 . . . . 72.120000000000005 110.913 -179.98 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 97.7 m -98.55 -35.46 10.22 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.226 -0.443 . . . . 72.349999999999994 111.124 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.495 ' O ' ' C ' ' A' ' 17' ' ' PHE . . . -103.78 -7.4 41.87 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.743 -0.741 . . . . 62.200000000000003 112.489 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.495 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.6 -54.23 0.15 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.985 0.421 . . . . 71.299999999999997 110.933 -179.906 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.449 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.4 m -116.08 -14.45 11.18 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.128 -0.487 . . . . 75.510000000000005 111.182 -179.951 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -82.51 -14.54 54.79 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.222 -0.445 . . . . 73.519999999999996 110.941 179.919 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.575 ' N ' ' HD2' ' A' ' 21' ' ' PRO . 14.3 t -75.71 -55.16 2.06 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.595 0.712 . . . . 73.510000000000005 111.122 179.803 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . 0.575 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.7 Cg_endo -69.8 -21.0 33.9 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.615 2.21 . . . . 73.040000000000006 112.37 179.987 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 45.1 t -99.4 -11.74 8.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.208 -0.451 . . . . 74.540000000000006 111.097 179.911 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.329 -0.3 0 CA-C-N 116.212 -0.449 . . . . 72.319999999999993 110.884 179.971 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.572 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 0.5 OUTLIER . . . . . 0 C--O 1.231 0.091 0 CA-C-O 121.702 0.763 . . . . 74.010000000000005 110.882 . . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . 0.572 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 54.4 Cg_endo -69.72 -7.32 20.75 Favored 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 122.682 2.255 . . . . 61.539999999999999 112.327 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -121.33 -15.24 4.66 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.721 -0.752 . . . . 71.310000000000002 112.439 -179.948 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.7 tt -80.05 -40.72 27.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.832 0.349 . . . . 73.310000000000002 110.946 -179.903 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -78.32 -20.14 52.07 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.201 -0.454 . . . . 74.129999999999995 110.913 -179.979 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 86.0 m -86.22 -22.48 26.88 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.086 -0.507 . . . . 73.140000000000001 111.105 -179.907 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.495 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -91.97 -35.34 14.04 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.214 -0.448 . . . . 73.519999999999996 111.051 179.892 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -75.87 -12.06 60.09 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.244 -0.434 . . . . 73.239999999999995 110.912 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 97.8 m -98.6 -35.31 10.25 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.202 -0.454 . . . . 71.319999999999993 111.176 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.492 ' O ' ' C ' ' A' ' 17' ' ' PHE . . . -103.83 -7.45 41.64 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.778 -0.725 . . . . 64.400000000000006 112.477 179.979 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.495 ' HB3' ' O ' ' A' ' 13' ' ' ALA . 1.4 p90 -29.57 -54.31 0.15 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.953 0.406 . . . . 73.450000000000003 110.889 -179.891 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.448 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.4 m -116.04 -14.46 11.21 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.126 -0.488 . . . . 74.430000000000007 111.146 -179.938 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -82.45 -14.57 54.87 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.248 -0.433 . . . . 72.430000000000007 110.937 179.913 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.571 ' N ' ' HD2' ' A' ' 21' ' ' PRO . 14.2 t -75.75 -55.14 2.05 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.629 0.728 . . . . 75.25 111.117 179.858 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . 0.571 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.8 Cg_endo -69.78 -21.07 33.91 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.67 2.246 . . . . 71.109999999999999 112.346 179.951 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 45.0 t -99.37 -11.75 8.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.234 -0.439 . . . . 72.420000000000002 111.151 179.905 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--N 1.329 -0.284 0 CA-C-N 116.152 -0.476 . . . . 72.150000000000006 110.886 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.568 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 0.5 OUTLIER . . . . . 0 C--O 1.231 0.105 0 CA-C-O 121.647 0.737 . . . . 74.420000000000002 110.875 . . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . 0.568 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 54.3 Cg_endo -69.69 -7.28 20.62 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.676 2.251 . . . . 74.439999999999998 112.397 179.935 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -121.32 -15.27 4.65 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.749 -0.738 . . . . 71.329999999999998 112.48 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 5.2 tt -79.94 -40.89 27.15 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.838 0.352 . . . . 64.230000000000004 110.935 -179.929 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.7 t -78.28 -20.16 52.17 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.141 -0.481 . . . . 64.329999999999998 110.846 -179.899 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 85.6 m -86.19 -22.48 26.94 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.137 -0.483 . . . . 72.049999999999997 111.136 -179.929 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.493 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -91.92 -35.38 14.05 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.23 -0.441 . . . . 72.420000000000002 111.083 179.895 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -75.95 -11.95 60.06 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.185 -0.461 . . . . 74.340000000000003 110.882 -179.929 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 97.6 m -98.57 -35.45 10.22 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.213 -0.449 . . . . 72.040000000000006 111.155 179.901 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.495 ' O ' ' C ' ' A' ' 17' ' ' PHE . . . -103.75 -7.47 41.82 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.772 -0.727 . . . . 64.319999999999993 112.449 -179.979 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.495 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.5 p90 -29.59 -54.25 0.15 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.961 0.41 . . . . 73.450000000000003 110.886 -179.855 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.448 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.3 m -116.07 -14.5 11.19 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.116 -0.493 . . . . 74.010000000000005 111.133 -179.896 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -82.47 -14.59 54.79 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.234 -0.439 . . . . 74.519999999999996 110.893 179.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.574 ' N ' ' HD2' ' A' ' 21' ' ' PRO . 14.0 t -75.73 -55.13 2.06 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.605 0.717 . . . . 75.239999999999995 111.116 179.844 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . 0.574 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.4 Cg_endo -69.8 -21.06 33.84 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.696 2.264 . . . . 74.409999999999997 112.304 -179.982 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 44.7 t -99.41 -11.77 8.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.205 -0.452 . . . . 70.310000000000002 111.134 179.932 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.33 -0.279 0 CA-C-N 116.178 -0.465 . . . . 75.219999999999999 110.933 179.964 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.565 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 0.5 OUTLIER . . . . . 0 C--O 1.231 0.103 0 CA-C-O 121.7 0.762 . . . . 73.540000000000006 110.849 . . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . 0.565 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 54.1 Cg_endo -69.71 -7.29 20.67 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.747 2.298 . . . . 74.420000000000002 112.325 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -121.34 -15.23 4.66 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.735 -0.745 . . . . 72.219999999999999 112.479 179.988 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 2.1 tp -80.04 -40.76 27.07 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.821 0.344 . . . . 72.340000000000003 110.942 -179.937 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -78.37 -20.11 51.97 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.196 -0.456 . . . . 65.109999999999999 110.865 -179.955 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 40.0 m -86.22 -22.48 26.89 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.135 -0.484 . . . . 53.310000000000002 111.123 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.494 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -91.95 -35.34 14.05 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.222 -0.444 . . . . 73.400000000000006 111.076 179.896 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -75.93 -11.98 60.06 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.201 -0.454 . . . . 74.430000000000007 110.931 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 97.6 m -98.53 -35.46 10.23 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.179 -0.464 . . . . 75.230000000000004 111.154 179.892 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.494 ' O ' ' C ' ' A' ' 17' ' ' PHE . . . -103.78 -7.43 41.79 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.773 -0.727 . . . . 73.209999999999994 112.485 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.494 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.63 -54.27 0.15 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.852 0.358 . . . . 64.400000000000006 110.864 -179.893 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.449 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.4 m -116.01 -14.48 11.22 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.171 -0.468 . . . . 65.219999999999999 111.144 -179.922 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -82.51 -14.54 54.81 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.225 -0.443 . . . . 74.049999999999997 110.953 179.94 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.574 ' N ' ' HD2' ' A' ' 21' ' ' PRO . 14.1 t -75.79 -55.1 2.03 Favored Pre-proline 0 C--N 1.33 -0.251 0 CA-C-O 121.587 0.708 . . . . 73.450000000000003 111.118 179.838 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . 0.574 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.7 Cg_endo -69.79 -21.04 33.92 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.643 2.229 . . . . 75.219999999999999 112.336 179.978 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 45.2 t -99.4 -11.74 8.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.223 -0.444 . . . . 73.219999999999999 111.137 179.917 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--N 1.33 -0.26 0 CA-C-N 116.145 -0.48 . . . . 74.200000000000003 110.918 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 12.5 m . . . . . 0 N--CA 1.458 -0.058 0 CA-C-O 120.841 0.353 . . . . 61.229999999999997 111.105 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -62.63 -21.7 63.1 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.705 -0.76 . . . . 75.349999999999994 112.538 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 61.0 m-20 -115.07 -5.31 12.47 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.876 0.37 . . . . 75.400000000000006 110.889 -179.895 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 21.0 t -94.31 -11.37 8.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.175 -0.466 . . . . 64.349999999999994 111.138 179.915 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -110.74 34.84 5.13 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.773 -0.727 . . . . 61.240000000000002 112.501 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -88.42 -75.5 0.42 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.788 0.328 . . . . 72.140000000000001 110.87 -179.878 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.546 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.0 OUTLIER -69.09 -56.8 8.31 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.677 0.751 . . . . 74.549999999999997 110.845 -179.91 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.546 ' HD2' ' N ' ' A' ' 7' ' ' SER . 54.4 Cg_endo -69.69 -4.89 14.89 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.678 2.252 . . . . 75.010000000000005 112.341 179.959 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -111.07 -26.33 4.7 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.72 -0.753 . . . . 65.299999999999997 112.503 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.4 tt -77.93 -40.96 37.92 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.856 0.36 . . . . 71.209999999999994 110.943 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 10.4 t -79.05 -19.41 51.46 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.17 -0.468 . . . . 62.020000000000003 110.898 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 96.9 m -86.87 -22.16 25.92 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.128 -0.487 . . . . 73.409999999999997 111.173 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.497 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -92.36 -35.29 13.8 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.214 -0.448 . . . . 63.549999999999997 111.094 179.876 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -76.07 -12.03 60.05 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.224 -0.444 . . . . 73.019999999999996 110.924 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 97.1 m -98.61 -35.26 10.27 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.158 -0.473 . . . . 71.150000000000006 111.175 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.51 ' O ' ' C ' ' A' ' 17' ' ' PHE . . . -103.89 -7.5 41.35 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.778 -0.725 . . . . 65.140000000000001 112.46 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.51 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.58 -54.36 0.15 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.943 0.401 . . . . 74.329999999999998 110.877 -179.859 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.445 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.4 m -115.92 -14.39 11.28 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.126 -0.488 . . . . 73.310000000000002 111.17 -179.916 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -82.46 -14.57 54.84 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.206 -0.452 . . . . 73.010000000000005 110.955 179.91 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.579 ' N ' ' HD2' ' A' ' 21' ' ' PRO . 16.5 t -75.7 -55.03 2.1 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.612 0.72 . . . . 73.319999999999993 111.166 179.818 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . 0.579 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 54.1 Cg_endo -69.79 -21.17 33.7 Favored 'Trans proline' 0 C--O 1.232 0.194 0 C-N-CA 122.695 2.264 . . . . 75.329999999999998 112.362 179.92 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 44.4 t -99.29 -11.73 8.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.261 -0.427 . . . . 74.340000000000003 111.149 179.91 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -58.11 -21.18 45.19 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.156 -0.474 . . . . 72.329999999999998 110.859 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 10.1 t70 -102.47 -6.01 23.4 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.201 -0.454 . . . . 72.129999999999995 110.884 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 25.6 t-80 . . . . . 0 C--N 1.329 -0.319 0 CA-C-N 116.179 -0.464 . . . . 73.099999999999994 110.862 -179.965 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.458 -0.057 0 CA-C-O 120.786 0.327 . . . . 72.430000000000007 111.122 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -56.61 -40.77 88.49 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.73 -0.747 . . . . 72.129999999999995 112.434 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 27.8 m120 -109.04 -5.41 16.04 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.835 0.35 . . . . 61.039999999999999 110.875 -179.892 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 21.3 t -92.54 -11.38 9.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.217 -0.447 . . . . 72.109999999999999 111.123 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -119.59 28.46 6.47 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.729 -0.748 . . . . 74.25 112.471 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -85.31 -74.59 0.4 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.831 0.348 . . . . 75.340000000000003 110.924 -179.959 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.544 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.0 OUTLIER -68.85 -56.87 8.66 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.707 0.765 . . . . 74.549999999999997 110.861 -179.976 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.544 ' HD2' ' N ' ' A' ' 7' ' ' SER . 53.3 Cg_endo -69.74 -4.76 14.66 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.693 2.262 . . . . 75.109999999999999 112.319 -179.978 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -111.24 -26.01 4.78 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.783 -0.722 . . . . 74.430000000000007 112.539 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 3.6 tt -78.17 -41.07 35.86 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.819 0.343 . . . . 72.019999999999996 110.891 -179.888 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 4.9 t -79.2 -19.27 51.22 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.193 -0.458 . . . . 74.310000000000002 110.866 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 97.1 m -86.93 -22.25 25.75 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.133 -0.485 . . . . 71.409999999999997 111.11 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.497 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -92.33 -35.32 13.8 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.217 -0.447 . . . . 71.129999999999995 111.087 179.88 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -76.07 -11.89 60.02 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.219 -0.446 . . . . 70.430000000000007 110.941 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 98.4 m -98.59 -35.33 10.25 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.161 -0.472 . . . . 74.420000000000002 111.174 179.897 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.511 ' O ' ' C ' ' A' ' 17' ' ' PHE . . . -103.91 -7.42 41.45 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.739 -0.744 . . . . 62.530000000000001 112.536 179.938 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.511 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.59 -54.22 0.15 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.926 0.393 . . . . 73.25 110.889 -179.911 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.44 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.3 m -116.08 -14.58 11.18 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.132 -0.485 . . . . 71.040000000000006 111.129 -179.886 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -82.36 -14.57 55.04 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.237 -0.438 . . . . 73.519999999999996 110.96 179.946 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.578 ' N ' ' HD2' ' A' ' 21' ' ' PRO . 14.3 t -75.76 -55.16 2.04 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-O 121.64 0.734 . . . . 60.210000000000001 111.099 179.843 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . 0.578 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.7 Cg_endo -69.73 -21.1 34.09 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.692 2.261 . . . . 72.400000000000006 112.326 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 45.3 t -99.37 -11.74 8.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.186 -0.461 . . . . 75.219999999999999 111.163 179.906 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -58.04 -21.05 43.52 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.177 -0.465 . . . . 75.120000000000005 110.921 -179.978 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 26.7 t70 -103.2 -5.79 22.79 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.125 -0.489 . . . . 65.409999999999997 110.883 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 17.9 t-80 . . . . . 0 C--N 1.33 -0.266 0 CA-C-N 116.199 -0.455 . . . . 74.510000000000005 110.891 -179.942 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.457 -0.113 0 CA-C-O 120.827 0.346 . . . . 73.230000000000004 111.187 . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -64.98 -34.76 90.75 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.701 -0.762 . . . . 51.439999999999998 112.461 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 5.5 t-20 -119.72 -5.59 10.18 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.851 0.358 . . . . 72.140000000000001 110.897 -179.877 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 21.2 t -97.35 -11.34 8.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.176 -0.465 . . . . 63.310000000000002 111.109 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -117.15 36.12 3.86 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.685 -0.769 . . . . 74.450000000000003 112.487 179.962 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 2.9 tt -85.06 -72.72 0.47 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.816 0.341 . . . . 73.299999999999997 110.959 -179.968 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.545 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.0 OUTLIER -68.97 -56.82 8.46 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.639 0.733 . . . . 64.450000000000003 110.869 -179.939 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.545 ' HD2' ' N ' ' A' ' 7' ' ' SER . 54.1 Cg_endo -69.75 -4.94 15.04 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.671 2.248 . . . . 64.310000000000002 112.324 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -111.0 -26.09 4.82 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.765 -0.731 . . . . 71.150000000000006 112.469 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -78.04 -41.35 35.92 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.797 0.332 . . . . 74.019999999999996 110.945 -179.938 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -78.64 -19.67 52.08 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.197 -0.456 . . . . 74.420000000000002 110.861 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 97.4 m -86.55 -22.44 26.31 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.084 -0.507 . . . . 74.040000000000006 111.167 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.495 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -92.18 -35.29 13.92 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.185 -0.461 . . . . 60.310000000000002 111.088 179.914 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -76.02 -11.96 60.04 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.201 -0.454 . . . . 73.519999999999996 110.921 -179.967 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 98.8 m -98.66 -35.24 10.25 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.152 -0.476 . . . . 74.230000000000004 111.115 179.942 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.51 ' O ' ' C ' ' A' ' 17' ' ' PHE . . . -103.92 -7.5 41.28 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.746 -0.74 . . . . 74.439999999999998 112.466 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.51 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.6 -54.31 0.15 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.885 0.374 . . . . 72.030000000000001 110.894 -179.852 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.442 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.5 m -115.91 -14.43 11.28 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.166 -0.47 . . . . 73.219999999999999 111.14 -179.931 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -82.55 -14.39 54.97 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.232 -0.44 . . . . 72.230000000000004 110.889 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.58 ' N ' ' HD2' ' A' ' 21' ' ' PRO . 15.2 t -75.95 -55.06 1.96 Allowed Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.607 0.717 . . . . 73.099999999999994 111.113 179.87 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . 0.58 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 54.1 Cg_endo -69.72 -21.2 34.0 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.708 2.272 . . . . 75.140000000000001 112.374 179.909 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 45.9 t -99.1 -11.98 8.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.24 -0.436 . . . . 74.150000000000006 111.118 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -58.23 -20.76 44.35 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.156 -0.475 . . . . 71.329999999999998 110.892 -179.968 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -76.72 -5.11 46.67 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.148 -0.478 . . . . 73.530000000000001 110.891 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.329 -0.301 0 CA-C-N 116.179 -0.464 . . . . 75.200000000000003 110.871 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.457 -0.097 0 CA-C-O 120.852 0.358 . . . . 74.219999999999999 111.168 . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -68.22 -23.44 74.78 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.765 -0.731 . . . . 60.240000000000002 112.474 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 68.2 m-20 -114.07 -5.46 13.1 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.81 0.338 . . . . 72.0 110.858 -179.874 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 21.2 t -107.07 -11.28 10.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.243 -0.435 . . . . 72.420000000000002 111.145 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -117.62 37.06 3.43 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.754 -0.736 . . . . 61.109999999999999 112.444 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 23.6 tp -88.89 -75.74 0.42 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.837 0.351 . . . . 71.299999999999997 110.882 -179.916 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.547 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.6 OUTLIER -69.0 -56.88 8.33 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-O 121.679 0.752 . . . . 74.200000000000003 110.857 -179.912 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.547 ' HD2' ' N ' ' A' ' 7' ' ' SER . 53.9 Cg_endo -69.7 -4.92 14.96 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.714 2.276 . . . . 71.239999999999995 112.358 179.991 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -111.11 -26.03 4.81 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.715 -0.755 . . . . 74.120000000000005 112.448 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -78.16 -41.07 35.96 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.81 0.338 . . . . 74.150000000000006 110.934 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -79.05 -19.48 51.26 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.161 -0.472 . . . . 73.349999999999994 110.861 -179.929 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 97.7 m -86.7 -22.39 26.07 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.175 -0.466 . . . . 73.400000000000006 111.13 -179.953 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.496 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -92.12 -35.43 13.88 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.265 -0.425 . . . . 73.109999999999999 111.147 179.84 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -75.99 -11.88 60.03 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.206 -0.452 . . . . 74.109999999999999 110.938 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 97.6 m -98.69 -35.4 10.19 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.194 -0.457 . . . . 72.439999999999998 111.149 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.51 ' O ' ' C ' ' A' ' 17' ' ' PHE . . . -103.83 -7.35 41.84 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.707 -0.758 . . . . 60.25 112.523 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.51 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.68 -54.24 0.15 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.893 0.378 . . . . 74.439999999999998 110.869 -179.869 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.438 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 20.5 m -116.08 -14.91 11.17 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.17 -0.468 . . . . 72.019999999999996 111.188 -179.936 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 10.5 mp -82.23 -15.02 54.57 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.179 -0.464 . . . . 74.109999999999999 110.937 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.574 ' N ' ' HD2' ' A' ' 21' ' ' PRO . 9.4 t -75.44 -55.35 2.14 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.588 0.709 . . . . 73.019999999999996 111.103 179.839 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . 0.574 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 54.2 Cg_endo -69.71 -20.54 34.94 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.687 2.258 . . . . 70.230000000000004 112.371 179.936 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 45.9 t -100.26 -11.76 8.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.179 -0.464 . . . . 75.420000000000002 111.118 179.919 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -56.69 -21.65 29.26 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.194 -0.457 . . . . 70.040000000000006 110.906 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 91.8 m-20 -120.0 -5.95 10.03 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.183 -0.462 . . . . 53.509999999999998 110.867 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 116.165 -0.471 . . . . 74.329999999999998 110.863 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.457 -0.092 0 CA-C-O 120.872 0.368 . . . . 74.329999999999998 111.144 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -64.49 -34.8 90.88 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.806 -0.711 . . . . 53.100000000000001 112.453 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 2.6 t-20 -88.26 -5.66 58.24 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.856 0.36 . . . . 72.329999999999998 110.877 -179.846 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 21.1 t -91.1 -11.4 9.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.147 -0.479 . . . . 64.109999999999999 111.087 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -110.12 33.61 5.9 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.775 -0.726 . . . . 72.430000000000007 112.534 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -86.12 -74.17 0.43 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.812 0.339 . . . . 73.439999999999998 110.854 -179.828 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.542 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.0 OUTLIER -68.7 -56.74 9.17 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.664 0.745 . . . . 74.400000000000006 110.837 -179.897 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.542 ' HD2' ' N ' ' A' ' 7' ' ' SER . 53.0 Cg_endo -69.81 -4.9 15.0 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.686 2.257 . . . . 75.319999999999993 112.312 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -111.1 -25.99 4.83 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.718 -0.753 . . . . 73.239999999999995 112.467 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -77.87 -41.65 36.08 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.813 0.34 . . . . 73.040000000000006 110.923 -179.947 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -78.5 -19.67 52.5 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.218 -0.446 . . . . 72.310000000000002 110.858 -179.917 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 97.6 m -86.51 -22.41 26.41 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.093 -0.503 . . . . 74.140000000000001 111.161 -179.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.496 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -92.16 -35.35 13.9 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.209 -0.45 . . . . 53.329999999999998 111.092 179.851 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -75.99 -12.08 60.07 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.202 -0.453 . . . . 75.230000000000004 110.887 -179.915 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 98.3 m -98.71 -35.27 10.22 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.218 -0.446 . . . . 72.450000000000003 111.167 179.905 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.507 ' O ' ' C ' ' A' ' 17' ' ' PHE . . . -103.84 -7.35 41.81 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.747 -0.74 . . . . 72.329999999999998 112.442 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.507 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.72 -54.13 0.15 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.966 0.412 . . . . 75.430000000000007 110.937 -179.872 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.44 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 20.5 m -116.24 -14.99 11.07 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.138 -0.483 . . . . 64.299999999999997 111.114 -179.924 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 10.5 mp -82.26 -15.1 54.22 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.261 -0.427 . . . . 75.549999999999997 110.885 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.574 ' N ' ' HD2' ' A' ' 21' ' ' PRO . 7.3 t -75.64 -55.34 2.05 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.644 0.735 . . . . 74.450000000000003 111.134 179.868 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . 0.574 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.5 Cg_endo -69.78 -20.27 34.96 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.699 2.266 . . . . 75.5 112.324 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 47.2 t -100.31 -11.66 8.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.217 -0.447 . . . . 73.439999999999998 111.164 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -57.81 -20.99 39.73 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.162 -0.472 . . . . 71.200000000000003 110.895 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -74.96 -6.72 50.83 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.14 -0.482 . . . . 60.420000000000002 110.855 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 2.1 t60 . . . . . 0 C--N 1.33 -0.28 0 CA-C-N 116.236 -0.438 . . . . 64.439999999999998 110.849 -179.953 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 4.0 m . . . . . 0 N--CA 1.457 -0.107 0 CA-C-O 120.82 0.343 . . . . 70.310000000000002 111.147 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -60.95 -42.29 99.67 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.774 -0.727 . . . . 70.150000000000006 112.513 179.935 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -95.19 -5.48 43.82 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.861 0.363 . . . . 72.219999999999999 110.912 -179.94 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 20.9 t -86.47 -11.4 11.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.185 -0.462 . . . . 73.409999999999997 111.135 179.921 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -116.97 37.04 3.49 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.762 -0.732 . . . . 74.040000000000006 112.502 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 1.7 mm? -88.65 -75.68 0.42 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.865 0.364 . . . . 74.329999999999998 110.949 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.543 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.5 OUTLIER -68.93 -56.81 8.59 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 121.668 0.747 . . . . 64.530000000000001 110.844 -179.924 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.543 ' HD2' ' N ' ' A' ' 7' ' ' SER . 53.2 Cg_endo -69.79 -4.87 14.92 Favored 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.676 2.251 . . . . 63.399999999999999 112.351 179.992 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -110.93 -26.22 4.78 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.747 -0.739 . . . . 75.340000000000003 112.486 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 3.0 tm? -78.42 -40.44 35.93 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.808 0.337 . . . . 73.230000000000004 110.916 -179.914 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 5.4 t -79.47 -19.49 49.68 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.258 -0.428 . . . . 75.510000000000005 110.843 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 97.8 m -86.81 -22.27 25.96 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.131 -0.486 . . . . 72.219999999999999 111.149 -179.927 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.495 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -92.15 -35.44 13.86 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.252 -0.431 . . . . 74.400000000000006 111.072 179.883 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -75.83 -12.02 60.09 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.236 -0.438 . . . . 74.400000000000006 110.896 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 97.7 m -98.53 -35.43 10.24 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.21 -0.45 . . . . 75.439999999999998 111.152 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.509 ' O ' ' C ' ' A' ' 17' ' ' PHE . . . -103.85 -7.43 41.61 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.732 -0.747 . . . . 72.409999999999997 112.457 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.509 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.67 -54.22 0.15 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.947 0.403 . . . . 73.519999999999996 110.844 -179.835 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.445 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.3 m -116.01 -14.54 11.22 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.198 -0.456 . . . . 74.120000000000005 111.159 -179.901 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -82.5 -14.52 54.84 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.224 -0.444 . . . . 73.129999999999995 110.945 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.577 ' N ' ' HD2' ' A' ' 21' ' ' PRO . 14.1 t -75.77 -55.11 2.04 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.6 0.714 . . . . 75.439999999999998 111.144 179.799 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . 0.577 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.7 Cg_endo -69.81 -21.08 33.77 Favored 'Trans proline' 0 C--O 1.232 0.18 0 C-N-CA 122.695 2.263 . . . . 75.430000000000007 112.298 179.964 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 44.8 t -99.34 -11.78 8.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.273 -0.422 . . . . 72.200000000000003 111.124 179.934 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -57.93 -20.98 41.55 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.178 -0.464 . . . . 74.109999999999999 110.914 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 87.7 m-20 -75.54 -6.26 49.39 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.136 -0.484 . . . . 75.219999999999999 110.862 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 8.8 t-160 . . . . . 0 C--N 1.329 -0.294 0 CA-C-N 116.204 -0.453 . . . . 75.319999999999993 110.88 -179.962 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.457 -0.083 0 CA-C-O 120.799 0.333 . . . . 73.219999999999999 111.16 . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -59.17 -36.73 89.96 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.767 -0.73 . . . . 73.299999999999997 112.434 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 9.8 m120 -95.3 -5.7 42.98 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.863 0.363 . . . . 71.430000000000007 110.874 -179.857 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 21.2 t -91.69 -11.18 9.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.196 -0.457 . . . . 73.430000000000007 111.181 179.882 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -109.8 33.66 5.92 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.752 -0.737 . . . . 74.239999999999995 112.481 179.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 1.1 tt -86.29 -74.87 0.4 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.85 0.357 . . . . 74.420000000000002 110.901 -179.912 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.541 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.3 OUTLIER -68.89 -56.93 8.49 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.649 0.738 . . . . 71.420000000000002 110.854 -179.947 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.541 ' HD2' ' N ' ' A' ' 7' ' ' SER . 54.2 Cg_endo -69.75 -4.55 14.25 Favored 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 122.666 2.244 . . . . 75.340000000000003 112.392 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -111.44 -25.93 4.75 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.775 -0.726 . . . . 50.210000000000001 112.442 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 2.5 tt -78.49 -40.82 34.25 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.826 0.346 . . . . 70.329999999999998 110.907 -179.901 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -79.23 -19.5 50.54 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.213 -0.448 . . . . 74.030000000000001 110.867 -179.933 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 94.8 m -86.81 -22.28 25.95 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.134 -0.485 . . . . 72.209999999999994 111.121 -179.924 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.494 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -92.11 -35.44 13.89 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.213 -0.449 . . . . 72.430000000000007 111.055 179.89 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -75.79 -12.06 60.1 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.271 -0.422 . . . . 74.040000000000006 110.889 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 98.9 m -98.6 -35.32 10.25 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.229 -0.441 . . . . 71.430000000000007 111.109 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.508 ' O ' ' C ' ' A' ' 17' ' ' PHE . . . -103.96 -7.32 41.51 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.725 -0.75 . . . . 62.210000000000001 112.487 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.508 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.74 -54.11 0.15 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.953 0.406 . . . . 73.120000000000005 110.885 -179.89 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.442 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.2 m -116.27 -14.65 11.06 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.152 -0.476 . . . . 73.420000000000002 111.127 -179.905 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -82.5 -14.66 54.62 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.25 -0.432 . . . . 75.109999999999999 110.907 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.577 ' N ' ' HD2' ' A' ' 21' ' ' PRO . 10.4 t -76.04 -55.21 1.89 Allowed Pre-proline 0 C--N 1.33 -0.257 0 CA-C-O 121.599 0.714 . . . . 71.310000000000002 111.098 179.819 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . 0.577 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.6 Cg_endo -69.76 -20.33 34.97 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.711 2.274 . . . . 74.409999999999997 112.31 179.994 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 46.9 t -100.07 -11.69 8.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.236 -0.438 . . . . 74.439999999999998 111.131 179.937 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 5.8 tp10 -58.64 -24.3 60.88 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.16 -0.473 . . . . 74.439999999999998 110.899 179.967 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 51.7 m-20 -76.5 -5.5 47.78 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.168 -0.469 . . . . 71.099999999999994 110.898 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 7.1 t-80 . . . . . 0 C--N 1.33 -0.272 0 CA-C-N 116.144 -0.48 . . . . 73.540000000000006 110.823 -179.972 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.457 -0.103 0 CA-C-O 120.827 0.346 . . . . 75.430000000000007 111.118 . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -70.08 -28.81 71.17 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.717 -0.754 . . . . 72.109999999999999 112.508 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 81.0 m-20 -114.03 -5.53 13.13 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.856 0.36 . . . . 65.109999999999999 110.92 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 21.2 t -105.52 -10.71 9.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.189 -0.46 . . . . 73.349999999999994 111.122 179.901 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -119.11 30.32 5.88 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.726 -0.75 . . . . 53.409999999999997 112.49 179.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -85.29 -68.71 0.71 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.818 0.342 . . . . 73.150000000000006 110.917 -179.872 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.54 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.0 OUTLIER -70.54 -56.8 6.06 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.613 0.721 . . . . 61.420000000000002 110.838 -179.948 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.54 ' HD2' ' N ' ' A' ' 7' ' ' SER . 54.4 Cg_endo -69.74 -4.88 14.91 Favored 'Trans proline' 0 C--N 1.341 0.153 0 C-N-CA 122.645 2.23 . . . . 73.140000000000001 112.382 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -111.06 -26.68 4.56 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.767 -0.73 . . . . 72.310000000000002 112.468 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -77.69 -40.59 40.91 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.826 0.346 . . . . 73.030000000000001 110.908 -179.906 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -79.35 -19.44 50.26 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.161 -0.472 . . . . 64.239999999999995 110.825 -179.878 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 92.1 m -87.38 -21.45 25.63 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.141 -0.481 . . . . 62.240000000000002 111.138 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.498 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -92.86 -35.44 13.37 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.181 -0.463 . . . . 72.230000000000004 111.071 179.922 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -76.3 -12.02 60.01 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.255 -0.43 . . . . 74.439999999999998 110.956 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 94.3 m -98.5 -35.37 10.27 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.153 -0.476 . . . . 74.450000000000003 111.152 179.922 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.508 ' O ' ' C ' ' A' ' 17' ' ' PHE . . . -103.83 -7.37 41.8 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.727 -0.749 . . . . 74.120000000000005 112.514 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.508 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.71 -54.24 0.15 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.924 0.392 . . . . 74.450000000000003 110.873 -179.914 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.44 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.2 m -116.01 -14.8 11.22 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.148 -0.478 . . . . 73.120000000000005 111.134 -179.905 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -82.29 -14.6 55.16 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.21 -0.45 . . . . 75.439999999999998 110.909 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.574 ' N ' ' HD2' ' A' ' 21' ' ' PRO . 10.0 t -76.53 -55.39 1.63 Allowed Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.651 0.739 . . . . 71.319999999999993 111.108 179.875 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . 0.574 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.4 Cg_endo -69.75 -19.83 35.64 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.712 2.274 . . . . 75.129999999999995 112.327 179.962 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 41.6 t -102.3 -11.92 8.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.195 -0.457 . . . . 72.5 111.12 179.911 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.9 tp10 -52.13 -35.42 48.24 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.207 -0.451 . . . . 73.099999999999994 110.897 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 52.1 m-20 -115.37 -5.71 12.32 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.142 -0.481 . . . . 51.420000000000002 110.886 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 28.5 m80 . . . . . 0 C--N 1.329 -0.303 0 CA-C-N 116.174 -0.466 . . . . 74.310000000000002 110.888 -179.999 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 3.1 m . . . . . 0 C--O 1.231 0.096 0 CA-C-O 120.777 0.323 . . . . 74.439999999999998 111.107 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -62.66 -39.72 98.27 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.738 -0.744 . . . . 63.409999999999997 112.483 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 7.6 t-20 -117.22 -5.44 11.34 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.858 0.361 . . . . 75.049999999999997 110.898 -179.872 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 21.2 t -86.79 -11.36 11.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.146 -0.479 . . . . 74.129999999999995 111.145 179.909 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -117.02 37.43 3.35 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.742 -0.742 . . . . 62.25 112.521 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -88.48 -75.57 0.42 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.791 0.329 . . . . 72.150000000000006 110.942 -179.938 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.547 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.6 OUTLIER -69.05 -56.76 8.43 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.726 0.774 . . . . 73.129999999999995 110.916 -179.963 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.547 ' HD2' ' N ' ' A' ' 7' ' ' SER . 53.7 Cg_endo -69.76 -4.78 14.73 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.704 2.269 . . . . 70.200000000000003 112.359 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -111.23 -25.96 4.81 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.685 -0.769 . . . . 75.430000000000007 112.481 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 6.4 tp -80.15 -37.15 34.06 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.849 0.357 . . . . 75.109999999999999 110.939 -179.962 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -82.52 -19.22 39.1 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.173 -0.467 . . . . 51.130000000000003 110.874 -179.926 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 99.5 m -86.56 -23.19 25.92 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.124 -0.489 . . . . 63.340000000000003 111.123 -179.922 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.505 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -92.62 -34.83 13.84 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.194 -0.457 . . . . 73.140000000000001 111.11 179.895 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -76.65 -11.8 59.91 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.203 -0.453 . . . . 74.540000000000006 110.933 179.987 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 98.9 m -99.14 -34.26 10.45 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.182 -0.463 . . . . 74.150000000000006 111.149 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.509 ' O ' ' C ' ' A' ' 17' ' ' PHE . . . -104.73 -7.77 38.46 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.731 -0.747 . . . . 74.329999999999998 112.537 179.921 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.509 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.5 p90 -29.81 -54.84 0.16 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.9 0.381 . . . . 75.540000000000006 110.887 -179.924 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.435 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 20.0 m -115.57 -14.95 11.48 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.175 -0.466 . . . . 74.120000000000005 111.135 -179.882 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 10.1 mp -82.11 -15.2 54.25 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.204 -0.453 . . . . 73.430000000000007 110.937 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.575 ' N ' ' HD2' ' A' ' 21' ' ' PRO . 8.5 t -75.68 -55.29 2.04 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.6 0.714 . . . . 72.200000000000003 111.162 179.826 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . 0.575 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.4 Cg_endo -69.79 -20.19 35.0 Favored 'Trans proline' 0 C--O 1.231 0.143 0 C-N-CA 122.669 2.246 . . . . 72.040000000000006 112.323 179.934 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 47.4 t -100.41 -11.65 8.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.228 -0.442 . . . . 72.120000000000005 111.142 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -57.83 -21.05 40.44 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.14 -0.482 . . . . 70.129999999999995 110.884 -179.998 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -75.3 -6.4 49.68 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.144 -0.48 . . . . 64.140000000000001 110.867 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 116.183 -0.462 . . . . 75.219999999999999 110.865 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.23 0.062 0 CA-C-O 120.788 0.328 . . . . 75.099999999999994 111.107 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -55.86 -30.92 57.74 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.777 -0.725 . . . . 72.329999999999998 112.465 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -106.63 -5.45 18.64 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.825 0.345 . . . . 74.140000000000001 110.858 -179.872 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 20.8 t -94.47 -11.52 8.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.206 -0.452 . . . . 74.239999999999995 111.117 179.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -106.77 23.92 26.7 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.724 -0.75 . . . . 74.049999999999997 112.457 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 5.5 tt -85.84 -41.65 14.83 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.822 0.344 . . . . 75.129999999999995 110.957 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.5 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.0 OUTLIER -83.62 -58.57 0.39 Allowed Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.704 0.764 . . . . 72.549999999999997 110.858 -179.935 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.5 ' HD2' ' N ' ' A' ' 7' ' ' SER . 53.3 Cg_endo -69.77 -6.84 19.57 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.704 2.269 . . . . 73.409999999999997 112.351 -179.998 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -107.17 -27.42 5.34 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.696 -0.764 . . . . 65.420000000000002 112.513 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -78.71 -40.01 34.86 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.823 0.344 . . . . 72.409999999999997 110.908 -179.942 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -79.59 -19.22 49.84 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.194 -0.457 . . . . 74.439999999999998 110.875 -179.925 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 47.3 m -86.48 -23.31 26.02 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.117 -0.492 . . . . 73.0 111.148 -179.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.5 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -91.59 -35.5 14.21 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.203 -0.453 . . . . 70.209999999999994 111.094 179.877 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -75.91 -11.8 60.03 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.247 -0.433 . . . . 73.329999999999998 110.909 179.999 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 98.3 m -98.45 -35.57 10.23 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.22 -0.445 . . . . 73.219999999999999 111.146 179.936 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.502 ' O ' ' C ' ' A' ' 17' ' ' PHE . . . -103.95 -7.47 41.26 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.783 -0.722 . . . . 53.409999999999997 112.483 179.98 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.502 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.71 -54.05 0.15 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.877 0.37 . . . . 73.549999999999997 110.878 -179.832 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.444 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.5 m -116.01 -14.62 11.22 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.151 -0.477 . . . . 74.329999999999998 111.133 -179.922 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -82.26 -14.78 54.93 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.19 -0.459 . . . . 72.209999999999994 110.893 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.564 ' N ' ' HD2' ' A' ' 21' ' ' PRO . 13.7 t -75.74 -55.32 2.01 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.625 0.726 . . . . 74.129999999999995 111.112 179.918 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . 0.564 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.6 Cg_endo -69.71 -20.95 34.41 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.735 2.29 . . . . 73.25 112.324 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 45.2 t -99.65 -11.78 8.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.2 -0.454 . . . . 63.140000000000001 111.145 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -58.14 -21.15 45.52 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.172 -0.467 . . . . 72.549999999999997 110.866 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 13.6 m-20 -102.95 -5.6 23.29 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.173 -0.467 . . . . 73.409999999999997 110.888 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.33 -0.28 0 CA-C-N 116.227 -0.442 . . . . 74.239999999999995 110.873 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.457 -0.077 0 CA-C-O 120.832 0.349 . . . . 75.040000000000006 111.13 . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -57.68 -22.07 45.32 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.75 -0.738 . . . . 73.230000000000004 112.479 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 8.0 t-20 -119.6 -5.5 10.24 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.885 0.374 . . . . 73.530000000000001 110.856 -179.859 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 21.1 t -94.31 -11.38 8.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.219 -0.446 . . . . 75.409999999999997 111.128 179.9 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -115.16 37.54 3.45 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.735 -0.745 . . . . 71.349999999999994 112.483 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 2.2 tt -81.16 -38.68 26.73 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.847 0.356 . . . . 75.430000000000007 110.946 -179.916 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.497 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.0 OUTLIER -86.18 -59.35 0.3 Allowed Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.668 0.747 . . . . 54.43 110.882 -179.957 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.497 ' HD2' ' N ' ' A' ' 7' ' ' SER . 53.8 Cg_endo -69.73 -5.65 16.69 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.695 2.263 . . . . 72.430000000000007 112.348 179.962 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -109.17 -26.5 5.17 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.724 -0.751 . . . . 73.25 112.501 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 6.5 tt -78.62 -41.68 30.94 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.79 0.329 . . . . 73.450000000000003 110.902 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 2.2 t -77.96 -19.88 53.72 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.211 -0.45 . . . . 75.439999999999998 110.844 -179.91 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 91.8 m -86.74 -22.71 25.81 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.137 -0.483 . . . . 62.420000000000002 111.137 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.492 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -91.65 -34.75 14.56 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.224 -0.444 . . . . 64.219999999999999 111.124 179.835 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -76.44 -11.53 59.9 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.197 -0.456 . . . . 74.209999999999994 110.913 -179.967 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 96.7 m -99.01 -35.44 10.05 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.191 -0.459 . . . . 65.040000000000006 111.117 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.512 ' O ' ' C ' ' A' ' 17' ' ' PHE . . . -103.57 -7.63 42.02 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.714 -0.755 . . . . 54.439999999999998 112.479 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.512 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.57 -54.21 0.15 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.914 0.388 . . . . 73.239999999999995 110.843 -179.87 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.44 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 23.3 m -116.05 -14.75 11.19 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.168 -0.469 . . . . 74.219999999999999 111.159 -179.92 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -82.21 -14.46 55.53 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.229 -0.441 . . . . 73.099999999999994 110.901 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.578 ' N ' ' HD2' ' A' ' 21' ' ' PRO . 14.9 t -75.71 -55.14 2.06 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.603 0.716 . . . . 62.25 111.097 179.839 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . 0.578 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.7 Cg_endo -69.69 -21.18 34.17 Favored 'Trans proline' 0 C--O 1.231 0.15 0 C-N-CA 122.729 2.286 . . . . 74.219999999999999 112.329 179.961 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 44.6 t -99.43 -11.88 8.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.224 -0.444 . . . . 72.150000000000006 111.104 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -56.98 -21.88 33.91 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.216 -0.447 . . . . 63.200000000000003 110.884 -179.956 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 39.0 m-20 -119.09 -5.8 10.48 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.18 -0.464 . . . . 73.129999999999995 110.868 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 3.4 t-160 . . . . . 0 C--N 1.33 -0.276 0 CA-C-N 116.193 -0.458 . . . . 74.430000000000007 110.85 -179.984 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 8.2 m . . . . . 0 N--CA 1.457 -0.09 0 CA-C-O 120.834 0.349 . . . . 71.510000000000005 111.132 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -69.26 -25.58 75.33 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.699 -0.762 . . . . 71.129999999999995 112.494 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 69.2 m-80 -117.63 -5.49 11.16 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.907 0.384 . . . . 65.109999999999999 110.904 -179.885 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 20.9 t -104.06 -11.39 9.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.154 -0.475 . . . . 75.420000000000002 111.133 179.894 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -120.09 40.01 2.31 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.74 -0.743 . . . . 74.120000000000005 112.474 179.975 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 44.6 tp -67.36 -36.13 80.76 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.84 0.353 . . . . 75.129999999999995 110.881 -179.912 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.509 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.3 OUTLIER -83.92 -58.44 0.38 Allowed Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.637 0.732 . . . . 61.420000000000002 110.856 -179.923 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.509 ' HD2' ' N ' ' A' ' 7' ' ' SER . 53.3 Cg_endo -69.75 -7.45 21.08 Favored 'Trans proline' 0 C--N 1.341 0.14 0 C-N-CA 122.736 2.291 . . . . 71.349999999999994 112.311 179.984 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -107.2 -26.26 5.79 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.723 -0.751 . . . . 65.319999999999993 112.449 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -78.44 -41.71 32.09 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.832 0.348 . . . . 51.43 110.954 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -77.54 -20.29 54.41 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.171 -0.468 . . . . 73.329999999999998 110.845 -179.917 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 86.1 m -86.67 -22.35 26.16 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.18 -0.464 . . . . 74.329999999999998 111.134 -179.951 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.491 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -91.76 -34.82 14.45 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.189 -0.459 . . . . 70.209999999999994 111.1 179.884 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -76.12 -11.97 60.03 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.182 -0.463 . . . . 75.120000000000005 110.883 -179.951 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 98.4 m -98.6 -35.33 10.24 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.229 -0.441 . . . . 73.5 111.138 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.504 ' O ' ' C ' ' A' ' 17' ' ' PHE . . . -103.87 -7.43 41.56 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.706 -0.759 . . . . 63.219999999999999 112.505 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.504 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.61 -54.28 0.15 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.957 0.408 . . . . 75.239999999999995 110.871 -179.874 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.443 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.4 m -116.01 -14.54 11.22 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.165 -0.471 . . . . 74.310000000000002 111.138 -179.886 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -82.45 -14.52 54.96 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.228 -0.442 . . . . 74.120000000000005 110.948 179.91 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.574 ' N ' ' HD2' ' A' ' 21' ' ' PRO . 14.0 t -75.77 -55.13 2.04 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.623 0.725 . . . . 74.329999999999998 111.149 179.818 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . 0.574 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.5 Cg_endo -69.81 -21.03 33.81 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.647 2.231 . . . . 72.439999999999998 112.375 179.934 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 44.9 t -99.35 -11.77 8.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.187 -0.46 . . . . 65.140000000000001 111.119 179.88 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -57.97 -20.98 42.07 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.219 -0.446 . . . . 65.439999999999998 110.889 -179.976 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 40.3 t0 -75.31 -6.5 50.18 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.149 -0.478 . . . . 72.25 110.873 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 27.1 m80 . . . . . 0 C--N 1.329 -0.303 0 CA-C-N 116.205 -0.452 . . . . 64.099999999999994 110.81 -179.984 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.231 0.096 0 CA-C-O 120.844 0.355 . . . . 73.140000000000001 111.124 . . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -65.48 -31.12 79.23 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.739 -0.743 . . . . 71.010000000000005 112.483 180.0 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 8.2 m120 -119.8 -5.51 10.14 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.894 0.378 . . . . 75.329999999999998 110.917 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 21.1 t -97.27 -11.4 8.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.124 -0.489 . . . . 70.549999999999997 111.138 179.904 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -116.17 37.41 3.42 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.703 -0.76 . . . . 61.420000000000002 112.471 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 2.4 tt -67.12 -32.42 73.54 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.861 0.362 . . . . 73.439999999999998 110.922 -179.936 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.494 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.0 OUTLIER -87.94 -59.5 0.26 Allowed Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.697 0.76 . . . . 75.010000000000005 110.868 -179.911 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.494 ' HD2' ' N ' ' A' ' 7' ' ' SER . 53.7 Cg_endo -69.75 -6.28 18.23 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.708 2.272 . . . . 71.209999999999994 112.337 179.963 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -108.72 -25.82 5.56 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.715 -0.755 . . . . 63.240000000000002 112.45 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.8 tt -79.13 -40.98 29.62 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.88 0.371 . . . . 75.140000000000001 110.955 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 30.0 t -78.7 -19.88 51.42 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.185 -0.461 . . . . 75.230000000000004 110.855 -179.919 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 92.3 m -86.77 -22.34 25.99 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.132 -0.486 . . . . 63.32 111.158 -179.974 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.494 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -91.88 -35.12 14.23 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.21 -0.45 . . . . 62.210000000000001 111.082 179.855 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -75.9 -12.14 60.1 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.236 -0.438 . . . . 74.129999999999995 110.898 -179.955 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 97.9 m -98.43 -35.3 10.32 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.196 -0.456 . . . . 74.040000000000006 111.153 179.96 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.509 ' O ' ' C ' ' A' ' 17' ' ' PHE . . . -103.99 -7.36 41.37 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.732 -0.747 . . . . 41.210000000000001 112.5 179.945 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.509 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.65 -54.2 0.15 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.915 0.388 . . . . 74.010000000000005 110.859 -179.87 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.44 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.2 m -116.15 -14.39 11.14 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.156 -0.475 . . . . 72.239999999999995 111.124 -179.912 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -82.56 -14.59 54.6 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.246 -0.434 . . . . 73.299999999999997 110.913 179.932 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.577 ' N ' ' HD2' ' A' ' 21' ' ' PRO . 13.4 t -75.74 -55.26 2.02 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.631 0.729 . . . . 71.099999999999994 111.11 179.847 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . 0.577 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.1 Cg_endo -69.78 -20.79 34.27 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.7 2.266 . . . . 62.240000000000002 112.316 179.989 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 44.1 t -99.98 -11.7 8.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.231 -0.44 . . . . 74.530000000000001 111.133 179.889 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -56.87 -21.57 30.41 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.197 -0.456 . . . . 72.25 110.884 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 36.3 t0 -120.03 -5.63 10.02 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.142 -0.481 . . . . 75.430000000000007 110.884 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 55.6 t-80 . . . . . 0 C--N 1.329 -0.314 0 CA-C-N 116.211 -0.45 . . . . 74.120000000000005 110.897 -179.996 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.457 -0.091 0 CA-C-O 120.779 0.323 . . . . 72.150000000000006 111.121 . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -59.26 -35.12 83.25 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.724 -0.75 . . . . 35.25 112.486 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 84.1 m-20 -103.97 -5.39 22.27 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.825 0.345 . . . . 72.310000000000002 110.889 -179.903 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 21.3 t -93.47 -11.36 9.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.206 -0.452 . . . . 71.310000000000002 111.112 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -101.37 29.76 11.83 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.773 -0.727 . . . . 72.299999999999997 112.478 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 1.9 tt -67.85 -29.15 68.21 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.813 0.34 . . . . 75.530000000000001 110.927 -179.89 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.498 ' H ' ' HD2' ' A' ' 8' ' ' PRO . 0.2 OUTLIER -89.6 -60.74 0.23 Allowed Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.66 0.743 . . . . 74.099999999999994 110.862 -179.983 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.498 ' HD2' ' H ' ' A' ' 7' ' ' SER . 53.3 Cg_endo -69.75 -6.62 19.04 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.649 2.233 . . . . 74.140000000000001 112.333 -179.976 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -108.0 -26.26 5.57 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.725 -0.75 . . . . 70.340000000000003 112.453 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -78.62 -41.81 30.57 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.848 0.356 . . . . 74.430000000000007 110.954 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 7.7 t -77.48 -20.53 54.22 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.157 -0.474 . . . . 70.040000000000006 110.874 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 98.0 m -86.65 -21.96 26.42 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.103 -0.498 . . . . 74.409999999999997 111.173 -179.918 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.488 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -92.06 -34.99 14.17 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.171 -0.468 . . . . 62.530000000000001 111.062 179.911 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -75.99 -11.72 60.01 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.214 -0.448 . . . . 74.540000000000006 110.892 -179.934 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 98.5 m -98.72 -35.38 10.18 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.164 -0.471 . . . . 64.420000000000002 111.162 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.501 ' O ' ' C ' ' A' ' 17' ' ' PHE . . . -103.94 -7.42 41.37 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.779 -0.724 . . . . 64.450000000000003 112.509 179.934 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.501 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.61 -54.27 0.15 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.913 0.387 . . . . 75.530000000000001 110.907 -179.869 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.445 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 20.6 m -115.91 -14.57 11.28 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.105 -0.498 . . . . 75.349999999999994 111.15 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -82.48 -14.33 55.2 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.211 -0.45 . . . . 74.150000000000006 110.933 179.952 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.57 ' N ' ' HD2' ' A' ' 21' ' ' PRO . 14.3 t -75.98 -55.22 1.92 Allowed Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.669 0.747 . . . . 75.409999999999997 111.169 179.789 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . 0.57 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.7 Cg_endo -69.74 -20.91 34.34 Favored 'Trans proline' 0 C--N 1.342 0.22 0 C-N-CA 122.631 2.221 . . . . 75.329999999999998 112.366 179.923 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 46.4 t -99.23 -12.17 8.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.212 -0.449 . . . . 75.310000000000002 111.124 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -58.07 -20.87 42.78 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.178 -0.465 . . . . 73.219999999999999 110.897 -179.936 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 25.3 t70 -76.46 -5.59 48.07 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.163 -0.471 . . . . 71.439999999999998 110.907 179.939 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.33 -0.263 0 CA-C-N 116.169 -0.469 . . . . 73.409999999999997 110.872 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 1.3 m . . . . . 0 N--CA 1.458 -0.06 0 CA-C-O 120.821 0.343 . . . . 73.209999999999994 111.151 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -56.32 -41.37 87.17 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.733 -0.746 . . . . 63.310000000000002 112.493 179.944 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 59.6 t30 -89.96 -5.45 56.7 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.907 0.384 . . . . 74.120000000000005 110.939 -179.909 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 21.2 t -98.68 -11.35 8.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.152 -0.477 . . . . 72.049999999999997 111.109 179.93 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -104.91 19.72 40.36 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.753 -0.737 . . . . 62.399999999999999 112.496 -179.998 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 5.2 tt -89.56 -5.1 57.53 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.822 0.344 . . . . 72.420000000000002 110.89 -179.896 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.572 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 0.5 OUTLIER -120.35 -66.72 0.02 OUTLIER Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.695 0.759 . . . . 70.329999999999998 110.904 -179.955 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.572 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 53.4 Cg_endo -69.75 -7.3 20.69 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.683 2.255 . . . . 73.340000000000003 112.32 -179.993 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -121.32 -15.21 4.67 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.726 -0.75 . . . . 33.340000000000003 112.483 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.1 tp -80.07 -40.72 27.07 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.841 0.353 . . . . 74.209999999999994 110.952 -179.932 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -78.41 -20.1 51.86 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.141 -0.481 . . . . 65.329999999999998 110.881 -179.944 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 87.9 m -86.21 -22.54 26.86 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.145 -0.479 . . . . 51.420000000000002 111.17 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.488 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -91.86 -35.34 14.12 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.19 -0.459 . . . . 73.329999999999998 111.14 179.839 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -75.87 -12.02 60.08 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.187 -0.46 . . . . 74.420000000000002 110.914 -179.972 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 97.7 m -98.64 -35.34 10.23 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.165 -0.47 . . . . 74.230000000000004 111.157 179.932 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.498 ' O ' ' C ' ' A' ' 17' ' ' PHE . . . -103.81 -7.38 41.84 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.711 -0.757 . . . . 73.319999999999993 112.468 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.498 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.7 -54.08 0.15 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.913 0.387 . . . . 72.299999999999997 110.824 -179.849 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.449 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.0 m -116.31 -14.74 11.03 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.194 -0.457 . . . . 74.140000000000001 111.131 -179.869 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -82.39 -14.64 54.87 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.218 -0.446 . . . . 74.230000000000004 110.947 179.938 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.575 ' N ' ' HD2' ' A' ' 21' ' ' PRO . 9.8 t -76.17 -55.31 1.81 Allowed Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.645 0.736 . . . . 72.319999999999993 111.138 179.848 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . 0.575 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 54.1 Cg_endo -69.74 -20.23 35.2 Favored 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 122.715 2.277 . . . . 74.549999999999997 112.364 179.922 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 45.1 t -100.67 -11.71 8.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.207 -0.451 . . . . 72.209999999999994 111.165 179.905 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -56.69 -21.7 29.62 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.18 -0.464 . . . . 71.420000000000002 110.878 -179.978 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 17.0 t70 -120.08 -5.93 9.99 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.17 -0.468 . . . . 70.109999999999999 110.845 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 1.3 t-80 . . . . . 0 C--N 1.329 -0.302 0 CA-C-N 116.174 -0.466 . . . . 62.549999999999997 110.815 -179.976 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.456 -0.135 0 CA-C-O 120.863 0.363 . . . . 71.230000000000004 111.143 . . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -62.19 -34.18 88.28 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.739 -0.743 . . . . 65.510000000000005 112.511 179.966 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 -112.48 -5.39 14.06 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.899 0.38 . . . . 74.549999999999997 110.908 -179.918 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 21.1 t -102.13 -11.36 8.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.168 -0.469 . . . . 75.239999999999995 111.114 179.913 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -100.61 22.11 41.15 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.705 -0.759 . . . . 75.200000000000003 112.489 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 3.9 tt -76.91 -5.2 47.54 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.834 0.349 . . . . 71.019999999999996 110.94 -179.921 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.574 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 0.5 OUTLIER -120.41 -66.62 0.02 OUTLIER Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.618 0.723 . . . . 74.140000000000001 110.855 -179.939 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.574 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 53.7 Cg_endo -69.81 -7.25 20.6 Favored 'Trans proline' 0 N--CA 1.466 -0.115 0 C-N-CA 122.673 2.249 . . . . 72.129999999999995 112.357 179.979 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -121.34 -15.18 4.67 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.685 -0.769 . . . . 71.329999999999998 112.479 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.1 tt -80.0 -40.9 26.91 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.851 0.358 . . . . 64.109999999999999 110.896 -179.902 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -78.24 -20.15 52.29 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.177 -0.465 . . . . 72.150000000000006 110.859 -179.918 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 81.8 m -86.15 -22.55 26.97 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.128 -0.487 . . . . 72.109999999999999 111.162 -179.929 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.494 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -91.91 -35.38 14.06 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.188 -0.46 . . . . 74.120000000000005 111.077 179.882 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -75.87 -11.98 60.07 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.247 -0.433 . . . . 64.340000000000003 110.925 -179.964 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 97.6 m -98.58 -35.39 10.23 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.171 -0.468 . . . . 70.120000000000005 111.163 179.89 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.494 ' O ' ' C ' ' A' ' 17' ' ' PHE . . . -103.8 -7.44 41.73 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.704 -0.76 . . . . 70.519999999999996 112.449 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.494 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.62 -54.23 0.15 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.907 0.384 . . . . 74.5 110.842 -179.846 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.448 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.1 m -116.05 -14.58 11.19 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.172 -0.467 . . . . 75.049999999999997 111.127 -179.864 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -82.46 -14.54 54.91 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.251 -0.431 . . . . 72.5 110.919 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.575 ' N ' ' HD2' ' A' ' 21' ' ' PRO . 13.6 t -75.85 -55.16 1.99 Allowed Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.649 0.738 . . . . 75.140000000000001 111.117 179.834 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . 0.575 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.5 Cg_endo -69.8 -20.82 34.15 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.652 2.235 . . . . 75.400000000000006 112.365 179.976 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 44.3 t -99.88 -11.81 8.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.194 -0.457 . . . . 75.140000000000001 111.116 179.909 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -56.9 -21.55 30.55 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.2 -0.455 . . . . 75.5 110.842 -179.932 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 25.1 t0 -120.02 -5.77 10.02 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.163 -0.472 . . . . 71.120000000000005 110.859 179.982 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 19.4 t-160 . . . . . 0 C--N 1.329 -0.315 0 CA-C-N 116.234 -0.439 . . . . 74.510000000000005 110.849 -179.98 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 11.9 m . . . . . 0 C--O 1.231 0.112 0 CA-C-O 120.82 0.343 . . . . 74.420000000000002 111.131 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -68.01 -24.28 74.48 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.737 -0.744 . . . . 75.340000000000003 112.532 179.923 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 6.7 m120 -109.68 -5.42 15.64 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.863 0.363 . . . . 72.120000000000005 110.894 -179.92 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 21.0 t -104.39 -11.37 9.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.176 -0.466 . . . . 75.349999999999994 111.111 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -98.09 22.17 42.24 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.757 -0.735 . . . . 64.299999999999997 112.49 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 4.6 mm? -81.53 -5.28 57.83 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.822 0.344 . . . . 72.109999999999999 110.933 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.568 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 0.5 OUTLIER -120.35 -66.61 0.02 OUTLIER Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.64 0.733 . . . . 73.329999999999998 110.877 -179.955 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.568 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 53.8 Cg_endo -69.79 -7.26 20.6 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.702 2.268 . . . . 72.030000000000001 112.347 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -121.37 -15.21 4.65 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.696 -0.764 . . . . 71.140000000000001 112.462 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 5.6 tp -80.05 -40.75 27.08 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.792 0.329 . . . . 64.150000000000006 110.911 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.9 t -78.38 -20.12 51.92 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.23 -0.441 . . . . 71.340000000000003 110.836 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 64.1 m -86.24 -22.42 26.89 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.159 -0.473 . . . . 73.049999999999997 111.183 -179.956 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.492 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -92.01 -35.32 14.03 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.18 -0.464 . . . . 71.340000000000003 111.073 179.876 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -75.87 -12.06 60.09 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.235 -0.439 . . . . 72.120000000000005 110.913 -179.98 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 97.7 m -98.55 -35.46 10.22 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.226 -0.443 . . . . 72.349999999999994 111.124 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.495 ' O ' ' C ' ' A' ' 17' ' ' PHE . . . -103.78 -7.4 41.87 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.743 -0.741 . . . . 62.200000000000003 112.489 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.495 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.6 -54.23 0.15 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.985 0.421 . . . . 71.299999999999997 110.933 -179.906 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.449 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.4 m -116.08 -14.45 11.18 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.128 -0.487 . . . . 75.510000000000005 111.182 -179.951 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -82.51 -14.54 54.79 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.222 -0.445 . . . . 73.519999999999996 110.941 179.919 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.575 ' N ' ' HD2' ' A' ' 21' ' ' PRO . 14.3 t -75.71 -55.16 2.06 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.595 0.712 . . . . 73.510000000000005 111.122 179.803 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . 0.575 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.7 Cg_endo -69.8 -21.0 33.9 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.615 2.21 . . . . 73.040000000000006 112.37 179.987 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 45.1 t -99.4 -11.74 8.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.208 -0.451 . . . . 74.540000000000006 111.097 179.911 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -57.94 -21.13 42.41 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.212 -0.449 . . . . 72.319999999999993 110.884 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 95.2 m-20 -103.17 -5.88 22.74 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.177 -0.465 . . . . 75.439999999999998 110.846 -179.989 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.33 -0.278 0 CA-C-N 116.233 -0.44 . . . . 73.409999999999997 110.887 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.457 -0.086 0 CA-C-O 120.856 0.36 . . . . 71.120000000000005 111.13 . . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -63.33 -29.09 73.47 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.735 -0.745 . . . . 55.439999999999998 112.482 -179.984 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 55.3 t30 -113.64 -5.49 13.38 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.853 0.359 . . . . 74.409999999999997 110.88 -179.893 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 21.1 t -103.47 -11.33 9.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.163 -0.471 . . . . 75.299999999999997 111.131 179.896 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -110.37 23.81 19.57 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.716 -0.754 . . . . 65.340000000000003 112.476 179.942 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 5.3 tt -83.52 -5.12 59.07 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.826 0.346 . . . . 73.129999999999995 110.923 -179.924 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.572 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 0.5 OUTLIER -120.36 -66.68 0.02 OUTLIER Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.702 0.763 . . . . 74.010000000000005 110.882 -179.959 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.572 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 54.4 Cg_endo -69.72 -7.32 20.75 Favored 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 122.682 2.255 . . . . 61.539999999999999 112.327 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -121.33 -15.24 4.66 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.721 -0.752 . . . . 71.310000000000002 112.439 -179.948 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.7 tt -80.05 -40.72 27.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.832 0.349 . . . . 73.310000000000002 110.946 -179.903 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -78.32 -20.14 52.07 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.201 -0.454 . . . . 74.129999999999995 110.913 -179.979 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 86.0 m -86.22 -22.48 26.88 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.086 -0.507 . . . . 73.140000000000001 111.105 -179.907 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.495 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -91.97 -35.34 14.04 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.214 -0.448 . . . . 73.519999999999996 111.051 179.892 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -75.87 -12.06 60.09 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.244 -0.434 . . . . 73.239999999999995 110.912 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 97.8 m -98.6 -35.31 10.25 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.202 -0.454 . . . . 71.319999999999993 111.176 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.492 ' O ' ' C ' ' A' ' 17' ' ' PHE . . . -103.83 -7.45 41.64 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.778 -0.725 . . . . 64.400000000000006 112.477 179.979 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.495 ' HB3' ' O ' ' A' ' 13' ' ' ALA . 1.4 p90 -29.57 -54.31 0.15 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.953 0.406 . . . . 73.450000000000003 110.889 -179.891 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.448 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.4 m -116.04 -14.46 11.21 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.126 -0.488 . . . . 74.430000000000007 111.146 -179.938 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -82.45 -14.57 54.87 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.248 -0.433 . . . . 72.430000000000007 110.937 179.913 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.571 ' N ' ' HD2' ' A' ' 21' ' ' PRO . 14.2 t -75.75 -55.14 2.05 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.629 0.728 . . . . 75.25 111.117 179.858 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . 0.571 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.8 Cg_endo -69.78 -21.07 33.91 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.67 2.246 . . . . 71.109999999999999 112.346 179.951 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 45.0 t -99.37 -11.75 8.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.234 -0.439 . . . . 72.420000000000002 111.151 179.905 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -57.95 -20.91 41.39 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.152 -0.476 . . . . 72.150000000000006 110.886 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -75.45 -6.31 49.45 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.126 -0.488 . . . . 73.409999999999997 110.886 179.971 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--N 1.329 -0.287 0 CA-C-N 116.187 -0.461 . . . . 75.319999999999993 110.83 179.983 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 48.6 m . . . . . 0 N--CA 1.458 -0.073 0 CA-C-O 120.796 0.331 . . . . 74.120000000000005 111.156 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -60.43 -32.74 78.53 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.73 -0.748 . . . . 53.240000000000002 112.486 179.95 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 16.8 m120 -105.1 -5.46 20.79 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.859 0.361 . . . . 71.299999999999997 110.844 -179.859 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 21.0 t -97.17 -11.33 8.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.193 -0.458 . . . . 74.010000000000005 111.149 179.911 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -95.62 20.15 51.02 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.754 -0.736 . . . . 60.109999999999999 112.487 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -84.03 -5.75 59.29 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.791 0.329 . . . . 72.230000000000004 110.872 -179.9 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.568 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 0.5 OUTLIER -120.4 -66.69 0.02 OUTLIER Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.647 0.737 . . . . 74.420000000000002 110.875 -179.955 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.568 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 54.3 Cg_endo -69.69 -7.28 20.62 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.676 2.251 . . . . 74.439999999999998 112.397 179.935 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -121.32 -15.27 4.65 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.749 -0.738 . . . . 71.329999999999998 112.48 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 5.2 tt -79.94 -40.89 27.15 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.838 0.352 . . . . 64.230000000000004 110.935 -179.929 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.7 t -78.28 -20.16 52.17 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.141 -0.481 . . . . 64.329999999999998 110.846 -179.899 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 85.6 m -86.19 -22.48 26.94 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.137 -0.483 . . . . 72.049999999999997 111.136 -179.929 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.493 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -91.92 -35.38 14.05 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.23 -0.441 . . . . 72.420000000000002 111.083 179.895 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -75.95 -11.95 60.06 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.185 -0.461 . . . . 74.340000000000003 110.882 -179.929 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 97.6 m -98.57 -35.45 10.22 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.213 -0.449 . . . . 72.040000000000006 111.155 179.901 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.495 ' O ' ' C ' ' A' ' 17' ' ' PHE . . . -103.75 -7.47 41.82 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.772 -0.727 . . . . 64.319999999999993 112.449 -179.979 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.495 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.5 p90 -29.59 -54.25 0.15 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.961 0.41 . . . . 73.450000000000003 110.886 -179.855 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.448 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.3 m -116.07 -14.5 11.19 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.116 -0.493 . . . . 74.010000000000005 111.133 -179.896 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -82.47 -14.59 54.79 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.234 -0.439 . . . . 74.519999999999996 110.893 179.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.574 ' N ' ' HD2' ' A' ' 21' ' ' PRO . 14.0 t -75.73 -55.13 2.06 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.605 0.717 . . . . 75.239999999999995 111.116 179.844 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . 0.574 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.4 Cg_endo -69.8 -21.06 33.84 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.696 2.264 . . . . 74.409999999999997 112.304 -179.982 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 44.7 t -99.41 -11.77 8.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.205 -0.452 . . . . 70.310000000000002 111.134 179.932 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -57.9 -20.96 40.92 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.178 -0.465 . . . . 75.219999999999999 110.933 179.964 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 81.7 m-20 -75.42 -6.36 49.65 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.129 -0.487 . . . . 73.120000000000005 110.852 179.969 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 26.8 t-80 . . . . . 0 C--N 1.329 -0.322 0 CA-C-N 116.187 -0.46 . . . . 72.120000000000005 110.871 179.983 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.231 0.085 0 CA-C-O 120.802 0.335 . . . . 75.109999999999999 111.108 . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -63.11 -40.29 99.01 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.769 -0.729 . . . . 65.299999999999997 112.46 179.963 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 29.8 m120 -109.71 -5.39 15.63 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.832 0.349 . . . . 74.409999999999997 110.872 -179.84 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 21.1 t -101.97 -11.33 8.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.162 -0.472 . . . . 63.109999999999999 111.142 179.883 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -101.42 26.22 25.32 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.726 -0.75 . . . . 61.240000000000002 112.521 179.922 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -83.18 -5.26 59.06 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.768 0.318 . . . . 73.450000000000003 110.902 -179.943 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.565 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 0.5 OUTLIER -120.32 -66.71 0.02 OUTLIER Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.7 0.762 . . . . 73.540000000000006 110.849 -179.948 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.565 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 54.1 Cg_endo -69.71 -7.29 20.67 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.747 2.298 . . . . 74.420000000000002 112.325 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -121.34 -15.23 4.66 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.735 -0.745 . . . . 72.219999999999999 112.479 179.988 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 2.1 tp -80.04 -40.76 27.07 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.821 0.344 . . . . 72.340000000000003 110.942 -179.937 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -78.37 -20.11 51.97 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.196 -0.456 . . . . 65.109999999999999 110.865 -179.955 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 40.0 m -86.22 -22.48 26.89 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.135 -0.484 . . . . 53.310000000000002 111.123 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.494 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -91.95 -35.34 14.05 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.222 -0.444 . . . . 73.400000000000006 111.076 179.896 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -75.93 -11.98 60.06 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.201 -0.454 . . . . 74.430000000000007 110.931 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 97.6 m -98.53 -35.46 10.23 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.179 -0.464 . . . . 75.230000000000004 111.154 179.892 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.494 ' O ' ' C ' ' A' ' 17' ' ' PHE . . . -103.78 -7.43 41.79 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.773 -0.727 . . . . 73.209999999999994 112.485 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.494 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.63 -54.27 0.15 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.852 0.358 . . . . 64.400000000000006 110.864 -179.893 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.449 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.4 m -116.01 -14.48 11.22 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.171 -0.468 . . . . 65.219999999999999 111.144 -179.922 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -82.51 -14.54 54.81 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.225 -0.443 . . . . 74.049999999999997 110.953 179.94 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.574 ' N ' ' HD2' ' A' ' 21' ' ' PRO . 14.1 t -75.79 -55.1 2.03 Favored Pre-proline 0 C--N 1.33 -0.251 0 CA-C-O 121.587 0.708 . . . . 73.450000000000003 111.118 179.838 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . 0.574 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.7 Cg_endo -69.79 -21.04 33.92 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.643 2.229 . . . . 75.219999999999999 112.336 179.978 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 45.2 t -99.4 -11.74 8.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.223 -0.444 . . . . 73.219999999999999 111.137 179.917 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -57.91 -20.93 40.89 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.145 -0.48 . . . . 74.200000000000003 110.918 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 10.4 t70 -75.4 -6.38 49.71 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.15 -0.477 . . . . 74.430000000000007 110.861 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--N 1.329 -0.319 0 CA-C-N 116.181 -0.463 . . . . 75.25 110.884 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.563 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.0 OUTLIER . . . . . 0 C--O 1.232 0.136 0 CA-C-O 121.677 0.751 . . . . 74.55 110.845 . . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 8' ' ' PRO . . . . . 0.563 ' HD2' ' N ' ' A' ' 7' ' ' SER . 54.4 Cg_endo -69.69 -4.89 14.89 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.678 2.252 . . . . 65.13 112.341 179.959 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -111.07 -26.33 4.7 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.72 -0.753 . . . . 65.3 112.503 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.4 tt -77.93 -40.96 37.92 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.856 0.36 . . . . 64.34 110.943 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 10.4 t -79.05 -19.41 51.46 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.17 -0.468 . . . . 62.02 110.898 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 96.9 m -86.87 -22.16 25.92 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.128 -0.487 . . . . 73.41 111.173 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.498 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -92.36 -35.29 13.8 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.214 -0.448 . . . . 63.55 111.094 179.876 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -76.07 -12.03 60.05 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.224 -0.444 . . . . 73.01 110.924 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 97.1 m -98.61 -35.26 10.27 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.158 -0.473 . . . . 71.15 111.175 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.818 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.89 -7.5 41.35 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.778 -0.725 . . . . 61.44 112.46 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.51 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.58 -54.36 0.15 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.943 0.401 . . . . 74.33 110.877 -179.859 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.445 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.4 m -115.92 -14.39 11.28 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.126 -0.488 . . . . 73.31 111.17 -179.916 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.437 HD13 ' HA ' ' A' ' 19' ' ' LEU . 4.0 mm? -82.46 -14.57 54.84 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.206 -0.452 . . . . 61.35 110.955 179.91 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.818 HG23 ' HA3' ' A' ' 16' ' ' GLY . 16.5 t -75.7 -55.03 2.1 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.612 0.72 . . . . 72.32 111.166 179.818 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.592 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 54.1 Cg_endo -69.79 -21.17 33.7 Favored 'Trans proline' 0 C--O 1.232 0.194 0 C-N-CA 122.695 2.264 . . . . 71.44 112.362 179.92 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.434 HG12 ' O ' ' A' ' 22' ' ' VAL . 44.4 t -99.29 -11.73 8.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.261 -0.427 . . . . 74.34 111.149 179.91 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.33 -0.246 0 CA-C-N 116.156 -0.474 . . . . 65.43 110.859 -179.994 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.56 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.0 OUTLIER . . . . . 0 C--O 1.232 0.142 0 CA-C-O 121.707 0.765 . . . . 74.55 110.861 . . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 8' ' ' PRO . . . . . 0.56 ' HD2' ' N ' ' A' ' 7' ' ' SER . 53.3 Cg_endo -69.74 -4.76 14.66 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.693 2.262 . . . . 75.11 112.319 -179.978 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -111.24 -26.01 4.78 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.783 -0.722 . . . . 71.5 112.539 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 3.6 tt -78.17 -41.07 35.86 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.819 0.343 . . . . 71.32 110.891 -179.888 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 4.9 t -79.2 -19.27 51.22 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.193 -0.458 . . . . 70.52 110.866 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 97.1 m -86.93 -22.25 25.75 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.133 -0.485 . . . . 71.41 111.11 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.499 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -92.33 -35.32 13.8 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.217 -0.447 . . . . 71.13 111.087 179.88 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -76.07 -11.89 60.02 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.219 -0.446 . . . . 70.43 110.941 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 98.4 m -98.59 -35.33 10.25 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.161 -0.472 . . . . 74.42 111.174 179.897 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.824 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.91 -7.42 41.45 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.739 -0.744 . . . . 61.31 112.536 179.938 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.511 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.59 -54.22 0.15 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.926 0.393 . . . . 73.25 110.889 -179.911 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.44 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.3 m -116.08 -14.58 11.18 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.132 -0.485 . . . . 60.1 111.129 -179.886 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -82.36 -14.57 55.04 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.237 -0.438 . . . . 73.52 110.96 179.946 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.824 HG23 ' HA3' ' A' ' 16' ' ' GLY . 14.3 t -75.76 -55.16 2.04 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-O 121.64 0.734 . . . . 60.04 111.099 179.843 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.592 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.7 Cg_endo -69.73 -21.1 34.09 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.692 2.261 . . . . 72.4 112.326 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.436 HG12 ' O ' ' A' ' 22' ' ' VAL . 45.3 t -99.37 -11.74 8.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.186 -0.461 . . . . 63.34 111.163 179.906 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.329 -0.284 0 CA-C-N 116.177 -0.465 . . . . 73.33 110.921 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.56 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.094 0 CA-C-O 121.639 0.733 . . . . 64.45 110.869 . . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 8' ' ' PRO . . . . . 0.56 ' HD2' ' N ' ' A' ' 7' ' ' SER . 54.1 Cg_endo -69.75 -4.94 15.04 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.671 2.248 . . . . 64.31 112.324 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -111.0 -26.09 4.82 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.765 -0.731 . . . . 71.15 112.469 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -78.04 -41.35 35.92 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.797 0.332 . . . . 60.53 110.945 -179.938 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -78.64 -19.67 52.08 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.197 -0.456 . . . . 74.42 110.861 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 97.4 m -86.55 -22.44 26.31 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.084 -0.507 . . . . 74.04 111.167 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.495 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -92.18 -35.29 13.92 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.185 -0.461 . . . . 60.31 111.088 179.914 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -76.02 -11.96 60.04 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.201 -0.454 . . . . 73.52 110.921 -179.967 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 98.8 m -98.66 -35.24 10.25 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.152 -0.476 . . . . 70.14 111.115 179.942 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.82 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.92 -7.5 41.28 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.746 -0.74 . . . . 74.44 112.466 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.51 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.6 -54.31 0.15 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.885 0.374 . . . . 72.03 110.894 -179.852 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.442 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.5 m -115.91 -14.43 11.28 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.166 -0.47 . . . . 73.22 111.14 -179.931 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.441 HD13 ' HA ' ' A' ' 19' ' ' LEU . 4.0 mm? -82.55 -14.39 54.97 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.232 -0.44 . . . . 65.31 110.889 179.989 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.82 HG23 ' HA3' ' A' ' 16' ' ' GLY . 15.2 t -75.95 -55.06 1.96 Allowed Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.607 0.717 . . . . 52.41 111.113 179.87 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.593 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 54.1 Cg_endo -69.72 -21.2 34.0 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.708 2.272 . . . . 71.41 112.374 179.909 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.436 HG12 ' O ' ' A' ' 22' ' ' VAL . 45.9 t -99.1 -11.98 8.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.24 -0.436 . . . . 74.15 111.118 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 116.156 -0.475 . . . . 71.33 110.892 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.562 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.6 OUTLIER . . . . . 0 C--O 1.231 0.126 0 CA-C-O 121.679 0.752 . . . . 73.21 110.857 . . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 8' ' ' PRO . . . . . 0.562 ' HD2' ' N ' ' A' ' 7' ' ' SER . 53.9 Cg_endo -69.7 -4.92 14.96 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.714 2.276 . . . . 71.24 112.358 179.991 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -111.11 -26.03 4.81 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.715 -0.755 . . . . 74.12 112.448 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -78.16 -41.07 35.96 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.81 0.338 . . . . 71.31 110.934 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -79.05 -19.48 51.26 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.161 -0.472 . . . . 52.02 110.861 -179.929 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 97.7 m -86.7 -22.39 26.07 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.175 -0.466 . . . . 73.4 111.13 -179.953 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.497 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -92.12 -35.43 13.88 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.265 -0.425 . . . . 41.44 111.147 179.84 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -75.99 -11.88 60.03 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.206 -0.452 . . . . 63.3 110.938 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 97.6 m -98.69 -35.4 10.19 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.194 -0.457 . . . . 65.02 111.149 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.843 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.83 -7.35 41.84 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.707 -0.758 . . . . 60.25 112.523 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.51 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.68 -54.24 0.15 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.893 0.378 . . . . 73.21 110.869 -179.869 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.438 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 20.5 m -116.08 -14.91 11.17 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.17 -0.468 . . . . 72.02 111.188 -179.936 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 10.5 mp -82.23 -15.02 54.57 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.179 -0.464 . . . . 74.11 110.937 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.843 HG23 ' HA3' ' A' ' 16' ' ' GLY . 9.4 t -75.44 -55.35 2.14 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.588 0.709 . . . . 63.34 111.103 179.839 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.587 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 54.2 Cg_endo -69.71 -20.54 34.94 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.687 2.258 . . . . 70.23 112.371 179.936 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.443 HG12 ' O ' ' A' ' 22' ' ' VAL . 45.9 t -100.26 -11.76 8.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.179 -0.464 . . . . 75.42 111.118 179.919 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.329 -0.289 0 CA-C-N 116.194 -0.457 . . . . 70.04 110.906 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.558 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.126 0 CA-C-O 121.664 0.745 . . . . 53.24 110.837 . . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 8' ' ' PRO . . . . . 0.558 ' HD2' ' N ' ' A' ' 7' ' ' SER . 53.0 Cg_endo -69.81 -4.9 15.0 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.686 2.257 . . . . 75.3 112.312 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -111.1 -25.99 4.83 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.718 -0.753 . . . . 71.15 112.467 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -77.87 -41.65 36.08 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.813 0.34 . . . . 72.12 110.923 -179.947 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -78.5 -19.67 52.5 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.218 -0.446 . . . . 60.03 110.858 -179.917 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 97.6 m -86.51 -22.41 26.41 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.093 -0.503 . . . . 74.14 111.161 -179.944 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.496 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -92.16 -35.35 13.9 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.209 -0.45 . . . . 51.43 111.092 179.851 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -75.99 -12.08 60.07 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.202 -0.453 . . . . 73.43 110.887 -179.915 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 98.3 m -98.71 -35.27 10.22 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.218 -0.446 . . . . 64.12 111.167 179.905 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.846 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.84 -7.35 41.81 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.747 -0.74 . . . . 72.33 112.442 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.507 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.72 -54.13 0.15 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.966 0.412 . . . . 73.4 110.937 -179.872 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.44 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 20.5 m -116.24 -14.99 11.07 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.138 -0.483 . . . . 61.42 111.114 -179.924 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 10.5 mp -82.26 -15.1 54.22 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.261 -0.427 . . . . 75.55 110.885 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.846 HG23 ' HA3' ' A' ' 16' ' ' GLY . 7.3 t -75.64 -55.34 2.05 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.644 0.735 . . . . 74.22 111.134 179.868 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.587 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.5 Cg_endo -69.78 -20.27 34.96 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.699 2.266 . . . . 75.5 112.324 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.437 HG12 ' O ' ' A' ' 22' ' ' VAL . 47.2 t -100.31 -11.66 8.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.217 -0.447 . . . . 73.44 111.164 179.922 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--N 1.33 -0.25 0 CA-C-N 116.162 -0.472 . . . . 63.54 110.895 -179.978 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.559 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.5 OUTLIER . . . . . 0 C--O 1.232 0.163 0 CA-C-O 121.668 0.747 . . . . 63.31 110.844 . . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 8' ' ' PRO . . . . . 0.559 ' HD2' ' N ' ' A' ' 7' ' ' SER . 53.2 Cg_endo -69.79 -4.87 14.92 Favored 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.676 2.251 . . . . 63.4 112.351 179.992 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -110.93 -26.22 4.78 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.747 -0.739 . . . . 75.34 112.486 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.491 HD13 ' C ' ' A' ' 10' ' ' LEU . 3.0 tm? -78.42 -40.44 35.93 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.808 0.337 . . . . 71.11 110.916 -179.914 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 5.4 t -79.47 -19.49 49.68 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.258 -0.428 . . . . 42.34 110.843 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 97.8 m -86.81 -22.27 25.96 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.131 -0.486 . . . . 64.25 111.149 -179.927 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.496 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -92.15 -35.44 13.86 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.252 -0.431 . . . . 60.21 111.072 179.883 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -75.83 -12.02 60.09 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.236 -0.438 . . . . 74.4 110.896 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 97.7 m -98.53 -35.43 10.24 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.21 -0.45 . . . . 75.44 111.152 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.826 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.85 -7.43 41.61 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.732 -0.747 . . . . 54.31 112.457 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.509 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.67 -54.22 0.15 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.947 0.403 . . . . 73.52 110.844 -179.835 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.445 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.3 m -116.01 -14.54 11.22 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.198 -0.456 . . . . 74.12 111.159 -179.901 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.428 HD13 ' HA ' ' A' ' 19' ' ' LEU . 4.0 mm? -82.5 -14.52 54.84 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.224 -0.444 . . . . 64.43 110.945 179.962 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.826 HG23 ' HA3' ' A' ' 16' ' ' GLY . 14.1 t -75.77 -55.11 2.04 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.6 0.714 . . . . 73.34 111.144 179.799 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.591 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.7 Cg_endo -69.81 -21.08 33.77 Favored 'Trans proline' 0 C--O 1.232 0.18 0 C-N-CA 122.695 2.263 . . . . 74.43 112.298 179.964 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.433 HG12 ' O ' ' A' ' 22' ' ' VAL . 44.8 t -99.34 -11.78 8.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.273 -0.422 . . . . 72.2 111.124 179.934 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--N 1.33 -0.276 0 CA-C-N 116.178 -0.464 . . . . 74.11 110.914 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.558 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.3 OUTLIER . . . . . 0 C--O 1.231 0.11 0 CA-C-O 121.649 0.738 . . . . 61.32 110.854 . . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 8' ' ' PRO . . . . . 0.558 ' HD2' ' N ' ' A' ' 7' ' ' SER . 54.2 Cg_endo -69.75 -4.55 14.25 Favored 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 122.666 2.244 . . . . 75.34 112.392 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -111.44 -25.93 4.75 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.775 -0.726 . . . . 42.41 112.442 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 2.5 tt -78.49 -40.82 34.25 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.826 0.346 . . . . 70.33 110.907 -179.901 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -79.23 -19.5 50.54 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.213 -0.448 . . . . 61.42 110.867 -179.933 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 94.8 m -86.81 -22.28 25.95 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.134 -0.485 . . . . 72.21 111.121 -179.924 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.495 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -92.11 -35.44 13.89 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.213 -0.449 . . . . 72.43 111.055 179.89 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -75.79 -12.06 60.1 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.271 -0.422 . . . . 74.04 110.889 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 98.9 m -98.6 -35.32 10.25 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.229 -0.441 . . . . 60.03 111.109 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.841 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.96 -7.32 41.51 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.725 -0.75 . . . . 62.21 112.487 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.508 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.74 -54.11 0.15 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.953 0.406 . . . . 63.54 110.885 -179.89 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.442 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.2 m -116.27 -14.65 11.06 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.152 -0.476 . . . . 73.12 111.127 -179.905 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.429 HD13 ' HA ' ' A' ' 19' ' ' LEU . 4.1 mm? -82.5 -14.66 54.62 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.25 -0.432 . . . . 75.11 110.907 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.841 HG23 ' HA3' ' A' ' 16' ' ' GLY . 10.4 t -76.04 -55.21 1.89 Allowed Pre-proline 0 C--N 1.33 -0.257 0 CA-C-O 121.599 0.714 . . . . 71.31 111.098 179.819 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.59 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.6 Cg_endo -69.76 -20.33 34.97 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.711 2.274 . . . . 74.41 112.31 179.994 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.435 HG12 ' O ' ' A' ' 22' ' ' VAL . 46.9 t -100.07 -11.69 8.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.236 -0.438 . . . . 74.44 111.131 179.937 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 5.8 tp10 . . . . . 0 C--N 1.329 -0.29 0 CA-C-N 116.16 -0.473 . . . . 74.44 110.899 179.967 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.555 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.0 OUTLIER . . . . . 0 C--O 1.232 0.136 0 CA-C-O 121.613 0.721 . . . . 61.42 110.838 . . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 8' ' ' PRO . . . . . 0.555 ' HD2' ' N ' ' A' ' 7' ' ' SER . 54.4 Cg_endo -69.74 -4.88 14.91 Favored 'Trans proline' 0 C--N 1.341 0.153 0 C-N-CA 122.645 2.23 . . . . 73.14 112.382 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -111.06 -26.68 4.56 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.767 -0.73 . . . . 72.31 112.468 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -77.69 -40.59 40.91 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.826 0.346 . . . . 64.3 110.908 -179.906 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -79.35 -19.44 50.26 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.161 -0.472 . . . . 64.24 110.825 -179.878 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 92.1 m -87.38 -21.45 25.63 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.141 -0.481 . . . . 54.23 111.138 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.5 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -92.86 -35.44 13.37 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.181 -0.463 . . . . 72.23 111.071 179.922 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -76.3 -12.02 60.01 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.255 -0.43 . . . . 74.44 110.956 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 94.3 m -98.5 -35.37 10.27 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.153 -0.476 . . . . 74.45 111.152 179.922 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.831 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.83 -7.37 41.8 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.727 -0.749 . . . . 74.12 112.514 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.508 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.71 -54.24 0.15 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.924 0.392 . . . . 74.45 110.873 -179.914 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.44 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.2 m -116.01 -14.8 11.22 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.148 -0.478 . . . . 61.25 111.134 -179.905 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -82.29 -14.6 55.16 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.21 -0.45 . . . . 75.44 110.909 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.831 HG23 ' HA3' ' A' ' 16' ' ' GLY . 10.0 t -76.53 -55.39 1.63 Allowed Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.651 0.739 . . . . 71.32 111.108 179.875 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.586 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.4 Cg_endo -69.75 -19.83 35.64 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.712 2.274 . . . . 75.13 112.327 179.962 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.432 HG12 ' O ' ' A' ' 22' ' ' VAL . 41.6 t -102.3 -11.92 8.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.195 -0.457 . . . . 63.12 111.12 179.911 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.9 tp10 . . . . . 0 C--N 1.329 -0.286 0 CA-C-N 116.207 -0.451 . . . . 54.25 110.897 -179.959 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.562 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.6 OUTLIER . . . . . 0 C--O 1.231 0.095 0 CA-C-O 121.726 0.774 . . . . 73.13 110.916 . . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 8' ' ' PRO . . . . . 0.562 ' HD2' ' N ' ' A' ' 7' ' ' SER . 53.7 Cg_endo -69.76 -4.78 14.73 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.704 2.269 . . . . 62.24 112.359 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -111.23 -25.96 4.81 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.685 -0.769 . . . . 75.43 112.481 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 6.4 tp -80.15 -37.15 34.06 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.849 0.357 . . . . 73.41 110.939 -179.962 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -82.52 -19.22 39.1 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.173 -0.467 . . . . 43.52 110.874 -179.926 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 99.5 m -86.56 -23.19 25.92 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.124 -0.489 . . . . 63.34 111.123 -179.922 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.505 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -92.62 -34.83 13.84 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.194 -0.457 . . . . 73.14 111.11 179.895 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 14' ' ' LEU . . . . . 0.533 HD23 ' O ' ' A' ' 14' ' ' LEU . 1.0 OUTLIER -76.65 -11.8 59.91 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.203 -0.453 . . . . 43.32 110.933 179.987 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 98.9 m -99.14 -34.26 10.45 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.182 -0.463 . . . . 64.32 111.149 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.838 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -104.73 -7.77 38.46 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.731 -0.747 . . . . 74.33 112.537 179.921 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.509 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.5 p90 -29.81 -54.84 0.16 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.9 0.381 . . . . 75.54 110.887 -179.924 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.435 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 20.0 m -115.57 -14.95 11.48 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.175 -0.466 . . . . 74.12 111.135 -179.882 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 10.1 mp -82.11 -15.2 54.25 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.204 -0.453 . . . . 72.31 110.937 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.838 HG23 ' HA3' ' A' ' 16' ' ' GLY . 8.5 t -75.68 -55.29 2.04 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.6 0.714 . . . . 72.2 111.162 179.826 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.588 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.4 Cg_endo -69.79 -20.19 35.0 Favored 'Trans proline' 0 C--O 1.231 0.143 0 C-N-CA 122.669 2.246 . . . . 62.43 112.323 179.934 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.447 HG12 ' O ' ' A' ' 22' ' ' VAL . 47.4 t -100.41 -11.65 8.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.228 -0.442 . . . . 72.12 111.142 179.943 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 116.14 -0.482 . . . . 70.13 110.884 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.516 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.086 0 CA-C-O 121.704 0.764 . . . . 72.55 110.858 . . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 8' ' ' PRO . . . . . 0.516 ' HD2' ' N ' ' A' ' 7' ' ' SER . 53.3 Cg_endo -69.77 -6.84 19.57 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.704 2.269 . . . . 73.41 112.351 -179.998 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -107.17 -27.42 5.34 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.696 -0.764 . . . . 65.42 112.513 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -78.71 -40.01 34.86 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.823 0.344 . . . . 64.21 110.908 -179.942 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -79.59 -19.22 49.84 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.194 -0.457 . . . . 63.52 110.875 -179.925 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 47.3 m -86.48 -23.31 26.02 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.117 -0.492 . . . . 73.0 111.148 -179.95 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.5 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -91.59 -35.5 14.21 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.203 -0.453 . . . . 70.21 111.094 179.877 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -75.91 -11.8 60.03 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.247 -0.433 . . . . 73.33 110.909 179.999 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 98.3 m -98.45 -35.57 10.23 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.22 -0.445 . . . . 73.22 111.146 179.936 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.808 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.95 -7.47 41.26 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.783 -0.722 . . . . 53.41 112.483 179.98 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.502 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.71 -54.05 0.15 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.877 0.37 . . . . 73.4 110.878 -179.832 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.444 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.5 m -116.01 -14.62 11.22 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.151 -0.477 . . . . 52.32 111.133 -179.922 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.413 HD13 ' HA ' ' A' ' 19' ' ' LEU . 4.0 mm? -82.26 -14.78 54.93 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.19 -0.459 . . . . 63.45 110.893 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.808 HG23 ' HA3' ' A' ' 16' ' ' GLY . 13.7 t -75.74 -55.32 2.01 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.625 0.726 . . . . 74.13 111.112 179.918 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.578 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.6 Cg_endo -69.71 -20.95 34.41 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.735 2.29 . . . . 73.25 112.324 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.433 HG12 ' O ' ' A' ' 22' ' ' VAL . 45.2 t -99.65 -11.78 8.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.2 -0.454 . . . . 63.14 111.145 179.94 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.329 -0.308 0 CA-C-N 116.172 -0.467 . . . . 64.52 110.866 -179.989 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.512 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.094 0 CA-C-O 121.668 0.747 . . . . 33.13 110.882 . . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 8' ' ' PRO . . . . . 0.512 ' HD2' ' N ' ' A' ' 7' ' ' SER . 53.8 Cg_endo -69.73 -5.65 16.69 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.695 2.263 . . . . 70.31 112.348 179.962 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -109.17 -26.5 5.17 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.724 -0.751 . . . . 63.1 112.501 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 6.5 tt -78.62 -41.68 30.94 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.79 0.329 . . . . 73.45 110.902 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 2.2 t -77.96 -19.88 53.72 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.211 -0.45 . . . . 75.44 110.844 -179.91 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 91.8 m -86.74 -22.71 25.81 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.137 -0.483 . . . . 54.44 111.137 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.494 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -91.65 -34.75 14.56 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.224 -0.444 . . . . 51.23 111.124 179.835 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -76.44 -11.53 59.9 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.197 -0.456 . . . . 74.21 110.913 -179.967 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 96.7 m -99.01 -35.44 10.05 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.191 -0.459 . . . . 65.04 111.117 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.817 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.57 -7.63 42.02 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.714 -0.755 . . . . 54.44 112.479 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.512 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.57 -54.21 0.15 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.914 0.388 . . . . 73.24 110.843 -179.87 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.44 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 23.3 m -116.05 -14.75 11.19 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.168 -0.469 . . . . 74.11 111.159 -179.92 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -82.21 -14.46 55.53 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.229 -0.441 . . . . 61.45 110.901 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.817 HG23 ' HA3' ' A' ' 16' ' ' GLY . 14.9 t -75.71 -55.14 2.06 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.603 0.716 . . . . 54.43 111.097 179.839 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.592 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.7 Cg_endo -69.69 -21.18 34.17 Favored 'Trans proline' 0 C--O 1.231 0.15 0 C-N-CA 122.729 2.286 . . . . 71.35 112.329 179.961 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.435 HG12 ' O ' ' A' ' 22' ' ' VAL . 44.6 t -99.43 -11.88 8.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.224 -0.444 . . . . 72.13 111.104 179.965 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--N 1.329 -0.313 0 CA-C-N 116.216 -0.447 . . . . 34.03 110.884 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.524 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.3 OUTLIER . . . . . 0 C--O 1.232 0.16 0 CA-C-O 121.637 0.732 . . . . 61.42 110.856 . . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 8' ' ' PRO . . . . . 0.524 ' HD2' ' N ' ' A' ' 7' ' ' SER . 53.3 Cg_endo -69.75 -7.45 21.08 Favored 'Trans proline' 0 C--N 1.341 0.14 0 C-N-CA 122.736 2.291 . . . . 71.35 112.311 179.984 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -107.2 -26.26 5.79 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.723 -0.751 . . . . 65.32 112.449 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -78.44 -41.71 32.09 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.832 0.348 . . . . 51.43 110.954 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -77.54 -20.29 54.41 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.171 -0.468 . . . . 73.33 110.845 -179.917 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 86.1 m -86.67 -22.35 26.16 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.18 -0.464 . . . . 62.34 111.134 -179.951 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.492 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -91.76 -34.82 14.45 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.189 -0.459 . . . . 62.35 111.1 179.884 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -76.12 -11.97 60.03 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.182 -0.463 . . . . 74.44 110.883 -179.951 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 98.4 m -98.6 -35.33 10.24 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.229 -0.441 . . . . 73.5 111.138 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.823 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.87 -7.43 41.56 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.706 -0.759 . . . . 63.22 112.505 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.504 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.61 -54.28 0.15 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.957 0.408 . . . . 75.24 110.871 -179.874 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.443 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.4 m -116.01 -14.54 11.22 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.165 -0.471 . . . . 74.31 111.138 -179.886 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.424 HD13 ' HA ' ' A' ' 19' ' ' LEU . 4.0 mm? -82.45 -14.52 54.96 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.228 -0.442 . . . . 65.31 110.948 179.91 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.823 HG23 ' HA3' ' A' ' 16' ' ' GLY . 14.0 t -75.77 -55.13 2.04 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.623 0.725 . . . . 54.1 111.149 179.818 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.586 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.5 Cg_endo -69.81 -21.03 33.81 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.647 2.231 . . . . 72.44 112.375 179.934 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.433 HG12 ' O ' ' A' ' 22' ' ' VAL . 44.9 t -99.35 -11.77 8.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.187 -0.46 . . . . 65.14 111.119 179.88 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--N 1.329 -0.308 0 CA-C-N 116.219 -0.446 . . . . 55.44 110.889 -179.976 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.51 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.123 0 CA-C-O 121.697 0.76 . . . . 75.01 110.868 . . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 8' ' ' PRO . . . . . 0.51 ' HD2' ' N ' ' A' ' 7' ' ' SER . 53.7 Cg_endo -69.75 -6.28 18.23 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.708 2.272 . . . . 71.21 112.337 179.963 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -108.72 -25.82 5.56 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.715 -0.755 . . . . 63.24 112.45 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.8 tt -79.13 -40.98 29.62 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.88 0.371 . . . . 71.31 110.955 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 30.0 t -78.7 -19.88 51.42 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.185 -0.461 . . . . 73.21 110.855 -179.919 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 92.3 m -86.77 -22.34 25.99 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.132 -0.486 . . . . 60.34 111.158 -179.974 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.495 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -91.88 -35.12 14.23 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.21 -0.45 . . . . 54.23 111.082 179.855 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -75.9 -12.14 60.1 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.236 -0.438 . . . . 74.13 110.898 -179.955 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 97.9 m -98.43 -35.3 10.32 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.196 -0.456 . . . . 52.13 111.153 179.96 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.829 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.99 -7.36 41.37 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.732 -0.747 . . . . 41.21 112.5 179.945 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.509 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.65 -54.2 0.15 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.915 0.388 . . . . 73.41 110.859 -179.87 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.44 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.2 m -116.15 -14.39 11.14 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.156 -0.475 . . . . 62.42 111.124 -179.912 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.402 ' HA ' HD13 ' A' ' 19' ' ' LEU . 4.0 mm? -82.56 -14.59 54.6 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.246 -0.434 . . . . 73.3 110.913 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.829 HG23 ' HA3' ' A' ' 16' ' ' GLY . 13.4 t -75.74 -55.26 2.02 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.631 0.729 . . . . 55.54 111.11 179.847 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.591 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.1 Cg_endo -69.78 -20.79 34.27 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.7 2.266 . . . . 60.15 112.316 179.989 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.439 HG12 ' O ' ' A' ' 22' ' ' VAL . 44.1 t -99.98 -11.7 8.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.231 -0.44 . . . . 63.24 111.133 179.889 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--N 1.329 -0.306 0 CA-C-N 116.197 -0.456 . . . . 72.25 110.884 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.479 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.231 0.131 0 CA-C-O 121.66 0.743 . . . . 73.51 110.862 . . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 8' ' ' PRO . . . . . 0.479 ' HD2' ' N ' ' A' ' 7' ' ' SER . 53.3 Cg_endo -69.75 -6.62 19.04 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.649 2.233 . . . . 74.14 112.333 -179.976 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -108.0 -26.26 5.57 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.725 -0.75 . . . . 53.32 112.453 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -78.62 -41.81 30.57 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.848 0.356 . . . . 74.43 110.954 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 7.7 t -77.48 -20.53 54.22 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.157 -0.474 . . . . 70.04 110.874 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 98.0 m -86.65 -21.96 26.42 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.103 -0.498 . . . . 63.12 111.173 -179.918 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.488 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -92.06 -34.99 14.17 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.171 -0.468 . . . . 40.33 111.062 179.911 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -75.99 -11.72 60.01 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.214 -0.448 . . . . 65.41 110.892 -179.934 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 98.5 m -98.72 -35.38 10.18 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.164 -0.471 . . . . 64.42 111.162 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.815 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.94 -7.42 41.37 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.779 -0.724 . . . . 63.11 112.509 179.934 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.501 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.61 -54.27 0.15 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.913 0.387 . . . . 75.53 110.907 -179.869 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.445 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 20.6 m -115.91 -14.57 11.28 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.105 -0.498 . . . . 74.23 111.15 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.426 HD13 ' HA ' ' A' ' 19' ' ' LEU . 4.0 mm? -82.48 -14.33 55.2 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.211 -0.45 . . . . 65.42 110.933 179.952 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.815 HG23 ' HA3' ' A' ' 16' ' ' GLY . 14.3 t -75.98 -55.22 1.92 Allowed Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.669 0.747 . . . . 75.41 111.169 179.789 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.582 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.7 Cg_endo -69.74 -20.91 34.34 Favored 'Trans proline' 0 C--N 1.342 0.22 0 C-N-CA 122.631 2.221 . . . . 75.33 112.366 179.923 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.43 HG12 ' O ' ' A' ' 22' ' ' VAL . 46.4 t -99.23 -12.17 8.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.212 -0.449 . . . . 75.31 111.124 179.922 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.178 -0.465 . . . . 73.22 110.897 -179.936 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.572 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 0.5 OUTLIER . . . . . 0 C--O 1.231 0.094 0 CA-C-O 121.695 0.759 . . . . 61.32 110.904 . . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 8' ' ' PRO . . . . . 0.572 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 53.4 Cg_endo -69.75 -7.3 20.69 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.683 2.255 . . . . 72.15 112.32 -179.993 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -121.32 -15.21 4.67 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.726 -0.75 . . . . 22.32 112.483 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.1 tp -80.07 -40.72 27.07 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.841 0.353 . . . . 70.5 110.952 -179.932 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -78.41 -20.1 51.86 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.141 -0.481 . . . . 65.33 110.881 -179.944 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 87.9 m -86.21 -22.54 26.86 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.145 -0.479 . . . . 51.42 111.17 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.492 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -91.86 -35.34 14.12 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.19 -0.459 . . . . 71.01 111.14 179.839 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -75.87 -12.02 60.08 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.187 -0.46 . . . . 72.04 110.914 -179.972 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 97.7 m -98.64 -35.34 10.23 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.165 -0.47 . . . . 73.24 111.157 179.932 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.844 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.81 -7.38 41.84 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.711 -0.757 . . . . 42.23 112.468 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.498 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.7 -54.08 0.15 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.913 0.387 . . . . 72.11 110.824 -179.849 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.449 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.0 m -116.31 -14.74 11.03 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.194 -0.457 . . . . 74.14 111.131 -179.869 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -82.39 -14.64 54.87 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.218 -0.446 . . . . 44.5 110.947 179.938 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.844 HG23 ' HA3' ' A' ' 16' ' ' GLY . 9.8 t -76.17 -55.31 1.81 Allowed Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.645 0.736 . . . . 71.52 111.138 179.848 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.586 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 54.1 Cg_endo -69.74 -20.23 35.2 Favored 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 122.715 2.277 . . . . 51.44 112.364 179.922 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.447 HG12 ' O ' ' A' ' 22' ' ' VAL . 45.1 t -100.67 -11.71 8.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.207 -0.451 . . . . 64.33 111.165 179.905 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--N 1.329 -0.286 0 CA-C-N 116.18 -0.464 . . . . 71.42 110.878 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.574 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 0.5 OUTLIER . . . . . 0 C--O 1.232 0.151 0 CA-C-O 121.618 0.723 . . . . 74.14 110.855 . . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 8' ' ' PRO . . . . . 0.574 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 53.7 Cg_endo -69.81 -7.25 20.6 Favored 'Trans proline' 0 N--CA 1.466 -0.115 0 C-N-CA 122.673 2.249 . . . . 54.41 112.357 179.979 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -121.34 -15.18 4.67 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.685 -0.769 . . . . 71.33 112.479 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.1 tt -80.0 -40.9 26.91 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.851 0.358 . . . . 54.2 110.896 -179.902 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -78.24 -20.15 52.29 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.177 -0.465 . . . . 72.15 110.859 -179.918 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 81.8 m -86.15 -22.55 26.97 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.128 -0.487 . . . . 71.44 111.162 -179.929 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.497 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -91.91 -35.38 14.06 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.188 -0.46 . . . . 73.2 111.077 179.882 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -75.87 -11.98 60.07 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.247 -0.433 . . . . 64.34 110.925 -179.964 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 97.6 m -98.58 -35.39 10.23 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.171 -0.468 . . . . 61.42 111.163 179.89 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.821 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.8 -7.44 41.73 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.704 -0.76 . . . . 70.52 112.449 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.497 ' HB3' ' O ' ' A' ' 13' ' ' ALA . 1.4 p90 -29.62 -54.23 0.15 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.907 0.384 . . . . 74.5 110.842 -179.846 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.448 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.1 m -116.05 -14.58 11.19 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.172 -0.467 . . . . 75.05 111.127 -179.864 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.413 ' HA ' HD13 ' A' ' 19' ' ' LEU . 4.0 mm? -82.46 -14.54 54.91 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.251 -0.431 . . . . 72.5 110.919 179.975 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.821 HG23 ' HA3' ' A' ' 16' ' ' GLY . 13.6 t -75.85 -55.16 1.99 Allowed Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.649 0.738 . . . . 72.24 111.117 179.834 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.586 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.5 Cg_endo -69.8 -20.82 34.15 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.652 2.235 . . . . 75.4 112.365 179.976 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.441 HG12 ' O ' ' A' ' 22' ' ' VAL . 44.3 t -99.88 -11.81 8.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.194 -0.457 . . . . 73.22 111.116 179.909 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.2 -0.455 . . . . 75.5 110.842 -179.932 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.568 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 0.5 OUTLIER . . . . . 0 C--O 1.232 0.138 0 CA-C-O 121.64 0.733 . . . . 63.02 110.877 . . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 8' ' ' PRO . . . . . 0.568 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 53.8 Cg_endo -69.79 -7.26 20.6 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.702 2.268 . . . . 72.03 112.347 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -121.37 -15.21 4.65 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.696 -0.764 . . . . 35.31 112.462 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 5.6 tp -80.05 -40.75 27.08 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.792 0.329 . . . . 64.15 110.911 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.9 t -78.38 -20.12 51.92 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.23 -0.441 . . . . 71.34 110.836 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 64.1 m -86.24 -22.42 26.89 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.159 -0.473 . . . . 73.05 111.183 -179.956 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.495 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -92.01 -35.32 14.03 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.18 -0.464 . . . . 71.34 111.073 179.876 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -75.87 -12.06 60.09 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.235 -0.439 . . . . 71.21 110.913 -179.98 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 97.7 m -98.55 -35.46 10.22 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.226 -0.443 . . . . 60.25 111.124 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.824 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.78 -7.4 41.87 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.743 -0.741 . . . . 62.2 112.489 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.495 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.6 -54.23 0.15 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.985 0.421 . . . . 71.3 110.933 -179.906 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.449 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.4 m -116.08 -14.45 11.18 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.128 -0.487 . . . . 74.54 111.182 -179.951 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.445 HD13 ' HA ' ' A' ' 19' ' ' LEU . 4.0 mm? -82.51 -14.54 54.79 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.222 -0.445 . . . . 70.25 110.941 179.919 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.824 HG23 ' HA3' ' A' ' 16' ' ' GLY . 14.3 t -75.71 -55.16 2.06 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.595 0.712 . . . . 63.41 111.122 179.803 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.585 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.7 Cg_endo -69.8 -21.0 33.9 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.615 2.21 . . . . 72.43 112.37 179.987 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.444 HG12 ' O ' ' A' ' 22' ' ' VAL . 45.1 t -99.4 -11.74 8.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.208 -0.451 . . . . 73.44 111.097 179.911 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.329 -0.3 0 CA-C-N 116.212 -0.449 . . . . 72.32 110.884 179.971 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.572 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 0.5 OUTLIER . . . . . 0 C--O 1.231 0.091 0 CA-C-O 121.702 0.763 . . . . 72.22 110.882 . . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 8' ' ' PRO . . . . . 0.572 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 54.4 Cg_endo -69.72 -7.32 20.75 Favored 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 122.682 2.255 . . . . 61.54 112.327 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -121.33 -15.24 4.66 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.721 -0.752 . . . . 71.31 112.439 -179.948 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.7 tt -80.05 -40.72 27.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.832 0.349 . . . . 65.54 110.946 -179.903 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -78.32 -20.14 52.07 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.201 -0.454 . . . . 62.43 110.913 -179.979 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 86.0 m -86.22 -22.48 26.88 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.086 -0.507 . . . . 62.4 111.105 -179.907 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.498 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -91.97 -35.34 14.04 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.214 -0.448 . . . . 73.52 111.051 179.892 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -75.87 -12.06 60.09 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.244 -0.434 . . . . 73.24 110.912 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 97.8 m -98.6 -35.31 10.25 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.202 -0.454 . . . . 70.15 111.176 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.825 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.83 -7.45 41.64 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.778 -0.725 . . . . 60.13 112.477 179.979 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.498 ' HB3' ' O ' ' A' ' 13' ' ' ALA . 1.4 p90 -29.57 -54.31 0.15 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.953 0.406 . . . . 73.2 110.889 -179.891 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.448 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.4 m -116.04 -14.46 11.21 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.126 -0.488 . . . . 74.43 111.146 -179.938 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.446 HD13 ' HA ' ' A' ' 19' ' ' LEU . 4.0 mm? -82.45 -14.57 54.87 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.248 -0.433 . . . . 72.35 110.937 179.913 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.825 HG23 ' HA3' ' A' ' 16' ' ' GLY . 14.2 t -75.75 -55.14 2.05 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.629 0.728 . . . . 73.21 111.117 179.858 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.582 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.8 Cg_endo -69.78 -21.07 33.91 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.67 2.246 . . . . 64.52 112.346 179.951 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.445 HG12 ' O ' ' A' ' 22' ' ' VAL . 45.0 t -99.37 -11.75 8.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.234 -0.439 . . . . 72.1 111.151 179.905 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--N 1.329 -0.284 0 CA-C-N 116.152 -0.476 . . . . 72.15 110.886 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.568 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 0.5 OUTLIER . . . . . 0 C--O 1.231 0.105 0 CA-C-O 121.647 0.737 . . . . 53.43 110.875 . . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 8' ' ' PRO . . . . . 0.568 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 54.3 Cg_endo -69.69 -7.28 20.62 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.676 2.251 . . . . 74.44 112.397 179.935 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -121.32 -15.27 4.65 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.749 -0.738 . . . . 71.33 112.48 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 5.2 tt -79.94 -40.89 27.15 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.838 0.352 . . . . 63.02 110.935 -179.929 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.7 t -78.28 -20.16 52.17 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.141 -0.481 . . . . 64.33 110.846 -179.899 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 85.6 m -86.19 -22.48 26.94 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.137 -0.483 . . . . 72.05 111.136 -179.929 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.497 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -91.92 -35.38 14.05 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.23 -0.441 . . . . 71.24 111.083 179.895 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -75.95 -11.95 60.06 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.185 -0.461 . . . . 73.13 110.882 -179.929 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 97.6 m -98.57 -35.45 10.22 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.213 -0.449 . . . . 71.3 111.155 179.901 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.825 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.75 -7.47 41.82 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.772 -0.727 . . . . 53.34 112.449 -179.979 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.497 ' HB3' ' O ' ' A' ' 13' ' ' ALA . 1.5 p90 -29.59 -54.25 0.15 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.961 0.41 . . . . 65.53 110.886 -179.855 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.448 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.3 m -116.07 -14.5 11.19 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.116 -0.493 . . . . 74.01 111.133 -179.896 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.446 HD13 ' HA ' ' A' ' 19' ' ' LEU . 4.0 mm? -82.47 -14.59 54.79 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.234 -0.439 . . . . 74.52 110.893 179.958 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.825 HG23 ' HA3' ' A' ' 16' ' ' GLY . 14.0 t -75.73 -55.13 2.06 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.605 0.717 . . . . 75.24 111.116 179.844 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.584 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.4 Cg_endo -69.8 -21.06 33.84 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.696 2.264 . . . . 74.41 112.304 -179.982 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.444 HG12 ' O ' ' A' ' 22' ' ' VAL . 44.7 t -99.41 -11.77 8.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.205 -0.452 . . . . 70.31 111.134 179.932 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.33 -0.279 0 CA-C-N 116.178 -0.465 . . . . 75.22 110.933 179.964 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.565 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 0.5 OUTLIER . . . . . 0 C--O 1.231 0.103 0 CA-C-O 121.7 0.762 . . . . 64.44 110.849 . . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 8' ' ' PRO . . . . . 0.565 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 54.1 Cg_endo -69.71 -7.29 20.67 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.747 2.298 . . . . 70.32 112.325 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -121.34 -15.23 4.66 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.735 -0.745 . . . . 23.21 112.479 179.988 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 2.1 tp -80.04 -40.76 27.07 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.821 0.344 . . . . 72.34 110.942 -179.937 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -78.37 -20.11 51.97 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.196 -0.456 . . . . 43.53 110.865 -179.955 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 40.0 m -86.22 -22.48 26.89 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.135 -0.484 . . . . 53.31 111.123 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.496 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -91.95 -35.34 14.05 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.222 -0.444 . . . . 71.15 111.076 179.896 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -75.93 -11.98 60.06 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.201 -0.454 . . . . 62.51 110.931 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 97.6 m -98.53 -35.46 10.23 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.179 -0.464 . . . . 75.23 111.154 179.892 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.825 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.78 -7.43 41.79 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.773 -0.727 . . . . 71.42 112.485 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.496 ' HB3' ' O ' ' A' ' 13' ' ' ALA . 1.4 p90 -29.63 -54.27 0.15 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.852 0.358 . . . . 64.4 110.864 -179.893 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.449 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.4 m -116.01 -14.48 11.22 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.171 -0.468 . . . . 51.22 111.144 -179.922 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.445 HD13 ' HA ' ' A' ' 19' ' ' LEU . 4.0 mm? -82.51 -14.54 54.81 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.225 -0.443 . . . . 53.44 110.953 179.94 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.825 HG23 ' HA3' ' A' ' 16' ' ' GLY . 14.1 t -75.79 -55.1 2.03 Favored Pre-proline 0 C--N 1.33 -0.251 0 CA-C-O 121.587 0.708 . . . . 60.13 111.118 179.838 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.585 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.7 Cg_endo -69.79 -21.04 33.92 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.643 2.229 . . . . 61.43 112.336 179.978 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.443 HG12 ' O ' ' A' ' 22' ' ' VAL . 45.2 t -99.4 -11.74 8.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.223 -0.444 . . . . 52.22 111.137 179.917 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--N 1.33 -0.26 0 CA-C-N 116.145 -0.48 . . . . 74.2 110.918 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 12.5 m . . . . . 0 N--CA 1.458 -0.058 0 CA-C-O 120.841 0.353 . . . . 61.23 111.105 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -62.63 -21.7 63.1 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.705 -0.76 . . . . 73.21 112.538 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' ASN . . . . . 0.473 ' HA ' HD23 ' A' ' 6' ' ' LEU . 61.0 m-20 -115.07 -5.31 12.47 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.876 0.37 . . . . 75.4 110.889 -179.895 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 21.0 t -94.31 -11.37 8.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.175 -0.466 . . . . 62.45 111.138 179.915 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -110.74 34.84 5.13 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.773 -0.727 . . . . 61.24 112.501 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.473 HD23 ' HA ' ' A' ' 3' ' ' ASN . 3.6 mm? -88.42 -75.5 0.42 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.788 0.328 . . . . 72.14 110.87 -179.878 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.563 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.0 OUTLIER -69.09 -56.8 8.31 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.677 0.751 . . . . 74.55 110.845 -179.91 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.563 ' HD2' ' N ' ' A' ' 7' ' ' SER . 54.4 Cg_endo -69.69 -4.89 14.89 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.678 2.252 . . . . 65.13 112.341 179.959 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -111.07 -26.33 4.7 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.72 -0.753 . . . . 65.3 112.503 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.4 tt -77.93 -40.96 37.92 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.856 0.36 . . . . 64.34 110.943 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 10.4 t -79.05 -19.41 51.46 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.17 -0.468 . . . . 62.02 110.898 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 96.9 m -86.87 -22.16 25.92 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.128 -0.487 . . . . 73.41 111.173 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.498 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -92.36 -35.29 13.8 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.214 -0.448 . . . . 63.55 111.094 179.876 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -76.07 -12.03 60.05 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.224 -0.444 . . . . 73.01 110.924 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 97.1 m -98.61 -35.26 10.27 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.158 -0.473 . . . . 71.15 111.175 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.818 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.89 -7.5 41.35 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.778 -0.725 . . . . 61.44 112.46 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.51 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.58 -54.36 0.15 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.943 0.401 . . . . 74.33 110.877 -179.859 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.445 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.4 m -115.92 -14.39 11.28 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.126 -0.488 . . . . 73.31 111.17 -179.916 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.437 HD13 ' HA ' ' A' ' 19' ' ' LEU . 4.0 mm? -82.46 -14.57 54.84 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.206 -0.452 . . . . 61.35 110.955 179.91 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.818 HG23 ' HA3' ' A' ' 16' ' ' GLY . 16.5 t -75.7 -55.03 2.1 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.612 0.72 . . . . 72.32 111.166 179.818 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.592 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 54.1 Cg_endo -69.79 -21.17 33.7 Favored 'Trans proline' 0 C--O 1.232 0.194 0 C-N-CA 122.695 2.264 . . . . 71.44 112.362 179.92 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.434 HG12 ' O ' ' A' ' 22' ' ' VAL . 44.4 t -99.29 -11.73 8.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.261 -0.427 . . . . 74.34 111.149 179.91 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -58.11 -21.18 45.19 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.156 -0.474 . . . . 65.43 110.859 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 10.1 t70 -102.47 -6.01 23.4 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.201 -0.454 . . . . 72.13 110.884 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 25.6 t-80 . . . . . 0 C--N 1.329 -0.319 0 CA-C-N 116.179 -0.464 . . . . 73.1 110.862 -179.965 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.458 -0.057 0 CA-C-O 120.786 0.327 . . . . 54.54 111.122 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -56.61 -40.77 88.49 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.73 -0.747 . . . . 65.54 112.434 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 27.8 m120 -109.04 -5.41 16.04 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.835 0.35 . . . . 52.44 110.875 -179.892 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 21.3 t -92.54 -11.38 9.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.217 -0.447 . . . . 62.32 111.123 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -119.59 28.46 6.47 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.729 -0.748 . . . . 74.25 112.471 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -85.31 -74.59 0.4 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.831 0.348 . . . . 61.41 110.924 -179.959 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.56 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.0 OUTLIER -68.85 -56.87 8.66 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.707 0.765 . . . . 74.55 110.861 -179.976 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.56 ' HD2' ' N ' ' A' ' 7' ' ' SER . 53.3 Cg_endo -69.74 -4.76 14.66 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.693 2.262 . . . . 75.11 112.319 -179.978 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -111.24 -26.01 4.78 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.783 -0.722 . . . . 71.5 112.539 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 3.6 tt -78.17 -41.07 35.86 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.819 0.343 . . . . 71.32 110.891 -179.888 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 4.9 t -79.2 -19.27 51.22 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.193 -0.458 . . . . 70.52 110.866 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 97.1 m -86.93 -22.25 25.75 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.133 -0.485 . . . . 71.41 111.11 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.499 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -92.33 -35.32 13.8 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.217 -0.447 . . . . 71.13 111.087 179.88 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -76.07 -11.89 60.02 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.219 -0.446 . . . . 70.43 110.941 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 98.4 m -98.59 -35.33 10.25 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.161 -0.472 . . . . 74.42 111.174 179.897 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.824 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.91 -7.42 41.45 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.739 -0.744 . . . . 61.31 112.536 179.938 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.511 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.59 -54.22 0.15 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.926 0.393 . . . . 73.25 110.889 -179.911 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.44 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.3 m -116.08 -14.58 11.18 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.132 -0.485 . . . . 60.1 111.129 -179.886 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -82.36 -14.57 55.04 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.237 -0.438 . . . . 73.52 110.96 179.946 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.824 HG23 ' HA3' ' A' ' 16' ' ' GLY . 14.3 t -75.76 -55.16 2.04 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-O 121.64 0.734 . . . . 60.04 111.099 179.843 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.592 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.7 Cg_endo -69.73 -21.1 34.09 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.692 2.261 . . . . 72.4 112.326 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.436 HG12 ' O ' ' A' ' 22' ' ' VAL . 45.3 t -99.37 -11.74 8.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.186 -0.461 . . . . 63.34 111.163 179.906 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -58.04 -21.05 43.52 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.177 -0.465 . . . . 73.33 110.921 -179.978 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 26.7 t70 -103.2 -5.79 22.79 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.125 -0.489 . . . . 63.41 110.883 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 17.9 t-80 . . . . . 0 C--N 1.33 -0.266 0 CA-C-N 116.199 -0.455 . . . . 74.04 110.891 -179.942 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.457 -0.113 0 CA-C-O 120.827 0.346 . . . . 52.12 111.187 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -64.98 -34.76 90.75 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.701 -0.762 . . . . 43.33 112.461 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 5.5 t-20 -119.72 -5.59 10.18 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.851 0.358 . . . . 52.31 110.897 -179.877 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.4 HG12 ' O ' ' A' ' 4' ' ' VAL . 21.2 t -97.35 -11.34 8.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.176 -0.465 . . . . 63.31 111.109 179.933 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -117.15 36.12 3.86 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.685 -0.769 . . . . 74.45 112.487 179.962 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 2.9 tt -85.06 -72.72 0.47 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.816 0.341 . . . . 73.3 110.959 -179.968 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.56 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.0 OUTLIER -68.97 -56.82 8.46 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.639 0.733 . . . . 64.45 110.869 -179.939 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.56 ' HD2' ' N ' ' A' ' 7' ' ' SER . 54.1 Cg_endo -69.75 -4.94 15.04 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.671 2.248 . . . . 64.31 112.324 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -111.0 -26.09 4.82 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.765 -0.731 . . . . 71.15 112.469 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -78.04 -41.35 35.92 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.797 0.332 . . . . 60.53 110.945 -179.938 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -78.64 -19.67 52.08 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.197 -0.456 . . . . 74.42 110.861 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 97.4 m -86.55 -22.44 26.31 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.084 -0.507 . . . . 74.04 111.167 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.495 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -92.18 -35.29 13.92 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.185 -0.461 . . . . 60.31 111.088 179.914 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -76.02 -11.96 60.04 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.201 -0.454 . . . . 73.52 110.921 -179.967 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 98.8 m -98.66 -35.24 10.25 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.152 -0.476 . . . . 70.14 111.115 179.942 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.82 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.92 -7.5 41.28 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.746 -0.74 . . . . 74.44 112.466 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.51 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.6 -54.31 0.15 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.885 0.374 . . . . 72.03 110.894 -179.852 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.442 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.5 m -115.91 -14.43 11.28 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.166 -0.47 . . . . 73.22 111.14 -179.931 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.441 HD13 ' HA ' ' A' ' 19' ' ' LEU . 4.0 mm? -82.55 -14.39 54.97 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.232 -0.44 . . . . 65.31 110.889 179.989 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.82 HG23 ' HA3' ' A' ' 16' ' ' GLY . 15.2 t -75.95 -55.06 1.96 Allowed Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.607 0.717 . . . . 52.41 111.113 179.87 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.593 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 54.1 Cg_endo -69.72 -21.2 34.0 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.708 2.272 . . . . 71.41 112.374 179.909 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.436 HG12 ' O ' ' A' ' 22' ' ' VAL . 45.9 t -99.1 -11.98 8.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.24 -0.436 . . . . 74.15 111.118 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -58.23 -20.76 44.35 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.156 -0.475 . . . . 71.33 110.892 -179.968 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -76.72 -5.11 46.67 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.148 -0.478 . . . . 71.02 110.891 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.329 -0.301 0 CA-C-N 116.179 -0.464 . . . . 71.11 110.871 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.457 -0.097 0 CA-C-O 120.852 0.358 . . . . 74.22 111.168 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -68.22 -23.44 74.78 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.765 -0.731 . . . . 60.24 112.474 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 68.2 m-20 -114.07 -5.46 13.1 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.81 0.338 . . . . 72.0 110.858 -179.874 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 21.2 t -107.07 -11.28 10.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.243 -0.435 . . . . 72.42 111.145 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -117.62 37.06 3.43 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.754 -0.736 . . . . 43.34 112.444 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 23.6 tp -88.89 -75.74 0.42 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.837 0.351 . . . . 54.31 110.882 -179.916 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.562 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.6 OUTLIER -69.0 -56.88 8.33 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-O 121.679 0.752 . . . . 73.21 110.857 -179.912 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.562 ' HD2' ' N ' ' A' ' 7' ' ' SER . 53.9 Cg_endo -69.7 -4.92 14.96 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.714 2.276 . . . . 71.24 112.358 179.991 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -111.11 -26.03 4.81 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.715 -0.755 . . . . 74.12 112.448 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -78.16 -41.07 35.96 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.81 0.338 . . . . 71.31 110.934 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -79.05 -19.48 51.26 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.161 -0.472 . . . . 52.02 110.861 -179.929 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 97.7 m -86.7 -22.39 26.07 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.175 -0.466 . . . . 73.4 111.13 -179.953 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.497 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -92.12 -35.43 13.88 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.265 -0.425 . . . . 41.44 111.147 179.84 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -75.99 -11.88 60.03 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.206 -0.452 . . . . 63.3 110.938 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 97.6 m -98.69 -35.4 10.19 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.194 -0.457 . . . . 65.02 111.149 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.843 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.83 -7.35 41.84 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.707 -0.758 . . . . 60.25 112.523 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.51 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.68 -54.24 0.15 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.893 0.378 . . . . 73.21 110.869 -179.869 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.438 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 20.5 m -116.08 -14.91 11.17 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.17 -0.468 . . . . 72.02 111.188 -179.936 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 10.5 mp -82.23 -15.02 54.57 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.179 -0.464 . . . . 74.11 110.937 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.843 HG23 ' HA3' ' A' ' 16' ' ' GLY . 9.4 t -75.44 -55.35 2.14 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.588 0.709 . . . . 63.34 111.103 179.839 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.587 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 54.2 Cg_endo -69.71 -20.54 34.94 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.687 2.258 . . . . 70.23 112.371 179.936 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.443 HG12 ' O ' ' A' ' 22' ' ' VAL . 45.9 t -100.26 -11.76 8.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.179 -0.464 . . . . 75.42 111.118 179.919 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -56.69 -21.65 29.26 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.194 -0.457 . . . . 70.04 110.906 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 91.8 m-20 -120.0 -5.95 10.03 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.183 -0.462 . . . . 53.51 110.867 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 116.165 -0.471 . . . . 74.33 110.863 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.457 -0.092 0 CA-C-O 120.872 0.368 . . . . 74.33 111.144 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -64.49 -34.8 90.88 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.806 -0.711 . . . . 53.1 112.453 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 2.6 t-20 -88.26 -5.66 58.24 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.856 0.36 . . . . 72.33 110.877 -179.846 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.401 HG12 ' O ' ' A' ' 4' ' ' VAL . 21.1 t -91.1 -11.4 9.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.147 -0.479 . . . . 63.11 111.087 179.923 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -110.12 33.61 5.9 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.775 -0.726 . . . . 43.41 112.534 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -86.12 -74.17 0.43 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.812 0.339 . . . . 73.41 110.854 -179.828 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.558 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.0 OUTLIER -68.7 -56.74 9.17 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.664 0.745 . . . . 53.24 110.837 -179.897 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.558 ' HD2' ' N ' ' A' ' 7' ' ' SER . 53.0 Cg_endo -69.81 -4.9 15.0 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.686 2.257 . . . . 75.3 112.312 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -111.1 -25.99 4.83 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.718 -0.753 . . . . 71.15 112.467 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -77.87 -41.65 36.08 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.813 0.34 . . . . 72.12 110.923 -179.947 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -78.5 -19.67 52.5 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.218 -0.446 . . . . 60.03 110.858 -179.917 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 97.6 m -86.51 -22.41 26.41 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.093 -0.503 . . . . 74.14 111.161 -179.944 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.496 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -92.16 -35.35 13.9 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.209 -0.45 . . . . 51.43 111.092 179.851 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -75.99 -12.08 60.07 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.202 -0.453 . . . . 73.43 110.887 -179.915 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 98.3 m -98.71 -35.27 10.22 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.218 -0.446 . . . . 64.12 111.167 179.905 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.846 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.84 -7.35 41.81 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.747 -0.74 . . . . 72.33 112.442 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.507 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.72 -54.13 0.15 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.966 0.412 . . . . 73.4 110.937 -179.872 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.44 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 20.5 m -116.24 -14.99 11.07 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.138 -0.483 . . . . 61.42 111.114 -179.924 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 10.5 mp -82.26 -15.1 54.22 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.261 -0.427 . . . . 75.55 110.885 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.846 HG23 ' HA3' ' A' ' 16' ' ' GLY . 7.3 t -75.64 -55.34 2.05 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.644 0.735 . . . . 74.22 111.134 179.868 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.587 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.5 Cg_endo -69.78 -20.27 34.96 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.699 2.266 . . . . 75.5 112.324 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.437 HG12 ' O ' ' A' ' 22' ' ' VAL . 47.2 t -100.31 -11.66 8.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.217 -0.447 . . . . 73.44 111.164 179.922 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -57.81 -20.99 39.73 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.162 -0.472 . . . . 63.54 110.895 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -74.96 -6.72 50.83 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.14 -0.482 . . . . 52.31 110.855 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 2.1 t60 . . . . . 0 C--N 1.33 -0.28 0 CA-C-N 116.236 -0.438 . . . . 64.11 110.849 -179.953 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 4.0 m . . . . . 0 N--CA 1.457 -0.107 0 CA-C-O 120.82 0.343 . . . . 50.22 111.147 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -60.95 -42.29 99.67 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.774 -0.727 . . . . 70.15 112.513 179.935 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' ASN . . . . . 0.554 ' HA ' HD23 ' A' ' 6' ' ' LEU . 2.6 m120 -95.19 -5.48 43.82 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.861 0.363 . . . . 72.22 110.912 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 20.9 t -86.47 -11.4 11.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.185 -0.462 . . . . 73.41 111.135 179.921 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -116.97 37.04 3.49 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.762 -0.732 . . . . 74.04 112.502 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.554 HD23 ' HA ' ' A' ' 3' ' ' ASN . 1.7 mm? -88.65 -75.68 0.42 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.865 0.364 . . . . 74.33 110.949 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.559 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.5 OUTLIER -68.93 -56.81 8.59 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 121.668 0.747 . . . . 63.31 110.844 -179.924 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.559 ' HD2' ' N ' ' A' ' 7' ' ' SER . 53.2 Cg_endo -69.79 -4.87 14.92 Favored 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.676 2.251 . . . . 63.4 112.351 179.992 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -110.93 -26.22 4.78 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.747 -0.739 . . . . 75.34 112.486 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.491 HD13 ' C ' ' A' ' 10' ' ' LEU . 3.0 tm? -78.42 -40.44 35.93 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.808 0.337 . . . . 71.11 110.916 -179.914 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 5.4 t -79.47 -19.49 49.68 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.258 -0.428 . . . . 42.34 110.843 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 97.8 m -86.81 -22.27 25.96 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.131 -0.486 . . . . 64.25 111.149 -179.927 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.496 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -92.15 -35.44 13.86 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.252 -0.431 . . . . 60.21 111.072 179.883 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -75.83 -12.02 60.09 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.236 -0.438 . . . . 74.4 110.896 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 97.7 m -98.53 -35.43 10.24 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.21 -0.45 . . . . 75.44 111.152 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.826 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.85 -7.43 41.61 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.732 -0.747 . . . . 54.31 112.457 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.509 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.67 -54.22 0.15 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.947 0.403 . . . . 73.52 110.844 -179.835 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.445 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.3 m -116.01 -14.54 11.22 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.198 -0.456 . . . . 74.12 111.159 -179.901 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.428 HD13 ' HA ' ' A' ' 19' ' ' LEU . 4.0 mm? -82.5 -14.52 54.84 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.224 -0.444 . . . . 64.43 110.945 179.962 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.826 HG23 ' HA3' ' A' ' 16' ' ' GLY . 14.1 t -75.77 -55.11 2.04 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.6 0.714 . . . . 73.34 111.144 179.799 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.591 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.7 Cg_endo -69.81 -21.08 33.77 Favored 'Trans proline' 0 C--O 1.232 0.18 0 C-N-CA 122.695 2.263 . . . . 74.43 112.298 179.964 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.433 HG12 ' O ' ' A' ' 22' ' ' VAL . 44.8 t -99.34 -11.78 8.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.273 -0.422 . . . . 72.2 111.124 179.934 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -57.93 -20.98 41.55 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.178 -0.464 . . . . 74.11 110.914 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 87.7 m-20 -75.54 -6.26 49.39 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.136 -0.484 . . . . 75.22 110.862 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 8.8 t-160 . . . . . 0 C--N 1.329 -0.294 0 CA-C-N 116.204 -0.453 . . . . 75.32 110.88 -179.962 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.457 -0.083 0 CA-C-O 120.799 0.333 . . . . 72.55 111.16 . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -59.17 -36.73 89.96 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.767 -0.73 . . . . 73.3 112.434 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 9.8 m120 -95.3 -5.7 42.98 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.863 0.363 . . . . 71.43 110.874 -179.857 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.403 HG12 ' O ' ' A' ' 4' ' ' VAL . 21.2 t -91.69 -11.18 9.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.196 -0.457 . . . . 54.03 111.181 179.882 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -109.8 33.66 5.92 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.752 -0.737 . . . . 64.4 112.481 179.964 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 1.1 tt -86.29 -74.87 0.4 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.85 0.357 . . . . 71.51 110.901 -179.912 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.558 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.3 OUTLIER -68.89 -56.93 8.49 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.649 0.738 . . . . 61.32 110.854 -179.947 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.558 ' HD2' ' N ' ' A' ' 7' ' ' SER . 54.2 Cg_endo -69.75 -4.55 14.25 Favored 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 122.666 2.244 . . . . 75.34 112.392 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -111.44 -25.93 4.75 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.775 -0.726 . . . . 42.41 112.442 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 2.5 tt -78.49 -40.82 34.25 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.826 0.346 . . . . 70.33 110.907 -179.901 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -79.23 -19.5 50.54 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.213 -0.448 . . . . 61.42 110.867 -179.933 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 94.8 m -86.81 -22.28 25.95 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.134 -0.485 . . . . 72.21 111.121 -179.924 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.495 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -92.11 -35.44 13.89 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.213 -0.449 . . . . 72.43 111.055 179.89 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -75.79 -12.06 60.1 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.271 -0.422 . . . . 74.04 110.889 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 98.9 m -98.6 -35.32 10.25 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.229 -0.441 . . . . 60.03 111.109 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.841 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.96 -7.32 41.51 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.725 -0.75 . . . . 62.21 112.487 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.508 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.74 -54.11 0.15 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.953 0.406 . . . . 63.54 110.885 -179.89 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.442 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.2 m -116.27 -14.65 11.06 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.152 -0.476 . . . . 73.12 111.127 -179.905 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.429 HD13 ' HA ' ' A' ' 19' ' ' LEU . 4.1 mm? -82.5 -14.66 54.62 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.25 -0.432 . . . . 75.11 110.907 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.841 HG23 ' HA3' ' A' ' 16' ' ' GLY . 10.4 t -76.04 -55.21 1.89 Allowed Pre-proline 0 C--N 1.33 -0.257 0 CA-C-O 121.599 0.714 . . . . 71.31 111.098 179.819 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.59 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.6 Cg_endo -69.76 -20.33 34.97 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.711 2.274 . . . . 74.41 112.31 179.994 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.435 HG12 ' O ' ' A' ' 22' ' ' VAL . 46.9 t -100.07 -11.69 8.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.236 -0.438 . . . . 74.44 111.131 179.937 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 5.8 tp10 -58.64 -24.3 60.88 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.16 -0.473 . . . . 74.44 110.899 179.967 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 51.7 m-20 -76.5 -5.5 47.78 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.168 -0.469 . . . . 71.05 110.898 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 7.1 t-80 . . . . . 0 C--N 1.33 -0.272 0 CA-C-N 116.144 -0.48 . . . . 73.54 110.823 -179.972 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.457 -0.103 0 CA-C-O 120.827 0.346 . . . . 75.43 111.118 . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 2' ' ' GLY . . . . . 0.566 ' O ' HD23 ' A' ' 6' ' ' LEU . . . -70.08 -28.81 71.17 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.717 -0.754 . . . . 72.11 112.508 179.95 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 81.0 m-20 -114.03 -5.53 13.13 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.856 0.36 . . . . 53.23 110.92 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.408 HG12 ' O ' ' A' ' 4' ' ' VAL . 21.2 t -105.52 -10.71 9.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.189 -0.46 . . . . 54.55 111.122 179.901 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -119.11 30.32 5.88 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.726 -0.75 . . . . 51.34 112.49 179.998 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.566 HD23 ' O ' ' A' ' 2' ' ' GLY . 0.2 OUTLIER -85.29 -68.71 0.71 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.818 0.342 . . . . 73.15 110.917 -179.872 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.555 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.0 OUTLIER -70.54 -56.8 6.06 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.613 0.721 . . . . 61.42 110.838 -179.948 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.555 ' HD2' ' N ' ' A' ' 7' ' ' SER . 54.4 Cg_endo -69.74 -4.88 14.91 Favored 'Trans proline' 0 C--N 1.341 0.153 0 C-N-CA 122.645 2.23 . . . . 73.14 112.382 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -111.06 -26.68 4.56 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.767 -0.73 . . . . 72.31 112.468 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -77.69 -40.59 40.91 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.826 0.346 . . . . 64.3 110.908 -179.906 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -79.35 -19.44 50.26 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.161 -0.472 . . . . 64.24 110.825 -179.878 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 92.1 m -87.38 -21.45 25.63 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.141 -0.481 . . . . 54.23 111.138 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.5 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -92.86 -35.44 13.37 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.181 -0.463 . . . . 72.23 111.071 179.922 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -76.3 -12.02 60.01 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.255 -0.43 . . . . 74.44 110.956 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 94.3 m -98.5 -35.37 10.27 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.153 -0.476 . . . . 74.45 111.152 179.922 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.831 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.83 -7.37 41.8 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.727 -0.749 . . . . 74.12 112.514 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.508 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.71 -54.24 0.15 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.924 0.392 . . . . 74.45 110.873 -179.914 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.44 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.2 m -116.01 -14.8 11.22 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.148 -0.478 . . . . 61.25 111.134 -179.905 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -82.29 -14.6 55.16 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.21 -0.45 . . . . 75.44 110.909 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.831 HG23 ' HA3' ' A' ' 16' ' ' GLY . 10.0 t -76.53 -55.39 1.63 Allowed Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.651 0.739 . . . . 71.32 111.108 179.875 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.586 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.4 Cg_endo -69.75 -19.83 35.64 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.712 2.274 . . . . 75.13 112.327 179.962 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.432 HG12 ' O ' ' A' ' 22' ' ' VAL . 41.6 t -102.3 -11.92 8.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.195 -0.457 . . . . 63.12 111.12 179.911 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.9 tp10 -52.13 -35.42 48.24 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.207 -0.451 . . . . 54.25 110.897 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 52.1 m-20 -115.37 -5.71 12.32 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.142 -0.481 . . . . 51.42 110.886 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 28.5 m80 . . . . . 0 C--N 1.329 -0.303 0 CA-C-N 116.174 -0.466 . . . . 74.0 110.888 -179.999 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 3.1 m . . . . . 0 C--O 1.231 0.096 0 CA-C-O 120.777 0.323 . . . . 74.44 111.107 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -62.66 -39.72 98.27 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.738 -0.744 . . . . 63.41 112.483 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' ASN . . . . . 0.569 ' HA ' HD23 ' A' ' 6' ' ' LEU . 7.6 t-20 -117.22 -5.44 11.34 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.858 0.361 . . . . 71.14 110.898 -179.872 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.4 HG12 ' O ' ' A' ' 4' ' ' VAL . 21.2 t -86.79 -11.36 11.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.146 -0.479 . . . . 74.13 111.145 179.909 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -117.02 37.43 3.35 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.742 -0.742 . . . . 62.25 112.521 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.569 HD23 ' HA ' ' A' ' 3' ' ' ASN . 1.9 mm? -88.48 -75.57 0.42 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.791 0.329 . . . . 72.15 110.942 -179.938 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.562 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.6 OUTLIER -69.05 -56.76 8.43 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.726 0.774 . . . . 73.13 110.916 -179.963 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.562 ' HD2' ' N ' ' A' ' 7' ' ' SER . 53.7 Cg_endo -69.76 -4.78 14.73 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.704 2.269 . . . . 62.24 112.359 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -111.23 -25.96 4.81 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.685 -0.769 . . . . 75.43 112.481 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 6.4 tp -80.15 -37.15 34.06 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.849 0.357 . . . . 73.41 110.939 -179.962 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -82.52 -19.22 39.1 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.173 -0.467 . . . . 43.52 110.874 -179.926 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 99.5 m -86.56 -23.19 25.92 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.124 -0.489 . . . . 63.34 111.123 -179.922 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.505 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -92.62 -34.83 13.84 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.194 -0.457 . . . . 73.14 111.11 179.895 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 14' ' ' LEU . . . . . 0.533 HD23 ' O ' ' A' ' 14' ' ' LEU . 1.0 OUTLIER -76.65 -11.8 59.91 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.203 -0.453 . . . . 43.32 110.933 179.987 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 98.9 m -99.14 -34.26 10.45 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.182 -0.463 . . . . 64.32 111.149 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.838 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -104.73 -7.77 38.46 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.731 -0.747 . . . . 74.33 112.537 179.921 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.509 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.5 p90 -29.81 -54.84 0.16 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.9 0.381 . . . . 75.54 110.887 -179.924 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.435 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 20.0 m -115.57 -14.95 11.48 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.175 -0.466 . . . . 74.12 111.135 -179.882 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 10.1 mp -82.11 -15.2 54.25 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.204 -0.453 . . . . 72.31 110.937 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.838 HG23 ' HA3' ' A' ' 16' ' ' GLY . 8.5 t -75.68 -55.29 2.04 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.6 0.714 . . . . 72.2 111.162 179.826 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.588 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.4 Cg_endo -69.79 -20.19 35.0 Favored 'Trans proline' 0 C--O 1.231 0.143 0 C-N-CA 122.669 2.246 . . . . 62.43 112.323 179.934 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.447 HG12 ' O ' ' A' ' 22' ' ' VAL . 47.4 t -100.41 -11.65 8.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.228 -0.442 . . . . 72.12 111.142 179.943 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -57.83 -21.05 40.44 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.14 -0.482 . . . . 70.13 110.884 -179.998 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -75.3 -6.4 49.68 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.144 -0.48 . . . . 64.14 110.867 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 116.183 -0.462 . . . . 75.22 110.865 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.23 0.062 0 CA-C-O 120.788 0.328 . . . . 75.1 111.107 . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -55.86 -30.92 57.74 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.777 -0.725 . . . . 32.55 112.465 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -106.63 -5.45 18.64 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.825 0.345 . . . . 74.14 110.858 -179.872 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 20.8 t -94.47 -11.52 8.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.206 -0.452 . . . . 74.24 111.117 179.95 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -106.77 23.92 26.7 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.724 -0.75 . . . . 74.05 112.457 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 5.5 tt -85.84 -41.65 14.83 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.822 0.344 . . . . 75.13 110.957 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.516 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.0 OUTLIER -83.62 -58.57 0.39 Allowed Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.704 0.764 . . . . 72.55 110.858 -179.935 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.516 ' HD2' ' N ' ' A' ' 7' ' ' SER . 53.3 Cg_endo -69.77 -6.84 19.57 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.704 2.269 . . . . 73.41 112.351 -179.998 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -107.17 -27.42 5.34 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.696 -0.764 . . . . 65.42 112.513 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -78.71 -40.01 34.86 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.823 0.344 . . . . 64.21 110.908 -179.942 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -79.59 -19.22 49.84 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.194 -0.457 . . . . 63.52 110.875 -179.925 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 47.3 m -86.48 -23.31 26.02 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.117 -0.492 . . . . 73.0 111.148 -179.95 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.5 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -91.59 -35.5 14.21 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.203 -0.453 . . . . 70.21 111.094 179.877 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -75.91 -11.8 60.03 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.247 -0.433 . . . . 73.33 110.909 179.999 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 98.3 m -98.45 -35.57 10.23 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.22 -0.445 . . . . 73.22 111.146 179.936 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.808 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.95 -7.47 41.26 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.783 -0.722 . . . . 53.41 112.483 179.98 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.502 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.71 -54.05 0.15 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.877 0.37 . . . . 73.4 110.878 -179.832 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.444 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.5 m -116.01 -14.62 11.22 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.151 -0.477 . . . . 52.32 111.133 -179.922 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.413 HD13 ' HA ' ' A' ' 19' ' ' LEU . 4.0 mm? -82.26 -14.78 54.93 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.19 -0.459 . . . . 63.45 110.893 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.808 HG23 ' HA3' ' A' ' 16' ' ' GLY . 13.7 t -75.74 -55.32 2.01 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.625 0.726 . . . . 74.13 111.112 179.918 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.578 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.6 Cg_endo -69.71 -20.95 34.41 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.735 2.29 . . . . 73.25 112.324 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.433 HG12 ' O ' ' A' ' 22' ' ' VAL . 45.2 t -99.65 -11.78 8.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.2 -0.454 . . . . 63.14 111.145 179.94 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -58.14 -21.15 45.52 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.172 -0.467 . . . . 64.52 110.866 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 13.6 m-20 -102.95 -5.6 23.29 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.173 -0.467 . . . . 73.41 110.888 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.33 -0.28 0 CA-C-N 116.227 -0.442 . . . . 72.2 110.873 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.457 -0.077 0 CA-C-O 120.832 0.349 . . . . 70.14 111.13 . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -57.68 -22.07 45.32 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.75 -0.738 . . . . 73.23 112.479 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 8.0 t-20 -119.6 -5.5 10.24 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.885 0.374 . . . . 73.53 110.856 -179.859 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.4 HG12 ' O ' ' A' ' 4' ' ' VAL . 21.1 t -94.31 -11.38 8.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.219 -0.446 . . . . 72.51 111.128 179.9 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -115.16 37.54 3.45 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.735 -0.745 . . . . 71.35 112.483 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 2.2 tt -81.16 -38.68 26.73 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.847 0.356 . . . . 75.2 110.946 -179.916 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.542 ' H ' ' HD2' ' A' ' 8' ' ' PRO . 0.0 OUTLIER -86.18 -59.35 0.3 Allowed Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.668 0.747 . . . . 33.13 110.882 -179.957 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.542 ' HD2' ' H ' ' A' ' 7' ' ' SER . 53.8 Cg_endo -69.73 -5.65 16.69 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.695 2.263 . . . . 70.31 112.348 179.962 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -109.17 -26.5 5.17 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.724 -0.751 . . . . 63.1 112.501 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 6.5 tt -78.62 -41.68 30.94 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.79 0.329 . . . . 73.45 110.902 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 2.2 t -77.96 -19.88 53.72 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.211 -0.45 . . . . 75.44 110.844 -179.91 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 91.8 m -86.74 -22.71 25.81 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.137 -0.483 . . . . 54.44 111.137 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.494 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -91.65 -34.75 14.56 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.224 -0.444 . . . . 51.23 111.124 179.835 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -76.44 -11.53 59.9 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.197 -0.456 . . . . 74.21 110.913 -179.967 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 96.7 m -99.01 -35.44 10.05 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.191 -0.459 . . . . 65.04 111.117 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.817 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.57 -7.63 42.02 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.714 -0.755 . . . . 54.44 112.479 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.512 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.57 -54.21 0.15 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.914 0.388 . . . . 73.24 110.843 -179.87 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.44 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 23.3 m -116.05 -14.75 11.19 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.168 -0.469 . . . . 74.11 111.159 -179.92 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -82.21 -14.46 55.53 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.229 -0.441 . . . . 61.45 110.901 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.817 HG23 ' HA3' ' A' ' 16' ' ' GLY . 14.9 t -75.71 -55.14 2.06 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.603 0.716 . . . . 54.43 111.097 179.839 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.592 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.7 Cg_endo -69.69 -21.18 34.17 Favored 'Trans proline' 0 C--O 1.231 0.15 0 C-N-CA 122.729 2.286 . . . . 71.35 112.329 179.961 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.435 HG12 ' O ' ' A' ' 22' ' ' VAL . 44.6 t -99.43 -11.88 8.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.224 -0.444 . . . . 72.13 111.104 179.965 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -56.98 -21.88 33.91 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.216 -0.447 . . . . 34.03 110.884 -179.956 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 39.0 m-20 -119.09 -5.8 10.48 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.18 -0.464 . . . . 61.23 110.868 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 3.4 t-160 . . . . . 0 C--N 1.33 -0.276 0 CA-C-N 116.193 -0.458 . . . . 74.43 110.85 -179.984 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 8.2 m . . . . . 0 N--CA 1.457 -0.09 0 CA-C-O 120.834 0.349 . . . . 71.25 111.132 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -69.26 -25.58 75.33 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.699 -0.762 . . . . 71.1 112.494 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 69.2 m-80 -117.63 -5.49 11.16 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.907 0.384 . . . . 65.11 110.904 -179.885 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 20.9 t -104.06 -11.39 9.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.154 -0.475 . . . . 35.25 111.133 179.894 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -120.09 40.01 2.31 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.74 -0.743 . . . . 74.12 112.474 179.975 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 44.6 tp -67.36 -36.13 80.76 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.84 0.353 . . . . 75.04 110.881 -179.912 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.524 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.3 OUTLIER -83.92 -58.44 0.38 Allowed Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.637 0.732 . . . . 61.42 110.856 -179.923 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.524 ' HD2' ' N ' ' A' ' 7' ' ' SER . 53.3 Cg_endo -69.75 -7.45 21.08 Favored 'Trans proline' 0 C--N 1.341 0.14 0 C-N-CA 122.736 2.291 . . . . 71.35 112.311 179.984 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -107.2 -26.26 5.79 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.723 -0.751 . . . . 65.32 112.449 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -78.44 -41.71 32.09 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.832 0.348 . . . . 51.43 110.954 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -77.54 -20.29 54.41 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.171 -0.468 . . . . 73.33 110.845 -179.917 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 86.1 m -86.67 -22.35 26.16 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.18 -0.464 . . . . 62.34 111.134 -179.951 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.492 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -91.76 -34.82 14.45 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.189 -0.459 . . . . 62.35 111.1 179.884 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -76.12 -11.97 60.03 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.182 -0.463 . . . . 74.44 110.883 -179.951 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 98.4 m -98.6 -35.33 10.24 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.229 -0.441 . . . . 73.5 111.138 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.823 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.87 -7.43 41.56 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.706 -0.759 . . . . 63.22 112.505 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.504 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.61 -54.28 0.15 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.957 0.408 . . . . 75.24 110.871 -179.874 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.443 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.4 m -116.01 -14.54 11.22 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.165 -0.471 . . . . 74.31 111.138 -179.886 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.424 HD13 ' HA ' ' A' ' 19' ' ' LEU . 4.0 mm? -82.45 -14.52 54.96 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.228 -0.442 . . . . 65.31 110.948 179.91 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.823 HG23 ' HA3' ' A' ' 16' ' ' GLY . 14.0 t -75.77 -55.13 2.04 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.623 0.725 . . . . 54.1 111.149 179.818 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.586 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.5 Cg_endo -69.81 -21.03 33.81 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.647 2.231 . . . . 72.44 112.375 179.934 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.433 HG12 ' O ' ' A' ' 22' ' ' VAL . 44.9 t -99.35 -11.77 8.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.187 -0.46 . . . . 65.14 111.119 179.88 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -57.97 -20.98 42.07 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.219 -0.446 . . . . 55.44 110.889 -179.976 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 40.3 t0 -75.31 -6.5 50.18 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.149 -0.478 . . . . 72.25 110.873 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 27.1 m80 . . . . . 0 C--N 1.329 -0.303 0 CA-C-N 116.205 -0.452 . . . . 64.1 110.81 -179.984 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.231 0.096 0 CA-C-O 120.844 0.355 . . . . 62.22 111.124 . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -65.48 -31.12 79.23 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.739 -0.743 . . . . 71.01 112.483 180.0 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 8.2 m120 -119.8 -5.51 10.14 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.894 0.378 . . . . 75.33 110.917 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 21.1 t -97.27 -11.4 8.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.124 -0.489 . . . . 62.1 111.138 179.904 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -116.17 37.41 3.42 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.703 -0.76 . . . . 61.42 112.471 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 2.4 tt -67.12 -32.42 73.54 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.861 0.362 . . . . 71.43 110.922 -179.936 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.566 ' H ' ' HD2' ' A' ' 8' ' ' PRO . 0.0 OUTLIER -87.94 -59.5 0.26 Allowed Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.697 0.76 . . . . 75.01 110.868 -179.911 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.566 ' HD2' ' H ' ' A' ' 7' ' ' SER . 53.7 Cg_endo -69.75 -6.28 18.23 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.708 2.272 . . . . 71.21 112.337 179.963 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -108.72 -25.82 5.56 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.715 -0.755 . . . . 63.24 112.45 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.8 tt -79.13 -40.98 29.62 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.88 0.371 . . . . 71.31 110.955 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 30.0 t -78.7 -19.88 51.42 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.185 -0.461 . . . . 73.21 110.855 -179.919 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 92.3 m -86.77 -22.34 25.99 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.132 -0.486 . . . . 60.34 111.158 -179.974 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.495 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -91.88 -35.12 14.23 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.21 -0.45 . . . . 54.23 111.082 179.855 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -75.9 -12.14 60.1 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.236 -0.438 . . . . 74.13 110.898 -179.955 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 97.9 m -98.43 -35.3 10.32 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.196 -0.456 . . . . 52.13 111.153 179.96 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.829 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.99 -7.36 41.37 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.732 -0.747 . . . . 41.21 112.5 179.945 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.509 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.65 -54.2 0.15 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.915 0.388 . . . . 73.41 110.859 -179.87 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.44 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.2 m -116.15 -14.39 11.14 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.156 -0.475 . . . . 62.42 111.124 -179.912 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.402 ' HA ' HD13 ' A' ' 19' ' ' LEU . 4.0 mm? -82.56 -14.59 54.6 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.246 -0.434 . . . . 73.3 110.913 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.829 HG23 ' HA3' ' A' ' 16' ' ' GLY . 13.4 t -75.74 -55.26 2.02 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.631 0.729 . . . . 55.54 111.11 179.847 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.591 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.1 Cg_endo -69.78 -20.79 34.27 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.7 2.266 . . . . 60.15 112.316 179.989 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.439 HG12 ' O ' ' A' ' 22' ' ' VAL . 44.1 t -99.98 -11.7 8.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.231 -0.44 . . . . 63.24 111.133 179.889 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -56.87 -21.57 30.41 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.197 -0.456 . . . . 72.25 110.884 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 36.3 t0 -120.03 -5.63 10.02 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.142 -0.481 . . . . 75.43 110.884 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 55.6 t-80 . . . . . 0 C--N 1.329 -0.314 0 CA-C-N 116.211 -0.45 . . . . 70.1 110.897 -179.996 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.457 -0.091 0 CA-C-O 120.779 0.323 . . . . 72.15 111.121 . . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -59.26 -35.12 83.25 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.724 -0.75 . . . . 35.25 112.486 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 84.1 m-20 -103.97 -5.39 22.27 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.825 0.345 . . . . 45.44 110.889 -179.903 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 21.3 t -93.47 -11.36 9.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.206 -0.452 . . . . 71.31 111.112 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -101.37 29.76 11.83 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.773 -0.727 . . . . 72.3 112.478 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 1.9 tt -67.85 -29.15 68.21 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.813 0.34 . . . . 75.14 110.927 -179.89 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.574 ' H ' ' HD2' ' A' ' 8' ' ' PRO . 0.2 OUTLIER -89.6 -60.74 0.23 Allowed Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.66 0.743 . . . . 73.51 110.862 -179.983 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.574 ' HD2' ' H ' ' A' ' 7' ' ' SER . 53.3 Cg_endo -69.75 -6.62 19.04 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.649 2.233 . . . . 74.14 112.333 -179.976 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -108.0 -26.26 5.57 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.725 -0.75 . . . . 53.32 112.453 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -78.62 -41.81 30.57 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.848 0.356 . . . . 74.43 110.954 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 7.7 t -77.48 -20.53 54.22 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.157 -0.474 . . . . 70.04 110.874 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 98.0 m -86.65 -21.96 26.42 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.103 -0.498 . . . . 63.12 111.173 -179.918 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.488 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -92.06 -34.99 14.17 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.171 -0.468 . . . . 40.33 111.062 179.911 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -75.99 -11.72 60.01 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.214 -0.448 . . . . 65.41 110.892 -179.934 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 98.5 m -98.72 -35.38 10.18 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.164 -0.471 . . . . 64.42 111.162 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.815 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.94 -7.42 41.37 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.779 -0.724 . . . . 63.11 112.509 179.934 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.501 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.61 -54.27 0.15 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.913 0.387 . . . . 75.53 110.907 -179.869 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.445 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 20.6 m -115.91 -14.57 11.28 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.105 -0.498 . . . . 74.23 111.15 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.426 HD13 ' HA ' ' A' ' 19' ' ' LEU . 4.0 mm? -82.48 -14.33 55.2 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.211 -0.45 . . . . 65.42 110.933 179.952 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.815 HG23 ' HA3' ' A' ' 16' ' ' GLY . 14.3 t -75.98 -55.22 1.92 Allowed Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.669 0.747 . . . . 75.41 111.169 179.789 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.582 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.7 Cg_endo -69.74 -20.91 34.34 Favored 'Trans proline' 0 C--N 1.342 0.22 0 C-N-CA 122.631 2.221 . . . . 75.33 112.366 179.923 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.43 HG12 ' O ' ' A' ' 22' ' ' VAL . 46.4 t -99.23 -12.17 8.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.212 -0.449 . . . . 75.31 111.124 179.922 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -58.07 -20.87 42.78 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.178 -0.465 . . . . 73.22 110.897 -179.936 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 25.3 t70 -76.46 -5.59 48.07 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.163 -0.471 . . . . 71.44 110.907 179.939 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.263 0 CA-C-N 116.169 -0.469 . . . . 73.03 110.872 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 1.3 m . . . . . 0 N--CA 1.458 -0.06 0 CA-C-O 120.821 0.343 . . . . 73.21 111.151 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -56.32 -41.37 87.17 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.733 -0.746 . . . . 62.05 112.493 179.944 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 59.6 t30 -89.96 -5.45 56.7 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.907 0.384 . . . . 73.21 110.939 -179.909 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 21.2 t -98.68 -11.35 8.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.152 -0.477 . . . . 72.05 111.109 179.93 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -104.91 19.72 40.36 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.753 -0.737 . . . . 60.33 112.496 -179.998 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.514 ' O ' HD23 ' A' ' 6' ' ' LEU . 5.2 tt -89.56 -5.1 57.53 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.822 0.344 . . . . 63.34 110.89 -179.896 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.659 ' H ' ' HD2' ' A' ' 8' ' ' PRO . 0.5 OUTLIER -120.35 -66.72 0.02 OUTLIER Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.695 0.759 . . . . 61.32 110.904 -179.955 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.659 ' HD2' ' H ' ' A' ' 7' ' ' SER . 53.4 Cg_endo -69.75 -7.3 20.69 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.683 2.255 . . . . 72.15 112.32 -179.993 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -121.32 -15.21 4.67 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.726 -0.75 . . . . 22.32 112.483 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.1 tp -80.07 -40.72 27.07 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.841 0.353 . . . . 70.5 110.952 -179.932 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -78.41 -20.1 51.86 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.141 -0.481 . . . . 65.33 110.881 -179.944 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 87.9 m -86.21 -22.54 26.86 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.145 -0.479 . . . . 51.42 111.17 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.492 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -91.86 -35.34 14.12 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.19 -0.459 . . . . 71.01 111.14 179.839 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -75.87 -12.02 60.08 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.187 -0.46 . . . . 72.04 110.914 -179.972 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 97.7 m -98.64 -35.34 10.23 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.165 -0.47 . . . . 73.24 111.157 179.932 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.844 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.81 -7.38 41.84 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.711 -0.757 . . . . 42.23 112.468 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.498 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.7 -54.08 0.15 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.913 0.387 . . . . 72.11 110.824 -179.849 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.449 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.0 m -116.31 -14.74 11.03 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.194 -0.457 . . . . 74.14 111.131 -179.869 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -82.39 -14.64 54.87 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.218 -0.446 . . . . 44.5 110.947 179.938 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.844 HG23 ' HA3' ' A' ' 16' ' ' GLY . 9.8 t -76.17 -55.31 1.81 Allowed Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.645 0.736 . . . . 71.52 111.138 179.848 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.586 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 54.1 Cg_endo -69.74 -20.23 35.2 Favored 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 122.715 2.277 . . . . 51.44 112.364 179.922 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.447 HG12 ' O ' ' A' ' 22' ' ' VAL . 45.1 t -100.67 -11.71 8.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.207 -0.451 . . . . 64.33 111.165 179.905 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -56.69 -21.7 29.62 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.18 -0.464 . . . . 71.42 110.878 -179.978 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 17.0 t70 -120.08 -5.93 9.99 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.17 -0.468 . . . . 70.11 110.845 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 1.3 t-80 . . . . . 0 C--N 1.329 -0.302 0 CA-C-N 116.174 -0.466 . . . . 62.55 110.815 -179.976 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.456 -0.135 0 CA-C-O 120.863 0.363 . . . . 71.23 111.143 . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -62.19 -34.18 88.28 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.739 -0.743 . . . . 65.51 112.511 179.966 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 -112.48 -5.39 14.06 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.899 0.38 . . . . 74.55 110.908 -179.918 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 21.1 t -102.13 -11.36 8.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.168 -0.469 . . . . 60.33 111.114 179.913 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -100.61 22.11 41.15 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.705 -0.759 . . . . 44.42 112.489 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 3.9 tt -76.91 -5.2 47.54 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.834 0.349 . . . . 71.02 110.94 -179.921 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.662 ' H ' ' HD2' ' A' ' 8' ' ' PRO . 0.5 OUTLIER -120.41 -66.62 0.02 OUTLIER Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.618 0.723 . . . . 74.14 110.855 -179.939 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.662 ' HD2' ' H ' ' A' ' 7' ' ' SER . 53.7 Cg_endo -69.81 -7.25 20.6 Favored 'Trans proline' 0 N--CA 1.466 -0.115 0 C-N-CA 122.673 2.249 . . . . 54.41 112.357 179.979 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -121.34 -15.18 4.67 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.685 -0.769 . . . . 71.33 112.479 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.1 tt -80.0 -40.9 26.91 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.851 0.358 . . . . 54.2 110.896 -179.902 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -78.24 -20.15 52.29 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.177 -0.465 . . . . 72.15 110.859 -179.918 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 81.8 m -86.15 -22.55 26.97 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.128 -0.487 . . . . 71.44 111.162 -179.929 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.497 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -91.91 -35.38 14.06 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.188 -0.46 . . . . 73.2 111.077 179.882 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -75.87 -11.98 60.07 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.247 -0.433 . . . . 64.34 110.925 -179.964 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 97.6 m -98.58 -35.39 10.23 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.171 -0.468 . . . . 61.42 111.163 179.89 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.821 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.8 -7.44 41.73 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.704 -0.76 . . . . 70.52 112.449 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.497 ' HB3' ' O ' ' A' ' 13' ' ' ALA . 1.4 p90 -29.62 -54.23 0.15 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.907 0.384 . . . . 74.5 110.842 -179.846 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.448 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.1 m -116.05 -14.58 11.19 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.172 -0.467 . . . . 75.05 111.127 -179.864 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.413 ' HA ' HD13 ' A' ' 19' ' ' LEU . 4.0 mm? -82.46 -14.54 54.91 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.251 -0.431 . . . . 72.5 110.919 179.975 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.821 HG23 ' HA3' ' A' ' 16' ' ' GLY . 13.6 t -75.85 -55.16 1.99 Allowed Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.649 0.738 . . . . 72.24 111.117 179.834 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.586 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.5 Cg_endo -69.8 -20.82 34.15 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.652 2.235 . . . . 75.4 112.365 179.976 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.441 HG12 ' O ' ' A' ' 22' ' ' VAL . 44.3 t -99.88 -11.81 8.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.194 -0.457 . . . . 73.22 111.116 179.909 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -56.9 -21.55 30.55 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.2 -0.455 . . . . 75.5 110.842 -179.932 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 25.1 t0 -120.02 -5.77 10.02 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.163 -0.472 . . . . 64.41 110.859 179.982 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 19.4 t-160 . . . . . 0 C--N 1.329 -0.315 0 CA-C-N 116.234 -0.439 . . . . 74.51 110.849 -179.98 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 11.9 m . . . . . 0 C--O 1.231 0.112 0 CA-C-O 120.82 0.343 . . . . 64.24 111.131 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -68.01 -24.28 74.48 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.737 -0.744 . . . . 75.34 112.532 179.923 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 6.7 m120 -109.68 -5.42 15.64 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.863 0.363 . . . . 72.12 110.894 -179.92 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.4 ' O ' HG12 ' A' ' 4' ' ' VAL . 21.0 t -104.39 -11.37 9.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.176 -0.466 . . . . 61.41 111.111 179.942 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -98.09 22.17 42.24 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.757 -0.735 . . . . 50.42 112.49 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 4.6 mm? -81.53 -5.28 57.83 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.822 0.344 . . . . 71.1 110.933 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.659 ' H ' ' HD2' ' A' ' 8' ' ' PRO . 0.5 OUTLIER -120.35 -66.61 0.02 OUTLIER Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.64 0.733 . . . . 63.02 110.877 -179.955 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.659 ' HD2' ' H ' ' A' ' 7' ' ' SER . 53.8 Cg_endo -69.79 -7.26 20.6 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.702 2.268 . . . . 72.03 112.347 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -121.37 -15.21 4.65 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.696 -0.764 . . . . 35.31 112.462 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 5.6 tp -80.05 -40.75 27.08 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.792 0.329 . . . . 64.15 110.911 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.9 t -78.38 -20.12 51.92 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.23 -0.441 . . . . 71.34 110.836 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 64.1 m -86.24 -22.42 26.89 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.159 -0.473 . . . . 73.05 111.183 -179.956 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.495 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -92.01 -35.32 14.03 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.18 -0.464 . . . . 71.34 111.073 179.876 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -75.87 -12.06 60.09 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.235 -0.439 . . . . 71.21 110.913 -179.98 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 97.7 m -98.55 -35.46 10.22 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.226 -0.443 . . . . 60.25 111.124 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.824 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.78 -7.4 41.87 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.743 -0.741 . . . . 62.2 112.489 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.495 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.6 -54.23 0.15 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.985 0.421 . . . . 71.3 110.933 -179.906 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.449 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.4 m -116.08 -14.45 11.18 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.128 -0.487 . . . . 74.54 111.182 -179.951 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.445 HD13 ' HA ' ' A' ' 19' ' ' LEU . 4.0 mm? -82.51 -14.54 54.79 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.222 -0.445 . . . . 70.25 110.941 179.919 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.824 HG23 ' HA3' ' A' ' 16' ' ' GLY . 14.3 t -75.71 -55.16 2.06 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.595 0.712 . . . . 63.41 111.122 179.803 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.585 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.7 Cg_endo -69.8 -21.0 33.9 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.615 2.21 . . . . 72.43 112.37 179.987 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.444 HG12 ' O ' ' A' ' 22' ' ' VAL . 45.1 t -99.4 -11.74 8.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.208 -0.451 . . . . 73.44 111.097 179.911 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -57.94 -21.13 42.41 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.212 -0.449 . . . . 72.32 110.884 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 95.2 m-20 -103.17 -5.88 22.74 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.177 -0.465 . . . . 64.31 110.846 -179.989 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.33 -0.278 0 CA-C-N 116.233 -0.44 . . . . 73.41 110.887 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.457 -0.086 0 CA-C-O 120.856 0.36 . . . . 71.12 111.13 . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -63.33 -29.09 73.47 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.735 -0.745 . . . . 55.44 112.482 -179.984 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 55.3 t30 -113.64 -5.49 13.38 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.853 0.359 . . . . 73.41 110.88 -179.893 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.402 ' O ' HG12 ' A' ' 4' ' ' VAL . 21.1 t -103.47 -11.33 9.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.163 -0.471 . . . . 64.21 111.131 179.896 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -110.37 23.81 19.57 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.716 -0.754 . . . . 65.34 112.476 179.942 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.425 ' O ' HD23 ' A' ' 6' ' ' LEU . 5.3 tt -83.52 -5.12 59.07 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.826 0.346 . . . . 51.31 110.923 -179.924 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.662 ' H ' ' HD2' ' A' ' 8' ' ' PRO . 0.5 OUTLIER -120.36 -66.68 0.02 OUTLIER Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.702 0.763 . . . . 72.22 110.882 -179.959 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.662 ' HD2' ' H ' ' A' ' 7' ' ' SER . 54.4 Cg_endo -69.72 -7.32 20.75 Favored 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 122.682 2.255 . . . . 61.54 112.327 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -121.33 -15.24 4.66 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.721 -0.752 . . . . 71.31 112.439 -179.948 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.7 tt -80.05 -40.72 27.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.832 0.349 . . . . 65.54 110.946 -179.903 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -78.32 -20.14 52.07 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.201 -0.454 . . . . 62.43 110.913 -179.979 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 86.0 m -86.22 -22.48 26.88 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.086 -0.507 . . . . 62.4 111.105 -179.907 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.498 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -91.97 -35.34 14.04 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.214 -0.448 . . . . 73.52 111.051 179.892 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -75.87 -12.06 60.09 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.244 -0.434 . . . . 73.24 110.912 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 97.8 m -98.6 -35.31 10.25 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.202 -0.454 . . . . 70.15 111.176 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.825 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.83 -7.45 41.64 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.778 -0.725 . . . . 60.13 112.477 179.979 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.498 ' HB3' ' O ' ' A' ' 13' ' ' ALA . 1.4 p90 -29.57 -54.31 0.15 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.953 0.406 . . . . 73.2 110.889 -179.891 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.448 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.4 m -116.04 -14.46 11.21 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.126 -0.488 . . . . 74.43 111.146 -179.938 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.446 HD13 ' HA ' ' A' ' 19' ' ' LEU . 4.0 mm? -82.45 -14.57 54.87 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.248 -0.433 . . . . 72.35 110.937 179.913 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.825 HG23 ' HA3' ' A' ' 16' ' ' GLY . 14.2 t -75.75 -55.14 2.05 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.629 0.728 . . . . 73.21 111.117 179.858 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.582 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.8 Cg_endo -69.78 -21.07 33.91 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.67 2.246 . . . . 64.52 112.346 179.951 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.445 HG12 ' O ' ' A' ' 22' ' ' VAL . 45.0 t -99.37 -11.75 8.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.234 -0.439 . . . . 72.1 111.151 179.905 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -57.95 -20.91 41.39 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.152 -0.476 . . . . 72.15 110.886 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -75.45 -6.31 49.45 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.126 -0.488 . . . . 73.41 110.886 179.971 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--N 1.329 -0.287 0 CA-C-N 116.187 -0.461 . . . . 75.21 110.83 179.983 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 48.6 m . . . . . 0 N--CA 1.458 -0.073 0 CA-C-O 120.796 0.331 . . . . 74.12 111.156 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -60.43 -32.74 78.53 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.73 -0.748 . . . . 53.0 112.486 179.95 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 16.8 m120 -105.1 -5.46 20.79 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.859 0.361 . . . . 71.14 110.844 -179.859 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.402 HG12 ' O ' ' A' ' 4' ' ' VAL . 21.0 t -97.17 -11.33 8.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.193 -0.458 . . . . 74.01 111.149 179.911 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -95.62 20.15 51.02 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.754 -0.736 . . . . 60.11 112.487 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -84.03 -5.75 59.29 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.791 0.329 . . . . 64.13 110.872 -179.9 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.661 ' H ' ' HD2' ' A' ' 8' ' ' PRO . 0.5 OUTLIER -120.4 -66.69 0.02 OUTLIER Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.647 0.737 . . . . 53.43 110.875 -179.955 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.661 ' HD2' ' H ' ' A' ' 7' ' ' SER . 54.3 Cg_endo -69.69 -7.28 20.62 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.676 2.251 . . . . 74.44 112.397 179.935 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -121.32 -15.27 4.65 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.749 -0.738 . . . . 71.33 112.48 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 5.2 tt -79.94 -40.89 27.15 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.838 0.352 . . . . 63.02 110.935 -179.929 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.7 t -78.28 -20.16 52.17 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.141 -0.481 . . . . 64.33 110.846 -179.899 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 85.6 m -86.19 -22.48 26.94 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.137 -0.483 . . . . 72.05 111.136 -179.929 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.497 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -91.92 -35.38 14.05 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.23 -0.441 . . . . 71.24 111.083 179.895 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -75.95 -11.95 60.06 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.185 -0.461 . . . . 73.13 110.882 -179.929 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 97.6 m -98.57 -35.45 10.22 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.213 -0.449 . . . . 71.3 111.155 179.901 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.825 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.75 -7.47 41.82 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.772 -0.727 . . . . 53.34 112.449 -179.979 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.497 ' HB3' ' O ' ' A' ' 13' ' ' ALA . 1.5 p90 -29.59 -54.25 0.15 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.961 0.41 . . . . 65.53 110.886 -179.855 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.448 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.3 m -116.07 -14.5 11.19 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.116 -0.493 . . . . 74.01 111.133 -179.896 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.446 HD13 ' HA ' ' A' ' 19' ' ' LEU . 4.0 mm? -82.47 -14.59 54.79 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.234 -0.439 . . . . 74.52 110.893 179.958 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.825 HG23 ' HA3' ' A' ' 16' ' ' GLY . 14.0 t -75.73 -55.13 2.06 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.605 0.717 . . . . 75.24 111.116 179.844 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.584 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.4 Cg_endo -69.8 -21.06 33.84 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.696 2.264 . . . . 74.41 112.304 -179.982 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.444 HG12 ' O ' ' A' ' 22' ' ' VAL . 44.7 t -99.41 -11.77 8.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.205 -0.452 . . . . 70.31 111.134 179.932 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -57.9 -20.96 40.92 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.178 -0.465 . . . . 75.22 110.933 179.964 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 81.7 m-20 -75.42 -6.36 49.65 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.129 -0.487 . . . . 73.12 110.852 179.969 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 26.8 t-80 . . . . . 0 C--N 1.329 -0.322 0 CA-C-N 116.187 -0.46 . . . . 72.12 110.871 179.983 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.231 0.085 0 CA-C-O 120.802 0.335 . . . . 64.54 111.108 . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -63.11 -40.29 99.01 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.769 -0.729 . . . . 55.1 112.46 179.963 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 29.8 m120 -109.71 -5.39 15.63 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.832 0.349 . . . . 71.34 110.872 -179.84 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 21.1 t -101.97 -11.33 8.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.162 -0.472 . . . . 62.14 111.142 179.883 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -101.42 26.22 25.32 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.726 -0.75 . . . . 61.24 112.521 179.922 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -83.18 -5.26 59.06 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.768 0.318 . . . . 73.45 110.902 -179.943 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.661 ' H ' ' HD2' ' A' ' 8' ' ' PRO . 0.5 OUTLIER -120.32 -66.71 0.02 OUTLIER Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.7 0.762 . . . . 64.44 110.849 -179.948 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.661 ' HD2' ' H ' ' A' ' 7' ' ' SER . 54.1 Cg_endo -69.71 -7.29 20.67 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.747 2.298 . . . . 70.32 112.325 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -121.34 -15.23 4.66 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.735 -0.745 . . . . 23.21 112.479 179.988 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 2.1 tp -80.04 -40.76 27.07 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.821 0.344 . . . . 72.34 110.942 -179.937 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -78.37 -20.11 51.97 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.196 -0.456 . . . . 43.53 110.865 -179.955 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 40.0 m -86.22 -22.48 26.89 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.135 -0.484 . . . . 53.31 111.123 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.496 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -91.95 -35.34 14.05 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.222 -0.444 . . . . 71.15 111.076 179.896 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -75.93 -11.98 60.06 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.201 -0.454 . . . . 62.51 110.931 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 97.6 m -98.53 -35.46 10.23 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.179 -0.464 . . . . 75.23 111.154 179.892 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.825 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.78 -7.43 41.79 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.773 -0.727 . . . . 71.42 112.485 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.496 ' HB3' ' O ' ' A' ' 13' ' ' ALA . 1.4 p90 -29.63 -54.27 0.15 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.852 0.358 . . . . 64.4 110.864 -179.893 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.449 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.4 m -116.01 -14.48 11.22 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.171 -0.468 . . . . 51.22 111.144 -179.922 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.445 HD13 ' HA ' ' A' ' 19' ' ' LEU . 4.0 mm? -82.51 -14.54 54.81 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.225 -0.443 . . . . 53.44 110.953 179.94 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.825 HG23 ' HA3' ' A' ' 16' ' ' GLY . 14.1 t -75.79 -55.1 2.03 Favored Pre-proline 0 C--N 1.33 -0.251 0 CA-C-O 121.587 0.708 . . . . 60.13 111.118 179.838 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.585 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.7 Cg_endo -69.79 -21.04 33.92 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.643 2.229 . . . . 61.43 112.336 179.978 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.443 HG12 ' O ' ' A' ' 22' ' ' VAL . 45.2 t -99.4 -11.74 8.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.223 -0.444 . . . . 52.22 111.137 179.917 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -57.91 -20.93 40.89 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.145 -0.48 . . . . 74.2 110.918 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 10.4 t70 -75.4 -6.38 49.71 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.15 -0.477 . . . . 74.43 110.861 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--N 1.329 -0.319 0 CA-C-N 116.181 -0.463 . . . . 75.25 110.884 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.563 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.0 OUTLIER . . . . . 0 C--O 1.232 0.136 0 CA-C-O 121.677 0.751 . . . . 74.549999999999997 110.845 . . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . 0.563 ' HD2' ' N ' ' A' ' 7' ' ' SER . 54.4 Cg_endo -69.69 -4.89 14.89 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.678 2.252 . . . . 65.129999999999995 112.341 179.959 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -111.07 -26.33 4.7 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.72 -0.753 . . . . 65.299999999999997 112.503 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.4 tt -77.93 -40.96 37.92 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.856 0.36 . . . . 64.340000000000003 110.943 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 10.4 t -79.05 -19.41 51.46 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.17 -0.468 . . . . 62.020000000000003 110.898 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 96.9 m -86.87 -22.16 25.92 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.128 -0.487 . . . . 73.409999999999997 111.173 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.498 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -92.36 -35.29 13.8 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.214 -0.448 . . . . 63.549999999999997 111.094 179.876 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -76.07 -12.03 60.05 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.224 -0.444 . . . . 73.010000000000005 110.924 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 97.1 m -98.61 -35.26 10.27 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.158 -0.473 . . . . 71.150000000000006 111.175 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.818 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.89 -7.5 41.35 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.778 -0.725 . . . . 61.439999999999998 112.46 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.51 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.58 -54.36 0.15 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.943 0.401 . . . . 74.329999999999998 110.877 -179.859 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.445 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.4 m -115.92 -14.39 11.28 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.126 -0.488 . . . . 73.310000000000002 111.17 -179.916 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.437 HD13 ' HA ' ' A' ' 19' ' ' LEU . 4.0 mm? -82.46 -14.57 54.84 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.206 -0.452 . . . . 61.350000000000001 110.955 179.91 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.818 HG23 ' HA3' ' A' ' 16' ' ' GLY . 16.5 t -75.7 -55.03 2.1 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.612 0.72 . . . . 72.319999999999993 111.166 179.818 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.592 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 54.1 Cg_endo -69.79 -21.17 33.7 Favored 'Trans proline' 0 C--O 1.232 0.194 0 C-N-CA 122.695 2.264 . . . . 71.439999999999998 112.362 179.92 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.434 ' O ' HG12 ' A' ' 22' ' ' VAL . 44.4 t -99.29 -11.73 8.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.261 -0.427 . . . . 74.340000000000003 111.149 179.91 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.33 -0.246 0 CA-C-N 116.156 -0.474 . . . . 65.430000000000007 110.859 -179.994 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.56 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.0 OUTLIER . . . . . 0 C--O 1.232 0.142 0 CA-C-O 121.707 0.765 . . . . 74.549999999999997 110.861 . . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . 0.56 ' HD2' ' N ' ' A' ' 7' ' ' SER . 53.3 Cg_endo -69.74 -4.76 14.66 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.693 2.262 . . . . 75.109999999999999 112.319 -179.978 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -111.24 -26.01 4.78 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.783 -0.722 . . . . 71.5 112.539 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 3.6 tt -78.17 -41.07 35.86 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.819 0.343 . . . . 71.319999999999993 110.891 -179.888 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 4.9 t -79.2 -19.27 51.22 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.193 -0.458 . . . . 70.519999999999996 110.866 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 97.1 m -86.93 -22.25 25.75 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.133 -0.485 . . . . 71.409999999999997 111.11 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.499 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -92.33 -35.32 13.8 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.217 -0.447 . . . . 71.129999999999995 111.087 179.88 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -76.07 -11.89 60.02 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.219 -0.446 . . . . 70.430000000000007 110.941 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 98.4 m -98.59 -35.33 10.25 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.161 -0.472 . . . . 74.420000000000002 111.174 179.897 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.824 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.91 -7.42 41.45 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.739 -0.744 . . . . 61.310000000000002 112.536 179.938 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.511 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.59 -54.22 0.15 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.926 0.393 . . . . 73.25 110.889 -179.911 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.44 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.3 m -116.08 -14.58 11.18 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.132 -0.485 . . . . 60.100000000000001 111.129 -179.886 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -82.36 -14.57 55.04 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.237 -0.438 . . . . 73.519999999999996 110.96 179.946 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.824 HG23 ' HA3' ' A' ' 16' ' ' GLY . 14.3 t -75.76 -55.16 2.04 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-O 121.64 0.734 . . . . 60.039999999999999 111.099 179.843 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.592 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.7 Cg_endo -69.73 -21.1 34.09 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.692 2.261 . . . . 72.400000000000006 112.326 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.436 ' O ' HG12 ' A' ' 22' ' ' VAL . 45.3 t -99.37 -11.74 8.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.186 -0.461 . . . . 63.340000000000003 111.163 179.906 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.329 -0.284 0 CA-C-N 116.177 -0.465 . . . . 73.329999999999998 110.921 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.56 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.094 0 CA-C-O 121.639 0.733 . . . . 64.450000000000003 110.869 . . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . 0.56 ' HD2' ' N ' ' A' ' 7' ' ' SER . 54.1 Cg_endo -69.75 -4.94 15.04 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.671 2.248 . . . . 64.310000000000002 112.324 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -111.0 -26.09 4.82 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.765 -0.731 . . . . 71.150000000000006 112.469 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -78.04 -41.35 35.92 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.797 0.332 . . . . 60.530000000000001 110.945 -179.938 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -78.64 -19.67 52.08 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.197 -0.456 . . . . 74.420000000000002 110.861 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 97.4 m -86.55 -22.44 26.31 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.084 -0.507 . . . . 74.040000000000006 111.167 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.495 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -92.18 -35.29 13.92 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.185 -0.461 . . . . 60.310000000000002 111.088 179.914 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -76.02 -11.96 60.04 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.201 -0.454 . . . . 73.519999999999996 110.921 -179.967 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 98.8 m -98.66 -35.24 10.25 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.152 -0.476 . . . . 70.140000000000001 111.115 179.942 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.82 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.92 -7.5 41.28 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.746 -0.74 . . . . 74.439999999999998 112.466 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.51 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.6 -54.31 0.15 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.885 0.374 . . . . 72.030000000000001 110.894 -179.852 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.442 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.5 m -115.91 -14.43 11.28 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.166 -0.47 . . . . 73.219999999999999 111.14 -179.931 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.441 ' HA ' HD13 ' A' ' 19' ' ' LEU . 4.0 mm? -82.55 -14.39 54.97 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.232 -0.44 . . . . 65.310000000000002 110.889 179.989 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.82 HG23 ' HA3' ' A' ' 16' ' ' GLY . 15.2 t -75.95 -55.06 1.96 Allowed Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.607 0.717 . . . . 52.409999999999997 111.113 179.87 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.593 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 54.1 Cg_endo -69.72 -21.2 34.0 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.708 2.272 . . . . 71.409999999999997 112.374 179.909 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.436 ' O ' HG12 ' A' ' 22' ' ' VAL . 45.9 t -99.1 -11.98 8.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.24 -0.436 . . . . 74.150000000000006 111.118 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 116.156 -0.475 . . . . 71.329999999999998 110.892 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.562 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.6 OUTLIER . . . . . 0 C--O 1.231 0.126 0 CA-C-O 121.679 0.752 . . . . 73.209999999999994 110.857 . . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . 0.562 ' HD2' ' N ' ' A' ' 7' ' ' SER . 53.9 Cg_endo -69.7 -4.92 14.96 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.714 2.276 . . . . 71.239999999999995 112.358 179.991 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -111.11 -26.03 4.81 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.715 -0.755 . . . . 74.120000000000005 112.448 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -78.16 -41.07 35.96 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.81 0.338 . . . . 71.310000000000002 110.934 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -79.05 -19.48 51.26 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.161 -0.472 . . . . 52.020000000000003 110.861 -179.929 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 97.7 m -86.7 -22.39 26.07 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.175 -0.466 . . . . 73.400000000000006 111.13 -179.953 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.497 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -92.12 -35.43 13.88 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.265 -0.425 . . . . 41.439999999999998 111.147 179.84 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -75.99 -11.88 60.03 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.206 -0.452 . . . . 63.299999999999997 110.938 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 97.6 m -98.69 -35.4 10.19 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.194 -0.457 . . . . 65.019999999999996 111.149 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.843 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.83 -7.35 41.84 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.707 -0.758 . . . . 60.25 112.523 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.51 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.68 -54.24 0.15 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.893 0.378 . . . . 73.209999999999994 110.869 -179.869 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.438 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 20.5 m -116.08 -14.91 11.17 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.17 -0.468 . . . . 72.019999999999996 111.188 -179.936 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 10.5 mp -82.23 -15.02 54.57 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.179 -0.464 . . . . 74.109999999999999 110.937 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.843 HG23 ' HA3' ' A' ' 16' ' ' GLY . 9.4 t -75.44 -55.35 2.14 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.588 0.709 . . . . 63.340000000000003 111.103 179.839 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.587 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 54.2 Cg_endo -69.71 -20.54 34.94 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.687 2.258 . . . . 70.230000000000004 112.371 179.936 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.443 ' O ' HG12 ' A' ' 22' ' ' VAL . 45.9 t -100.26 -11.76 8.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.179 -0.464 . . . . 75.420000000000002 111.118 179.919 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.329 -0.289 0 CA-C-N 116.194 -0.457 . . . . 70.040000000000006 110.906 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.558 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.126 0 CA-C-O 121.664 0.745 . . . . 53.240000000000002 110.837 . . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . 0.558 ' HD2' ' N ' ' A' ' 7' ' ' SER . 53.0 Cg_endo -69.81 -4.9 15.0 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.686 2.257 . . . . 75.299999999999997 112.312 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -111.1 -25.99 4.83 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.718 -0.753 . . . . 71.150000000000006 112.467 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -77.87 -41.65 36.08 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.813 0.34 . . . . 72.120000000000005 110.923 -179.947 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -78.5 -19.67 52.5 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.218 -0.446 . . . . 60.030000000000001 110.858 -179.917 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 97.6 m -86.51 -22.41 26.41 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.093 -0.503 . . . . 74.140000000000001 111.161 -179.944 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.496 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -92.16 -35.35 13.9 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.209 -0.45 . . . . 51.43 111.092 179.851 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -75.99 -12.08 60.07 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.202 -0.453 . . . . 73.430000000000007 110.887 -179.915 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 98.3 m -98.71 -35.27 10.22 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.218 -0.446 . . . . 64.120000000000005 111.167 179.905 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.846 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.84 -7.35 41.81 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.747 -0.74 . . . . 72.329999999999998 112.442 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.507 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.72 -54.13 0.15 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.966 0.412 . . . . 73.400000000000006 110.937 -179.872 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.44 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 20.5 m -116.24 -14.99 11.07 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.138 -0.483 . . . . 61.420000000000002 111.114 -179.924 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 10.5 mp -82.26 -15.1 54.22 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.261 -0.427 . . . . 75.549999999999997 110.885 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.846 HG23 ' HA3' ' A' ' 16' ' ' GLY . 7.3 t -75.64 -55.34 2.05 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.644 0.735 . . . . 74.219999999999999 111.134 179.868 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.587 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.5 Cg_endo -69.78 -20.27 34.96 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.699 2.266 . . . . 75.5 112.324 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.437 ' O ' HG12 ' A' ' 22' ' ' VAL . 47.2 t -100.31 -11.66 8.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.217 -0.447 . . . . 73.439999999999998 111.164 179.922 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--N 1.33 -0.25 0 CA-C-N 116.162 -0.472 . . . . 63.539999999999999 110.895 -179.978 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.559 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.5 OUTLIER . . . . . 0 C--O 1.232 0.163 0 CA-C-O 121.668 0.747 . . . . 63.310000000000002 110.844 . . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . 0.559 ' HD2' ' N ' ' A' ' 7' ' ' SER . 53.2 Cg_endo -69.79 -4.87 14.92 Favored 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.676 2.251 . . . . 63.399999999999999 112.351 179.992 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -110.93 -26.22 4.78 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.747 -0.739 . . . . 75.340000000000003 112.486 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.491 ' C ' HD13 ' A' ' 10' ' ' LEU . 3.0 tm? -78.42 -40.44 35.93 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.808 0.337 . . . . 71.109999999999999 110.916 -179.914 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 5.4 t -79.47 -19.49 49.68 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.258 -0.428 . . . . 42.340000000000003 110.843 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 97.8 m -86.81 -22.27 25.96 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.131 -0.486 . . . . 64.25 111.149 -179.927 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.496 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -92.15 -35.44 13.86 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.252 -0.431 . . . . 60.210000000000001 111.072 179.883 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -75.83 -12.02 60.09 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.236 -0.438 . . . . 74.400000000000006 110.896 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 97.7 m -98.53 -35.43 10.24 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.21 -0.45 . . . . 75.439999999999998 111.152 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.826 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.85 -7.43 41.61 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.732 -0.747 . . . . 54.310000000000002 112.457 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.509 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.67 -54.22 0.15 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.947 0.403 . . . . 73.519999999999996 110.844 -179.835 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.445 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.3 m -116.01 -14.54 11.22 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.198 -0.456 . . . . 74.120000000000005 111.159 -179.901 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.428 ' HA ' HD13 ' A' ' 19' ' ' LEU . 4.0 mm? -82.5 -14.52 54.84 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.224 -0.444 . . . . 64.430000000000007 110.945 179.962 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.826 HG23 ' HA3' ' A' ' 16' ' ' GLY . 14.1 t -75.77 -55.11 2.04 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.6 0.714 . . . . 73.340000000000003 111.144 179.799 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.591 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.7 Cg_endo -69.81 -21.08 33.77 Favored 'Trans proline' 0 C--O 1.232 0.18 0 C-N-CA 122.695 2.263 . . . . 74.430000000000007 112.298 179.964 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.433 ' O ' HG12 ' A' ' 22' ' ' VAL . 44.8 t -99.34 -11.78 8.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.273 -0.422 . . . . 72.200000000000003 111.124 179.934 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--N 1.33 -0.276 0 CA-C-N 116.178 -0.464 . . . . 74.109999999999999 110.914 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.558 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.3 OUTLIER . . . . . 0 C--O 1.231 0.11 0 CA-C-O 121.649 0.738 . . . . 61.32 110.854 . . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . 0.558 ' HD2' ' N ' ' A' ' 7' ' ' SER . 54.2 Cg_endo -69.75 -4.55 14.25 Favored 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 122.666 2.244 . . . . 75.340000000000003 112.392 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -111.44 -25.93 4.75 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.775 -0.726 . . . . 42.409999999999997 112.442 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 2.5 tt -78.49 -40.82 34.25 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.826 0.346 . . . . 70.329999999999998 110.907 -179.901 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -79.23 -19.5 50.54 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.213 -0.448 . . . . 61.420000000000002 110.867 -179.933 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 94.8 m -86.81 -22.28 25.95 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.134 -0.485 . . . . 72.209999999999994 111.121 -179.924 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.495 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -92.11 -35.44 13.89 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.213 -0.449 . . . . 72.430000000000007 111.055 179.89 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -75.79 -12.06 60.1 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.271 -0.422 . . . . 74.040000000000006 110.889 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 98.9 m -98.6 -35.32 10.25 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.229 -0.441 . . . . 60.030000000000001 111.109 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.841 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.96 -7.32 41.51 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.725 -0.75 . . . . 62.210000000000001 112.487 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.508 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.74 -54.11 0.15 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.953 0.406 . . . . 63.539999999999999 110.885 -179.89 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.442 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.2 m -116.27 -14.65 11.06 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.152 -0.476 . . . . 73.120000000000005 111.127 -179.905 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.429 HD13 ' HA ' ' A' ' 19' ' ' LEU . 4.1 mm? -82.5 -14.66 54.62 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.25 -0.432 . . . . 75.109999999999999 110.907 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.841 HG23 ' HA3' ' A' ' 16' ' ' GLY . 10.4 t -76.04 -55.21 1.89 Allowed Pre-proline 0 C--N 1.33 -0.257 0 CA-C-O 121.599 0.714 . . . . 71.310000000000002 111.098 179.819 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.59 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.6 Cg_endo -69.76 -20.33 34.97 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.711 2.274 . . . . 74.409999999999997 112.31 179.994 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.435 ' O ' HG12 ' A' ' 22' ' ' VAL . 46.9 t -100.07 -11.69 8.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.236 -0.438 . . . . 74.439999999999998 111.131 179.937 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 5.8 tp10 . . . . . 0 C--N 1.329 -0.29 0 CA-C-N 116.16 -0.473 . . . . 74.439999999999998 110.899 179.967 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.555 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.0 OUTLIER . . . . . 0 C--O 1.232 0.136 0 CA-C-O 121.613 0.721 . . . . 61.420000000000002 110.838 . . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . 0.555 ' HD2' ' N ' ' A' ' 7' ' ' SER . 54.4 Cg_endo -69.74 -4.88 14.91 Favored 'Trans proline' 0 C--N 1.341 0.153 0 C-N-CA 122.645 2.23 . . . . 73.140000000000001 112.382 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -111.06 -26.68 4.56 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.767 -0.73 . . . . 72.310000000000002 112.468 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -77.69 -40.59 40.91 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.826 0.346 . . . . 64.299999999999997 110.908 -179.906 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -79.35 -19.44 50.26 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.161 -0.472 . . . . 64.239999999999995 110.825 -179.878 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 92.1 m -87.38 -21.45 25.63 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.141 -0.481 . . . . 54.229999999999997 111.138 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.5 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -92.86 -35.44 13.37 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.181 -0.463 . . . . 72.230000000000004 111.071 179.922 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -76.3 -12.02 60.01 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.255 -0.43 . . . . 74.439999999999998 110.956 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 94.3 m -98.5 -35.37 10.27 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.153 -0.476 . . . . 74.450000000000003 111.152 179.922 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.831 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.83 -7.37 41.8 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.727 -0.749 . . . . 74.120000000000005 112.514 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.508 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.71 -54.24 0.15 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.924 0.392 . . . . 74.450000000000003 110.873 -179.914 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.44 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.2 m -116.01 -14.8 11.22 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.148 -0.478 . . . . 61.25 111.134 -179.905 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -82.29 -14.6 55.16 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.21 -0.45 . . . . 75.439999999999998 110.909 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.831 HG23 ' HA3' ' A' ' 16' ' ' GLY . 10.0 t -76.53 -55.39 1.63 Allowed Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.651 0.739 . . . . 71.319999999999993 111.108 179.875 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.586 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.4 Cg_endo -69.75 -19.83 35.64 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.712 2.274 . . . . 75.129999999999995 112.327 179.962 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.432 ' O ' HG12 ' A' ' 22' ' ' VAL . 41.6 t -102.3 -11.92 8.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.195 -0.457 . . . . 63.119999999999997 111.12 179.911 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.9 tp10 . . . . . 0 C--N 1.329 -0.286 0 CA-C-N 116.207 -0.451 . . . . 54.25 110.897 -179.959 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.562 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.6 OUTLIER . . . . . 0 C--O 1.231 0.095 0 CA-C-O 121.726 0.774 . . . . 73.129999999999995 110.916 . . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . 0.562 ' HD2' ' N ' ' A' ' 7' ' ' SER . 53.7 Cg_endo -69.76 -4.78 14.73 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.704 2.269 . . . . 62.240000000000002 112.359 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -111.23 -25.96 4.81 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.685 -0.769 . . . . 75.430000000000007 112.481 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 6.4 tp -80.15 -37.15 34.06 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.849 0.357 . . . . 73.409999999999997 110.939 -179.962 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -82.52 -19.22 39.1 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.173 -0.467 . . . . 43.520000000000003 110.874 -179.926 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 99.5 m -86.56 -23.19 25.92 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.124 -0.489 . . . . 63.340000000000003 111.123 -179.922 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.505 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -92.62 -34.83 13.84 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.194 -0.457 . . . . 73.140000000000001 111.11 179.895 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . 0.533 HD23 ' O ' ' A' ' 14' ' ' LEU . 1.0 OUTLIER -76.65 -11.8 59.91 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.203 -0.453 . . . . 43.32 110.933 179.987 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 98.9 m -99.14 -34.26 10.45 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.182 -0.463 . . . . 64.319999999999993 111.149 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.838 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -104.73 -7.77 38.46 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.731 -0.747 . . . . 74.329999999999998 112.537 179.921 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.509 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.5 p90 -29.81 -54.84 0.16 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.9 0.381 . . . . 75.540000000000006 110.887 -179.924 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.435 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 20.0 m -115.57 -14.95 11.48 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.175 -0.466 . . . . 74.120000000000005 111.135 -179.882 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 10.1 mp -82.11 -15.2 54.25 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.204 -0.453 . . . . 72.310000000000002 110.937 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.838 HG23 ' HA3' ' A' ' 16' ' ' GLY . 8.5 t -75.68 -55.29 2.04 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.6 0.714 . . . . 72.200000000000003 111.162 179.826 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.588 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.4 Cg_endo -69.79 -20.19 35.0 Favored 'Trans proline' 0 C--O 1.231 0.143 0 C-N-CA 122.669 2.246 . . . . 62.43 112.323 179.934 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.447 ' O ' HG12 ' A' ' 22' ' ' VAL . 47.4 t -100.41 -11.65 8.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.228 -0.442 . . . . 72.120000000000005 111.142 179.943 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 116.14 -0.482 . . . . 70.129999999999995 110.884 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.516 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.086 0 CA-C-O 121.704 0.764 . . . . 72.549999999999997 110.858 . . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . 0.516 ' HD2' ' N ' ' A' ' 7' ' ' SER . 53.3 Cg_endo -69.77 -6.84 19.57 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.704 2.269 . . . . 73.409999999999997 112.351 -179.998 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -107.17 -27.42 5.34 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.696 -0.764 . . . . 65.420000000000002 112.513 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -78.71 -40.01 34.86 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.823 0.344 . . . . 64.209999999999994 110.908 -179.942 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -79.59 -19.22 49.84 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.194 -0.457 . . . . 63.520000000000003 110.875 -179.925 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 47.3 m -86.48 -23.31 26.02 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.117 -0.492 . . . . 73.0 111.148 -179.95 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.5 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -91.59 -35.5 14.21 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.203 -0.453 . . . . 70.209999999999994 111.094 179.877 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -75.91 -11.8 60.03 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.247 -0.433 . . . . 73.329999999999998 110.909 179.999 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 98.3 m -98.45 -35.57 10.23 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.22 -0.445 . . . . 73.219999999999999 111.146 179.936 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.808 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.95 -7.47 41.26 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.783 -0.722 . . . . 53.409999999999997 112.483 179.98 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.502 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.71 -54.05 0.15 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.877 0.37 . . . . 73.400000000000006 110.878 -179.832 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.444 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.5 m -116.01 -14.62 11.22 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.151 -0.477 . . . . 52.32 111.133 -179.922 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.413 HD13 ' HA ' ' A' ' 19' ' ' LEU . 4.0 mm? -82.26 -14.78 54.93 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.19 -0.459 . . . . 63.450000000000003 110.893 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.808 HG23 ' HA3' ' A' ' 16' ' ' GLY . 13.7 t -75.74 -55.32 2.01 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.625 0.726 . . . . 74.129999999999995 111.112 179.918 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.578 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.6 Cg_endo -69.71 -20.95 34.41 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.735 2.29 . . . . 73.25 112.324 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.433 ' O ' HG12 ' A' ' 22' ' ' VAL . 45.2 t -99.65 -11.78 8.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.2 -0.454 . . . . 63.140000000000001 111.145 179.94 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.329 -0.308 0 CA-C-N 116.172 -0.467 . . . . 64.519999999999996 110.866 -179.989 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.512 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.094 0 CA-C-O 121.668 0.747 . . . . 33.130000000000003 110.882 . . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . 0.512 ' HD2' ' N ' ' A' ' 7' ' ' SER . 53.8 Cg_endo -69.73 -5.65 16.69 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.695 2.263 . . . . 70.310000000000002 112.348 179.962 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -109.17 -26.5 5.17 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.724 -0.751 . . . . 63.100000000000001 112.501 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 6.5 tt -78.62 -41.68 30.94 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.79 0.329 . . . . 73.450000000000003 110.902 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 2.2 t -77.96 -19.88 53.72 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.211 -0.45 . . . . 75.439999999999998 110.844 -179.91 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 91.8 m -86.74 -22.71 25.81 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.137 -0.483 . . . . 54.439999999999998 111.137 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.494 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -91.65 -34.75 14.56 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.224 -0.444 . . . . 51.229999999999997 111.124 179.835 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -76.44 -11.53 59.9 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.197 -0.456 . . . . 74.209999999999994 110.913 -179.967 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 96.7 m -99.01 -35.44 10.05 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.191 -0.459 . . . . 65.040000000000006 111.117 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.817 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.57 -7.63 42.02 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.714 -0.755 . . . . 54.439999999999998 112.479 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.512 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.57 -54.21 0.15 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.914 0.388 . . . . 73.239999999999995 110.843 -179.87 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.44 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 23.3 m -116.05 -14.75 11.19 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.168 -0.469 . . . . 74.109999999999999 111.159 -179.92 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -82.21 -14.46 55.53 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.229 -0.441 . . . . 61.450000000000003 110.901 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.817 HG23 ' HA3' ' A' ' 16' ' ' GLY . 14.9 t -75.71 -55.14 2.06 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.603 0.716 . . . . 54.43 111.097 179.839 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.592 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.7 Cg_endo -69.69 -21.18 34.17 Favored 'Trans proline' 0 C--O 1.231 0.15 0 C-N-CA 122.729 2.286 . . . . 71.349999999999994 112.329 179.961 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.435 ' O ' HG12 ' A' ' 22' ' ' VAL . 44.6 t -99.43 -11.88 8.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.224 -0.444 . . . . 72.129999999999995 111.104 179.965 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--N 1.329 -0.313 0 CA-C-N 116.216 -0.447 . . . . 34.030000000000001 110.884 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.524 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.3 OUTLIER . . . . . 0 C--O 1.232 0.16 0 CA-C-O 121.637 0.732 . . . . 61.420000000000002 110.856 . . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . 0.524 ' HD2' ' N ' ' A' ' 7' ' ' SER . 53.3 Cg_endo -69.75 -7.45 21.08 Favored 'Trans proline' 0 C--N 1.341 0.14 0 C-N-CA 122.736 2.291 . . . . 71.349999999999994 112.311 179.984 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -107.2 -26.26 5.79 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.723 -0.751 . . . . 65.319999999999993 112.449 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -78.44 -41.71 32.09 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.832 0.348 . . . . 51.43 110.954 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -77.54 -20.29 54.41 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.171 -0.468 . . . . 73.329999999999998 110.845 -179.917 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 86.1 m -86.67 -22.35 26.16 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.18 -0.464 . . . . 62.340000000000003 111.134 -179.951 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.492 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -91.76 -34.82 14.45 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.189 -0.459 . . . . 62.350000000000001 111.1 179.884 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -76.12 -11.97 60.03 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.182 -0.463 . . . . 74.439999999999998 110.883 -179.951 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 98.4 m -98.6 -35.33 10.24 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.229 -0.441 . . . . 73.5 111.138 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.823 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.87 -7.43 41.56 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.706 -0.759 . . . . 63.219999999999999 112.505 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.504 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.61 -54.28 0.15 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.957 0.408 . . . . 75.239999999999995 110.871 -179.874 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.443 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.4 m -116.01 -14.54 11.22 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.165 -0.471 . . . . 74.310000000000002 111.138 -179.886 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.424 ' HA ' HD13 ' A' ' 19' ' ' LEU . 4.0 mm? -82.45 -14.52 54.96 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.228 -0.442 . . . . 65.310000000000002 110.948 179.91 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.823 HG23 ' HA3' ' A' ' 16' ' ' GLY . 14.0 t -75.77 -55.13 2.04 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.623 0.725 . . . . 54.100000000000001 111.149 179.818 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.586 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.5 Cg_endo -69.81 -21.03 33.81 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.647 2.231 . . . . 72.439999999999998 112.375 179.934 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.433 ' O ' HG12 ' A' ' 22' ' ' VAL . 44.9 t -99.35 -11.77 8.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.187 -0.46 . . . . 65.140000000000001 111.119 179.88 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--N 1.329 -0.308 0 CA-C-N 116.219 -0.446 . . . . 55.439999999999998 110.889 -179.976 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.51 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.123 0 CA-C-O 121.697 0.76 . . . . 75.010000000000005 110.868 . . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . 0.51 ' HD2' ' N ' ' A' ' 7' ' ' SER . 53.7 Cg_endo -69.75 -6.28 18.23 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.708 2.272 . . . . 71.209999999999994 112.337 179.963 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -108.72 -25.82 5.56 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.715 -0.755 . . . . 63.240000000000002 112.45 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.8 tt -79.13 -40.98 29.62 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.88 0.371 . . . . 71.310000000000002 110.955 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 30.0 t -78.7 -19.88 51.42 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.185 -0.461 . . . . 73.209999999999994 110.855 -179.919 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 92.3 m -86.77 -22.34 25.99 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.132 -0.486 . . . . 60.340000000000003 111.158 -179.974 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.495 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -91.88 -35.12 14.23 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.21 -0.45 . . . . 54.229999999999997 111.082 179.855 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -75.9 -12.14 60.1 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.236 -0.438 . . . . 74.129999999999995 110.898 -179.955 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 97.9 m -98.43 -35.3 10.32 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.196 -0.456 . . . . 52.130000000000003 111.153 179.96 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.829 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.99 -7.36 41.37 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.732 -0.747 . . . . 41.210000000000001 112.5 179.945 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.509 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.65 -54.2 0.15 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.915 0.388 . . . . 73.409999999999997 110.859 -179.87 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.44 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.2 m -116.15 -14.39 11.14 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.156 -0.475 . . . . 62.420000000000002 111.124 -179.912 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.402 ' HA ' HD13 ' A' ' 19' ' ' LEU . 4.0 mm? -82.56 -14.59 54.6 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.246 -0.434 . . . . 73.299999999999997 110.913 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.829 HG23 ' HA3' ' A' ' 16' ' ' GLY . 13.4 t -75.74 -55.26 2.02 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.631 0.729 . . . . 55.539999999999999 111.11 179.847 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.591 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.1 Cg_endo -69.78 -20.79 34.27 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.7 2.266 . . . . 60.149999999999999 112.316 179.989 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.439 ' O ' HG12 ' A' ' 22' ' ' VAL . 44.1 t -99.98 -11.7 8.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.231 -0.44 . . . . 63.240000000000002 111.133 179.889 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--N 1.329 -0.306 0 CA-C-N 116.197 -0.456 . . . . 72.25 110.884 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.479 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.231 0.131 0 CA-C-O 121.66 0.743 . . . . 73.510000000000005 110.862 . . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . 0.479 ' HD2' ' N ' ' A' ' 7' ' ' SER . 53.3 Cg_endo -69.75 -6.62 19.04 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.649 2.233 . . . . 74.140000000000001 112.333 -179.976 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -108.0 -26.26 5.57 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.725 -0.75 . . . . 53.32 112.453 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -78.62 -41.81 30.57 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.848 0.356 . . . . 74.430000000000007 110.954 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 7.7 t -77.48 -20.53 54.22 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.157 -0.474 . . . . 70.040000000000006 110.874 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 98.0 m -86.65 -21.96 26.42 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.103 -0.498 . . . . 63.119999999999997 111.173 -179.918 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.488 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -92.06 -34.99 14.17 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.171 -0.468 . . . . 40.329999999999998 111.062 179.911 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -75.99 -11.72 60.01 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.214 -0.448 . . . . 65.409999999999997 110.892 -179.934 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 98.5 m -98.72 -35.38 10.18 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.164 -0.471 . . . . 64.420000000000002 111.162 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.815 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.94 -7.42 41.37 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.779 -0.724 . . . . 63.109999999999999 112.509 179.934 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.501 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.61 -54.27 0.15 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.913 0.387 . . . . 75.530000000000001 110.907 -179.869 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.445 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 20.6 m -115.91 -14.57 11.28 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.105 -0.498 . . . . 74.230000000000004 111.15 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.426 HD13 ' HA ' ' A' ' 19' ' ' LEU . 4.0 mm? -82.48 -14.33 55.2 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.211 -0.45 . . . . 65.420000000000002 110.933 179.952 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.815 HG23 ' HA3' ' A' ' 16' ' ' GLY . 14.3 t -75.98 -55.22 1.92 Allowed Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.669 0.747 . . . . 75.409999999999997 111.169 179.789 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.582 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.7 Cg_endo -69.74 -20.91 34.34 Favored 'Trans proline' 0 C--N 1.342 0.22 0 C-N-CA 122.631 2.221 . . . . 75.329999999999998 112.366 179.923 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.43 ' O ' HG12 ' A' ' 22' ' ' VAL . 46.4 t -99.23 -12.17 8.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.212 -0.449 . . . . 75.310000000000002 111.124 179.922 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.178 -0.465 . . . . 73.219999999999999 110.897 -179.936 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.572 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 0.5 OUTLIER . . . . . 0 C--O 1.231 0.094 0 CA-C-O 121.695 0.759 . . . . 61.32 110.904 . . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . 0.572 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 53.4 Cg_endo -69.75 -7.3 20.69 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.683 2.255 . . . . 72.150000000000006 112.32 -179.993 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -121.32 -15.21 4.67 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.726 -0.75 . . . . 22.32 112.483 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.1 tp -80.07 -40.72 27.07 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.841 0.353 . . . . 70.5 110.952 -179.932 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -78.41 -20.1 51.86 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.141 -0.481 . . . . 65.329999999999998 110.881 -179.944 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 87.9 m -86.21 -22.54 26.86 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.145 -0.479 . . . . 51.420000000000002 111.17 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.492 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -91.86 -35.34 14.12 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.19 -0.459 . . . . 71.010000000000005 111.14 179.839 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -75.87 -12.02 60.08 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.187 -0.46 . . . . 72.040000000000006 110.914 -179.972 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 97.7 m -98.64 -35.34 10.23 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.165 -0.47 . . . . 73.239999999999995 111.157 179.932 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.844 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.81 -7.38 41.84 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.711 -0.757 . . . . 42.229999999999997 112.468 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.498 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.7 -54.08 0.15 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.913 0.387 . . . . 72.109999999999999 110.824 -179.849 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.449 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.0 m -116.31 -14.74 11.03 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.194 -0.457 . . . . 74.140000000000001 111.131 -179.869 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -82.39 -14.64 54.87 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.218 -0.446 . . . . 44.5 110.947 179.938 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.844 HG23 ' HA3' ' A' ' 16' ' ' GLY . 9.8 t -76.17 -55.31 1.81 Allowed Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.645 0.736 . . . . 71.519999999999996 111.138 179.848 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.586 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 54.1 Cg_endo -69.74 -20.23 35.2 Favored 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 122.715 2.277 . . . . 51.439999999999998 112.364 179.922 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.447 ' O ' HG12 ' A' ' 22' ' ' VAL . 45.1 t -100.67 -11.71 8.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.207 -0.451 . . . . 64.329999999999998 111.165 179.905 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--N 1.329 -0.286 0 CA-C-N 116.18 -0.464 . . . . 71.420000000000002 110.878 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.574 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 0.5 OUTLIER . . . . . 0 C--O 1.232 0.151 0 CA-C-O 121.618 0.723 . . . . 74.140000000000001 110.855 . . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . 0.574 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 53.7 Cg_endo -69.81 -7.25 20.6 Favored 'Trans proline' 0 N--CA 1.466 -0.115 0 C-N-CA 122.673 2.249 . . . . 54.409999999999997 112.357 179.979 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -121.34 -15.18 4.67 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.685 -0.769 . . . . 71.329999999999998 112.479 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.1 tt -80.0 -40.9 26.91 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.851 0.358 . . . . 54.200000000000003 110.896 -179.902 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -78.24 -20.15 52.29 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.177 -0.465 . . . . 72.150000000000006 110.859 -179.918 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 81.8 m -86.15 -22.55 26.97 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.128 -0.487 . . . . 71.439999999999998 111.162 -179.929 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.497 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -91.91 -35.38 14.06 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.188 -0.46 . . . . 73.200000000000003 111.077 179.882 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -75.87 -11.98 60.07 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.247 -0.433 . . . . 64.340000000000003 110.925 -179.964 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 97.6 m -98.58 -35.39 10.23 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.171 -0.468 . . . . 61.420000000000002 111.163 179.89 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.821 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.8 -7.44 41.73 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.704 -0.76 . . . . 70.519999999999996 112.449 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.497 ' HB3' ' O ' ' A' ' 13' ' ' ALA . 1.4 p90 -29.62 -54.23 0.15 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.907 0.384 . . . . 74.5 110.842 -179.846 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.448 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.1 m -116.05 -14.58 11.19 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.172 -0.467 . . . . 75.049999999999997 111.127 -179.864 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.413 ' HA ' HD13 ' A' ' 19' ' ' LEU . 4.0 mm? -82.46 -14.54 54.91 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.251 -0.431 . . . . 72.5 110.919 179.975 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.821 HG23 ' HA3' ' A' ' 16' ' ' GLY . 13.6 t -75.85 -55.16 1.99 Allowed Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.649 0.738 . . . . 72.239999999999995 111.117 179.834 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.586 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.5 Cg_endo -69.8 -20.82 34.15 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.652 2.235 . . . . 75.400000000000006 112.365 179.976 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.441 ' O ' HG12 ' A' ' 22' ' ' VAL . 44.3 t -99.88 -11.81 8.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.194 -0.457 . . . . 73.219999999999999 111.116 179.909 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.2 -0.455 . . . . 75.5 110.842 -179.932 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.568 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 0.5 OUTLIER . . . . . 0 C--O 1.232 0.138 0 CA-C-O 121.64 0.733 . . . . 63.020000000000003 110.877 . . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . 0.568 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 53.8 Cg_endo -69.79 -7.26 20.6 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.702 2.268 . . . . 72.030000000000001 112.347 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -121.37 -15.21 4.65 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.696 -0.764 . . . . 35.310000000000002 112.462 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 5.6 tp -80.05 -40.75 27.08 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.792 0.329 . . . . 64.150000000000006 110.911 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.9 t -78.38 -20.12 51.92 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.23 -0.441 . . . . 71.340000000000003 110.836 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 64.1 m -86.24 -22.42 26.89 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.159 -0.473 . . . . 73.049999999999997 111.183 -179.956 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.495 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -92.01 -35.32 14.03 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.18 -0.464 . . . . 71.340000000000003 111.073 179.876 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -75.87 -12.06 60.09 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.235 -0.439 . . . . 71.209999999999994 110.913 -179.98 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 97.7 m -98.55 -35.46 10.22 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.226 -0.443 . . . . 60.25 111.124 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.824 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.78 -7.4 41.87 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.743 -0.741 . . . . 62.200000000000003 112.489 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.495 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.6 -54.23 0.15 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.985 0.421 . . . . 71.299999999999997 110.933 -179.906 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.449 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.4 m -116.08 -14.45 11.18 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.128 -0.487 . . . . 74.540000000000006 111.182 -179.951 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.445 HD13 ' HA ' ' A' ' 19' ' ' LEU . 4.0 mm? -82.51 -14.54 54.79 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.222 -0.445 . . . . 70.25 110.941 179.919 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.824 HG23 ' HA3' ' A' ' 16' ' ' GLY . 14.3 t -75.71 -55.16 2.06 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.595 0.712 . . . . 63.409999999999997 111.122 179.803 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.585 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.7 Cg_endo -69.8 -21.0 33.9 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.615 2.21 . . . . 72.430000000000007 112.37 179.987 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.444 ' O ' HG12 ' A' ' 22' ' ' VAL . 45.1 t -99.4 -11.74 8.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.208 -0.451 . . . . 73.439999999999998 111.097 179.911 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.329 -0.3 0 CA-C-N 116.212 -0.449 . . . . 72.319999999999993 110.884 179.971 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.572 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 0.5 OUTLIER . . . . . 0 C--O 1.231 0.091 0 CA-C-O 121.702 0.763 . . . . 72.219999999999999 110.882 . . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . 0.572 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 54.4 Cg_endo -69.72 -7.32 20.75 Favored 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 122.682 2.255 . . . . 61.539999999999999 112.327 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -121.33 -15.24 4.66 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.721 -0.752 . . . . 71.310000000000002 112.439 -179.948 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.7 tt -80.05 -40.72 27.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.832 0.349 . . . . 65.540000000000006 110.946 -179.903 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -78.32 -20.14 52.07 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.201 -0.454 . . . . 62.43 110.913 -179.979 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 86.0 m -86.22 -22.48 26.88 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.086 -0.507 . . . . 62.399999999999999 111.105 -179.907 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.498 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -91.97 -35.34 14.04 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.214 -0.448 . . . . 73.519999999999996 111.051 179.892 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -75.87 -12.06 60.09 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.244 -0.434 . . . . 73.239999999999995 110.912 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 97.8 m -98.6 -35.31 10.25 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.202 -0.454 . . . . 70.150000000000006 111.176 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.825 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.83 -7.45 41.64 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.778 -0.725 . . . . 60.130000000000003 112.477 179.979 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.498 ' HB3' ' O ' ' A' ' 13' ' ' ALA . 1.4 p90 -29.57 -54.31 0.15 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.953 0.406 . . . . 73.200000000000003 110.889 -179.891 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.448 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.4 m -116.04 -14.46 11.21 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.126 -0.488 . . . . 74.430000000000007 111.146 -179.938 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.446 HD13 ' HA ' ' A' ' 19' ' ' LEU . 4.0 mm? -82.45 -14.57 54.87 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.248 -0.433 . . . . 72.349999999999994 110.937 179.913 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.825 HG23 ' HA3' ' A' ' 16' ' ' GLY . 14.2 t -75.75 -55.14 2.05 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.629 0.728 . . . . 73.209999999999994 111.117 179.858 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.582 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.8 Cg_endo -69.78 -21.07 33.91 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.67 2.246 . . . . 64.519999999999996 112.346 179.951 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.445 ' O ' HG12 ' A' ' 22' ' ' VAL . 45.0 t -99.37 -11.75 8.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.234 -0.439 . . . . 72.099999999999994 111.151 179.905 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--N 1.329 -0.284 0 CA-C-N 116.152 -0.476 . . . . 72.150000000000006 110.886 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.568 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 0.5 OUTLIER . . . . . 0 C--O 1.231 0.105 0 CA-C-O 121.647 0.737 . . . . 53.43 110.875 . . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . 0.568 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 54.3 Cg_endo -69.69 -7.28 20.62 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.676 2.251 . . . . 74.439999999999998 112.397 179.935 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -121.32 -15.27 4.65 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.749 -0.738 . . . . 71.329999999999998 112.48 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 5.2 tt -79.94 -40.89 27.15 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.838 0.352 . . . . 63.020000000000003 110.935 -179.929 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.7 t -78.28 -20.16 52.17 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.141 -0.481 . . . . 64.329999999999998 110.846 -179.899 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 85.6 m -86.19 -22.48 26.94 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.137 -0.483 . . . . 72.049999999999997 111.136 -179.929 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.497 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -91.92 -35.38 14.05 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.23 -0.441 . . . . 71.239999999999995 111.083 179.895 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -75.95 -11.95 60.06 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.185 -0.461 . . . . 73.129999999999995 110.882 -179.929 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 97.6 m -98.57 -35.45 10.22 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.213 -0.449 . . . . 71.299999999999997 111.155 179.901 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.825 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.75 -7.47 41.82 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.772 -0.727 . . . . 53.340000000000003 112.449 -179.979 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.497 ' HB3' ' O ' ' A' ' 13' ' ' ALA . 1.5 p90 -29.59 -54.25 0.15 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.961 0.41 . . . . 65.530000000000001 110.886 -179.855 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.448 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.3 m -116.07 -14.5 11.19 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.116 -0.493 . . . . 74.010000000000005 111.133 -179.896 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.446 HD13 ' HA ' ' A' ' 19' ' ' LEU . 4.0 mm? -82.47 -14.59 54.79 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.234 -0.439 . . . . 74.519999999999996 110.893 179.958 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.825 HG23 ' HA3' ' A' ' 16' ' ' GLY . 14.0 t -75.73 -55.13 2.06 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.605 0.717 . . . . 75.239999999999995 111.116 179.844 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.584 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.4 Cg_endo -69.8 -21.06 33.84 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.696 2.264 . . . . 74.409999999999997 112.304 -179.982 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.444 ' O ' HG12 ' A' ' 22' ' ' VAL . 44.7 t -99.41 -11.77 8.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.205 -0.452 . . . . 70.310000000000002 111.134 179.932 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.33 -0.279 0 CA-C-N 116.178 -0.465 . . . . 75.219999999999999 110.933 179.964 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.565 ' CB ' ' CD ' ' A' ' 8' ' ' PRO . 0.5 OUTLIER . . . . . 0 C--O 1.231 0.103 0 CA-C-O 121.7 0.762 . . . . 64.439999999999998 110.849 . . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . 0.565 ' CD ' ' CB ' ' A' ' 7' ' ' SER . 54.1 Cg_endo -69.71 -7.29 20.67 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.747 2.298 . . . . 70.319999999999993 112.325 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -121.34 -15.23 4.66 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.735 -0.745 . . . . 23.210000000000001 112.479 179.988 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 2.1 tp -80.04 -40.76 27.07 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.821 0.344 . . . . 72.340000000000003 110.942 -179.937 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -78.37 -20.11 51.97 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.196 -0.456 . . . . 43.530000000000001 110.865 -179.955 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 40.0 m -86.22 -22.48 26.89 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.135 -0.484 . . . . 53.310000000000002 111.123 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.496 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -91.95 -35.34 14.05 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.222 -0.444 . . . . 71.150000000000006 111.076 179.896 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -75.93 -11.98 60.06 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.201 -0.454 . . . . 62.509999999999998 110.931 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 97.6 m -98.53 -35.46 10.23 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.179 -0.464 . . . . 75.230000000000004 111.154 179.892 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.825 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.78 -7.43 41.79 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.773 -0.727 . . . . 71.420000000000002 112.485 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.496 ' HB3' ' O ' ' A' ' 13' ' ' ALA . 1.4 p90 -29.63 -54.27 0.15 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.852 0.358 . . . . 64.400000000000006 110.864 -179.893 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.449 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.4 m -116.01 -14.48 11.22 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.171 -0.468 . . . . 51.219999999999999 111.144 -179.922 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.445 HD13 ' HA ' ' A' ' 19' ' ' LEU . 4.0 mm? -82.51 -14.54 54.81 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.225 -0.443 . . . . 53.439999999999998 110.953 179.94 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.825 HG23 ' HA3' ' A' ' 16' ' ' GLY . 14.1 t -75.79 -55.1 2.03 Favored Pre-proline 0 C--N 1.33 -0.251 0 CA-C-O 121.587 0.708 . . . . 60.130000000000003 111.118 179.838 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.585 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.7 Cg_endo -69.79 -21.04 33.92 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.643 2.229 . . . . 61.43 112.336 179.978 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.443 ' O ' HG12 ' A' ' 22' ' ' VAL . 45.2 t -99.4 -11.74 8.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.223 -0.444 . . . . 52.219999999999999 111.137 179.917 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--N 1.33 -0.26 0 CA-C-N 116.145 -0.48 . . . . 74.200000000000003 110.918 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 12.5 m . . . . . 0 N--CA 1.458 -0.058 0 CA-C-O 120.841 0.353 . . . . 61.229999999999997 111.105 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -62.63 -21.7 63.1 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.705 -0.76 . . . . 73.209999999999994 112.538 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . 0.473 ' HA ' HD23 ' A' ' 6' ' ' LEU . 61.0 m-20 -115.07 -5.31 12.47 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.876 0.37 . . . . 75.400000000000006 110.889 -179.895 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 21.0 t -94.31 -11.37 8.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.175 -0.466 . . . . 62.450000000000003 111.138 179.915 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -110.74 34.84 5.13 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.773 -0.727 . . . . 61.240000000000002 112.501 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.473 HD23 ' HA ' ' A' ' 3' ' ' ASN . 3.6 mm? -88.42 -75.5 0.42 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.788 0.328 . . . . 72.140000000000001 110.87 -179.878 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.563 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.0 OUTLIER -69.09 -56.8 8.31 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.677 0.751 . . . . 74.549999999999997 110.845 -179.91 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.563 ' HD2' ' N ' ' A' ' 7' ' ' SER . 54.4 Cg_endo -69.69 -4.89 14.89 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.678 2.252 . . . . 65.129999999999995 112.341 179.959 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -111.07 -26.33 4.7 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.72 -0.753 . . . . 65.299999999999997 112.503 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.4 tt -77.93 -40.96 37.92 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.856 0.36 . . . . 64.340000000000003 110.943 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 10.4 t -79.05 -19.41 51.46 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.17 -0.468 . . . . 62.020000000000003 110.898 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 96.9 m -86.87 -22.16 25.92 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.128 -0.487 . . . . 73.409999999999997 111.173 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.498 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -92.36 -35.29 13.8 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.214 -0.448 . . . . 63.549999999999997 111.094 179.876 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -76.07 -12.03 60.05 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.224 -0.444 . . . . 73.010000000000005 110.924 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 97.1 m -98.61 -35.26 10.27 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.158 -0.473 . . . . 71.150000000000006 111.175 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.818 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.89 -7.5 41.35 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.778 -0.725 . . . . 61.439999999999998 112.46 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.51 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.58 -54.36 0.15 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.943 0.401 . . . . 74.329999999999998 110.877 -179.859 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.445 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.4 m -115.92 -14.39 11.28 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.126 -0.488 . . . . 73.310000000000002 111.17 -179.916 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.437 HD13 ' HA ' ' A' ' 19' ' ' LEU . 4.0 mm? -82.46 -14.57 54.84 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.206 -0.452 . . . . 61.350000000000001 110.955 179.91 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.818 HG23 ' HA3' ' A' ' 16' ' ' GLY . 16.5 t -75.7 -55.03 2.1 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.612 0.72 . . . . 72.319999999999993 111.166 179.818 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.592 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 54.1 Cg_endo -69.79 -21.17 33.7 Favored 'Trans proline' 0 C--O 1.232 0.194 0 C-N-CA 122.695 2.264 . . . . 71.439999999999998 112.362 179.92 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.434 ' O ' HG12 ' A' ' 22' ' ' VAL . 44.4 t -99.29 -11.73 8.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.261 -0.427 . . . . 74.340000000000003 111.149 179.91 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -58.11 -21.18 45.19 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.156 -0.474 . . . . 65.430000000000007 110.859 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 10.1 t70 -102.47 -6.01 23.4 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.201 -0.454 . . . . 72.129999999999995 110.884 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 25.6 t-80 . . . . . 0 C--N 1.329 -0.319 0 CA-C-N 116.179 -0.464 . . . . 73.099999999999994 110.862 -179.965 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.458 -0.057 0 CA-C-O 120.786 0.327 . . . . 54.539999999999999 111.122 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -56.61 -40.77 88.49 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.73 -0.747 . . . . 65.540000000000006 112.434 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 27.8 m120 -109.04 -5.41 16.04 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.835 0.35 . . . . 52.439999999999998 110.875 -179.892 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 21.3 t -92.54 -11.38 9.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.217 -0.447 . . . . 62.32 111.123 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -119.59 28.46 6.47 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.729 -0.748 . . . . 74.25 112.471 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -85.31 -74.59 0.4 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.831 0.348 . . . . 61.409999999999997 110.924 -179.959 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.56 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.0 OUTLIER -68.85 -56.87 8.66 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.707 0.765 . . . . 74.549999999999997 110.861 -179.976 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.56 ' HD2' ' N ' ' A' ' 7' ' ' SER . 53.3 Cg_endo -69.74 -4.76 14.66 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.693 2.262 . . . . 75.109999999999999 112.319 -179.978 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -111.24 -26.01 4.78 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.783 -0.722 . . . . 71.5 112.539 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 3.6 tt -78.17 -41.07 35.86 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.819 0.343 . . . . 71.319999999999993 110.891 -179.888 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 4.9 t -79.2 -19.27 51.22 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.193 -0.458 . . . . 70.519999999999996 110.866 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 97.1 m -86.93 -22.25 25.75 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.133 -0.485 . . . . 71.409999999999997 111.11 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.499 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -92.33 -35.32 13.8 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.217 -0.447 . . . . 71.129999999999995 111.087 179.88 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -76.07 -11.89 60.02 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.219 -0.446 . . . . 70.430000000000007 110.941 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 98.4 m -98.59 -35.33 10.25 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.161 -0.472 . . . . 74.420000000000002 111.174 179.897 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.824 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.91 -7.42 41.45 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.739 -0.744 . . . . 61.310000000000002 112.536 179.938 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.511 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.59 -54.22 0.15 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.926 0.393 . . . . 73.25 110.889 -179.911 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.44 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.3 m -116.08 -14.58 11.18 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.132 -0.485 . . . . 60.100000000000001 111.129 -179.886 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -82.36 -14.57 55.04 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.237 -0.438 . . . . 73.519999999999996 110.96 179.946 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.824 HG23 ' HA3' ' A' ' 16' ' ' GLY . 14.3 t -75.76 -55.16 2.04 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-O 121.64 0.734 . . . . 60.039999999999999 111.099 179.843 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.592 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.7 Cg_endo -69.73 -21.1 34.09 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.692 2.261 . . . . 72.400000000000006 112.326 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.436 ' O ' HG12 ' A' ' 22' ' ' VAL . 45.3 t -99.37 -11.74 8.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.186 -0.461 . . . . 63.340000000000003 111.163 179.906 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -58.04 -21.05 43.52 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.177 -0.465 . . . . 73.329999999999998 110.921 -179.978 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 26.7 t70 -103.2 -5.79 22.79 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.125 -0.489 . . . . 63.409999999999997 110.883 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 17.9 t-80 . . . . . 0 C--N 1.33 -0.266 0 CA-C-N 116.199 -0.455 . . . . 74.040000000000006 110.891 -179.942 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.457 -0.113 0 CA-C-O 120.827 0.346 . . . . 52.119999999999997 111.187 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -64.98 -34.76 90.75 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.701 -0.762 . . . . 43.329999999999998 112.461 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 5.5 t-20 -119.72 -5.59 10.18 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.851 0.358 . . . . 52.310000000000002 110.897 -179.877 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.4 HG12 ' O ' ' A' ' 4' ' ' VAL . 21.2 t -97.35 -11.34 8.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.176 -0.465 . . . . 63.310000000000002 111.109 179.933 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -117.15 36.12 3.86 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.685 -0.769 . . . . 74.450000000000003 112.487 179.962 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 2.9 tt -85.06 -72.72 0.47 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.816 0.341 . . . . 73.299999999999997 110.959 -179.968 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.56 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.0 OUTLIER -68.97 -56.82 8.46 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.639 0.733 . . . . 64.450000000000003 110.869 -179.939 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.56 ' HD2' ' N ' ' A' ' 7' ' ' SER . 54.1 Cg_endo -69.75 -4.94 15.04 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.671 2.248 . . . . 64.310000000000002 112.324 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -111.0 -26.09 4.82 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.765 -0.731 . . . . 71.150000000000006 112.469 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -78.04 -41.35 35.92 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.797 0.332 . . . . 60.530000000000001 110.945 -179.938 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -78.64 -19.67 52.08 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.197 -0.456 . . . . 74.420000000000002 110.861 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 97.4 m -86.55 -22.44 26.31 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.084 -0.507 . . . . 74.040000000000006 111.167 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.495 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -92.18 -35.29 13.92 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.185 -0.461 . . . . 60.310000000000002 111.088 179.914 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -76.02 -11.96 60.04 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.201 -0.454 . . . . 73.519999999999996 110.921 -179.967 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 98.8 m -98.66 -35.24 10.25 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.152 -0.476 . . . . 70.140000000000001 111.115 179.942 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.82 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.92 -7.5 41.28 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.746 -0.74 . . . . 74.439999999999998 112.466 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.51 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.6 -54.31 0.15 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.885 0.374 . . . . 72.030000000000001 110.894 -179.852 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.442 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.5 m -115.91 -14.43 11.28 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.166 -0.47 . . . . 73.219999999999999 111.14 -179.931 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.441 ' HA ' HD13 ' A' ' 19' ' ' LEU . 4.0 mm? -82.55 -14.39 54.97 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.232 -0.44 . . . . 65.310000000000002 110.889 179.989 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.82 HG23 ' HA3' ' A' ' 16' ' ' GLY . 15.2 t -75.95 -55.06 1.96 Allowed Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.607 0.717 . . . . 52.409999999999997 111.113 179.87 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.593 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 54.1 Cg_endo -69.72 -21.2 34.0 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.708 2.272 . . . . 71.409999999999997 112.374 179.909 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.436 ' O ' HG12 ' A' ' 22' ' ' VAL . 45.9 t -99.1 -11.98 8.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.24 -0.436 . . . . 74.150000000000006 111.118 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -58.23 -20.76 44.35 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.156 -0.475 . . . . 71.329999999999998 110.892 -179.968 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -76.72 -5.11 46.67 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.148 -0.478 . . . . 71.019999999999996 110.891 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.329 -0.301 0 CA-C-N 116.179 -0.464 . . . . 71.109999999999999 110.871 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.457 -0.097 0 CA-C-O 120.852 0.358 . . . . 74.219999999999999 111.168 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -68.22 -23.44 74.78 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.765 -0.731 . . . . 60.240000000000002 112.474 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 68.2 m-20 -114.07 -5.46 13.1 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.81 0.338 . . . . 72.0 110.858 -179.874 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 21.2 t -107.07 -11.28 10.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.243 -0.435 . . . . 72.420000000000002 111.145 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -117.62 37.06 3.43 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.754 -0.736 . . . . 43.340000000000003 112.444 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 23.6 tp -88.89 -75.74 0.42 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.837 0.351 . . . . 54.310000000000002 110.882 -179.916 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.562 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.6 OUTLIER -69.0 -56.88 8.33 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-O 121.679 0.752 . . . . 73.209999999999994 110.857 -179.912 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.562 ' HD2' ' N ' ' A' ' 7' ' ' SER . 53.9 Cg_endo -69.7 -4.92 14.96 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.714 2.276 . . . . 71.239999999999995 112.358 179.991 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -111.11 -26.03 4.81 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.715 -0.755 . . . . 74.120000000000005 112.448 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -78.16 -41.07 35.96 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.81 0.338 . . . . 71.310000000000002 110.934 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -79.05 -19.48 51.26 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.161 -0.472 . . . . 52.020000000000003 110.861 -179.929 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 97.7 m -86.7 -22.39 26.07 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.175 -0.466 . . . . 73.400000000000006 111.13 -179.953 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.497 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -92.12 -35.43 13.88 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.265 -0.425 . . . . 41.439999999999998 111.147 179.84 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -75.99 -11.88 60.03 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.206 -0.452 . . . . 63.299999999999997 110.938 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 97.6 m -98.69 -35.4 10.19 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.194 -0.457 . . . . 65.019999999999996 111.149 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.843 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.83 -7.35 41.84 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.707 -0.758 . . . . 60.25 112.523 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.51 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.68 -54.24 0.15 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.893 0.378 . . . . 73.209999999999994 110.869 -179.869 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.438 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 20.5 m -116.08 -14.91 11.17 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.17 -0.468 . . . . 72.019999999999996 111.188 -179.936 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 10.5 mp -82.23 -15.02 54.57 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.179 -0.464 . . . . 74.109999999999999 110.937 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.843 HG23 ' HA3' ' A' ' 16' ' ' GLY . 9.4 t -75.44 -55.35 2.14 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.588 0.709 . . . . 63.340000000000003 111.103 179.839 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.587 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 54.2 Cg_endo -69.71 -20.54 34.94 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.687 2.258 . . . . 70.230000000000004 112.371 179.936 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.443 ' O ' HG12 ' A' ' 22' ' ' VAL . 45.9 t -100.26 -11.76 8.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.179 -0.464 . . . . 75.420000000000002 111.118 179.919 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -56.69 -21.65 29.26 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.194 -0.457 . . . . 70.040000000000006 110.906 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 91.8 m-20 -120.0 -5.95 10.03 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.183 -0.462 . . . . 53.509999999999998 110.867 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 116.165 -0.471 . . . . 74.329999999999998 110.863 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.457 -0.092 0 CA-C-O 120.872 0.368 . . . . 74.329999999999998 111.144 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -64.49 -34.8 90.88 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.806 -0.711 . . . . 53.100000000000001 112.453 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 2.6 t-20 -88.26 -5.66 58.24 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.856 0.36 . . . . 72.329999999999998 110.877 -179.846 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.401 HG12 ' O ' ' A' ' 4' ' ' VAL . 21.1 t -91.1 -11.4 9.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.147 -0.479 . . . . 63.109999999999999 111.087 179.923 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -110.12 33.61 5.9 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.775 -0.726 . . . . 43.409999999999997 112.534 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -86.12 -74.17 0.43 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.812 0.339 . . . . 73.409999999999997 110.854 -179.828 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.558 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.0 OUTLIER -68.7 -56.74 9.17 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.664 0.745 . . . . 53.240000000000002 110.837 -179.897 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.558 ' HD2' ' N ' ' A' ' 7' ' ' SER . 53.0 Cg_endo -69.81 -4.9 15.0 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.686 2.257 . . . . 75.299999999999997 112.312 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -111.1 -25.99 4.83 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.718 -0.753 . . . . 71.150000000000006 112.467 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -77.87 -41.65 36.08 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.813 0.34 . . . . 72.120000000000005 110.923 -179.947 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -78.5 -19.67 52.5 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.218 -0.446 . . . . 60.030000000000001 110.858 -179.917 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 97.6 m -86.51 -22.41 26.41 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.093 -0.503 . . . . 74.140000000000001 111.161 -179.944 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.496 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -92.16 -35.35 13.9 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.209 -0.45 . . . . 51.43 111.092 179.851 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -75.99 -12.08 60.07 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.202 -0.453 . . . . 73.430000000000007 110.887 -179.915 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 98.3 m -98.71 -35.27 10.22 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.218 -0.446 . . . . 64.120000000000005 111.167 179.905 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.846 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.84 -7.35 41.81 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.747 -0.74 . . . . 72.329999999999998 112.442 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.507 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.72 -54.13 0.15 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.966 0.412 . . . . 73.400000000000006 110.937 -179.872 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.44 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 20.5 m -116.24 -14.99 11.07 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.138 -0.483 . . . . 61.420000000000002 111.114 -179.924 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 10.5 mp -82.26 -15.1 54.22 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.261 -0.427 . . . . 75.549999999999997 110.885 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.846 HG23 ' HA3' ' A' ' 16' ' ' GLY . 7.3 t -75.64 -55.34 2.05 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.644 0.735 . . . . 74.219999999999999 111.134 179.868 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.587 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.5 Cg_endo -69.78 -20.27 34.96 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.699 2.266 . . . . 75.5 112.324 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.437 ' O ' HG12 ' A' ' 22' ' ' VAL . 47.2 t -100.31 -11.66 8.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.217 -0.447 . . . . 73.439999999999998 111.164 179.922 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -57.81 -20.99 39.73 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.162 -0.472 . . . . 63.539999999999999 110.895 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -74.96 -6.72 50.83 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.14 -0.482 . . . . 52.310000000000002 110.855 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 2.1 t60 . . . . . 0 C--N 1.33 -0.28 0 CA-C-N 116.236 -0.438 . . . . 64.109999999999999 110.849 -179.953 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 4.0 m . . . . . 0 N--CA 1.457 -0.107 0 CA-C-O 120.82 0.343 . . . . 50.219999999999999 111.147 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -60.95 -42.29 99.67 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.774 -0.727 . . . . 70.150000000000006 112.513 179.935 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . 0.554 ' HA ' HD23 ' A' ' 6' ' ' LEU . 2.6 m120 -95.19 -5.48 43.82 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.861 0.363 . . . . 72.219999999999999 110.912 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 20.9 t -86.47 -11.4 11.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.185 -0.462 . . . . 73.409999999999997 111.135 179.921 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -116.97 37.04 3.49 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.762 -0.732 . . . . 74.040000000000006 112.502 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.554 HD23 ' HA ' ' A' ' 3' ' ' ASN . 1.7 mm? -88.65 -75.68 0.42 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.865 0.364 . . . . 74.329999999999998 110.949 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.559 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.5 OUTLIER -68.93 -56.81 8.59 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 121.668 0.747 . . . . 63.310000000000002 110.844 -179.924 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.559 ' HD2' ' N ' ' A' ' 7' ' ' SER . 53.2 Cg_endo -69.79 -4.87 14.92 Favored 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.676 2.251 . . . . 63.399999999999999 112.351 179.992 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -110.93 -26.22 4.78 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.747 -0.739 . . . . 75.340000000000003 112.486 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.491 ' C ' HD13 ' A' ' 10' ' ' LEU . 3.0 tm? -78.42 -40.44 35.93 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.808 0.337 . . . . 71.109999999999999 110.916 -179.914 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 5.4 t -79.47 -19.49 49.68 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.258 -0.428 . . . . 42.340000000000003 110.843 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 97.8 m -86.81 -22.27 25.96 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.131 -0.486 . . . . 64.25 111.149 -179.927 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.496 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -92.15 -35.44 13.86 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.252 -0.431 . . . . 60.210000000000001 111.072 179.883 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -75.83 -12.02 60.09 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.236 -0.438 . . . . 74.400000000000006 110.896 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 97.7 m -98.53 -35.43 10.24 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.21 -0.45 . . . . 75.439999999999998 111.152 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.826 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.85 -7.43 41.61 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.732 -0.747 . . . . 54.310000000000002 112.457 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.509 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.67 -54.22 0.15 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.947 0.403 . . . . 73.519999999999996 110.844 -179.835 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.445 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.3 m -116.01 -14.54 11.22 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.198 -0.456 . . . . 74.120000000000005 111.159 -179.901 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.428 ' HA ' HD13 ' A' ' 19' ' ' LEU . 4.0 mm? -82.5 -14.52 54.84 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.224 -0.444 . . . . 64.430000000000007 110.945 179.962 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.826 HG23 ' HA3' ' A' ' 16' ' ' GLY . 14.1 t -75.77 -55.11 2.04 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.6 0.714 . . . . 73.340000000000003 111.144 179.799 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.591 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.7 Cg_endo -69.81 -21.08 33.77 Favored 'Trans proline' 0 C--O 1.232 0.18 0 C-N-CA 122.695 2.263 . . . . 74.430000000000007 112.298 179.964 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.433 ' O ' HG12 ' A' ' 22' ' ' VAL . 44.8 t -99.34 -11.78 8.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.273 -0.422 . . . . 72.200000000000003 111.124 179.934 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -57.93 -20.98 41.55 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.178 -0.464 . . . . 74.109999999999999 110.914 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 87.7 m-20 -75.54 -6.26 49.39 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.136 -0.484 . . . . 75.219999999999999 110.862 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 8.8 t-160 . . . . . 0 C--N 1.329 -0.294 0 CA-C-N 116.204 -0.453 . . . . 75.319999999999993 110.88 -179.962 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.457 -0.083 0 CA-C-O 120.799 0.333 . . . . 72.549999999999997 111.16 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -59.17 -36.73 89.96 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.767 -0.73 . . . . 73.299999999999997 112.434 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 9.8 m120 -95.3 -5.7 42.98 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.863 0.363 . . . . 71.430000000000007 110.874 -179.857 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.403 HG12 ' O ' ' A' ' 4' ' ' VAL . 21.2 t -91.69 -11.18 9.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.196 -0.457 . . . . 54.030000000000001 111.181 179.882 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -109.8 33.66 5.92 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.752 -0.737 . . . . 64.400000000000006 112.481 179.964 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 1.1 tt -86.29 -74.87 0.4 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.85 0.357 . . . . 71.510000000000005 110.901 -179.912 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.558 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.3 OUTLIER -68.89 -56.93 8.49 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.649 0.738 . . . . 61.32 110.854 -179.947 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.558 ' HD2' ' N ' ' A' ' 7' ' ' SER . 54.2 Cg_endo -69.75 -4.55 14.25 Favored 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 122.666 2.244 . . . . 75.340000000000003 112.392 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -111.44 -25.93 4.75 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.775 -0.726 . . . . 42.409999999999997 112.442 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 2.5 tt -78.49 -40.82 34.25 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.826 0.346 . . . . 70.329999999999998 110.907 -179.901 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -79.23 -19.5 50.54 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.213 -0.448 . . . . 61.420000000000002 110.867 -179.933 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 94.8 m -86.81 -22.28 25.95 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.134 -0.485 . . . . 72.209999999999994 111.121 -179.924 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.495 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -92.11 -35.44 13.89 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.213 -0.449 . . . . 72.430000000000007 111.055 179.89 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -75.79 -12.06 60.1 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.271 -0.422 . . . . 74.040000000000006 110.889 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 98.9 m -98.6 -35.32 10.25 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.229 -0.441 . . . . 60.030000000000001 111.109 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.841 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.96 -7.32 41.51 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.725 -0.75 . . . . 62.210000000000001 112.487 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.508 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.74 -54.11 0.15 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.953 0.406 . . . . 63.539999999999999 110.885 -179.89 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.442 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.2 m -116.27 -14.65 11.06 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.152 -0.476 . . . . 73.120000000000005 111.127 -179.905 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.429 HD13 ' HA ' ' A' ' 19' ' ' LEU . 4.1 mm? -82.5 -14.66 54.62 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.25 -0.432 . . . . 75.109999999999999 110.907 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.841 HG23 ' HA3' ' A' ' 16' ' ' GLY . 10.4 t -76.04 -55.21 1.89 Allowed Pre-proline 0 C--N 1.33 -0.257 0 CA-C-O 121.599 0.714 . . . . 71.310000000000002 111.098 179.819 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.59 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.6 Cg_endo -69.76 -20.33 34.97 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.711 2.274 . . . . 74.409999999999997 112.31 179.994 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.435 ' O ' HG12 ' A' ' 22' ' ' VAL . 46.9 t -100.07 -11.69 8.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.236 -0.438 . . . . 74.439999999999998 111.131 179.937 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 5.8 tp10 -58.64 -24.3 60.88 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.16 -0.473 . . . . 74.439999999999998 110.899 179.967 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 51.7 m-20 -76.5 -5.5 47.78 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.168 -0.469 . . . . 71.049999999999997 110.898 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 7.1 t-80 . . . . . 0 C--N 1.33 -0.272 0 CA-C-N 116.144 -0.48 . . . . 73.540000000000006 110.823 -179.972 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.457 -0.103 0 CA-C-O 120.827 0.346 . . . . 75.430000000000007 111.118 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . 0.566 ' O ' HD23 ' A' ' 6' ' ' LEU . . . -70.08 -28.81 71.17 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.717 -0.754 . . . . 72.109999999999999 112.508 179.95 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 81.0 m-20 -114.03 -5.53 13.13 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.856 0.36 . . . . 53.229999999999997 110.92 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.408 HG12 ' O ' ' A' ' 4' ' ' VAL . 21.2 t -105.52 -10.71 9.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.189 -0.46 . . . . 54.549999999999997 111.122 179.901 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -119.11 30.32 5.88 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.726 -0.75 . . . . 51.340000000000003 112.49 179.998 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.566 HD23 ' O ' ' A' ' 2' ' ' GLY . 0.2 OUTLIER -85.29 -68.71 0.71 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.818 0.342 . . . . 73.150000000000006 110.917 -179.872 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.555 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.0 OUTLIER -70.54 -56.8 6.06 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.613 0.721 . . . . 61.420000000000002 110.838 -179.948 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.555 ' HD2' ' N ' ' A' ' 7' ' ' SER . 54.4 Cg_endo -69.74 -4.88 14.91 Favored 'Trans proline' 0 C--N 1.341 0.153 0 C-N-CA 122.645 2.23 . . . . 73.140000000000001 112.382 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -111.06 -26.68 4.56 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.767 -0.73 . . . . 72.310000000000002 112.468 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -77.69 -40.59 40.91 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.826 0.346 . . . . 64.299999999999997 110.908 -179.906 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -79.35 -19.44 50.26 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.161 -0.472 . . . . 64.239999999999995 110.825 -179.878 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 92.1 m -87.38 -21.45 25.63 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.141 -0.481 . . . . 54.229999999999997 111.138 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.5 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -92.86 -35.44 13.37 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.181 -0.463 . . . . 72.230000000000004 111.071 179.922 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -76.3 -12.02 60.01 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.255 -0.43 . . . . 74.439999999999998 110.956 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 94.3 m -98.5 -35.37 10.27 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.153 -0.476 . . . . 74.450000000000003 111.152 179.922 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.831 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.83 -7.37 41.8 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.727 -0.749 . . . . 74.120000000000005 112.514 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.508 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.71 -54.24 0.15 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.924 0.392 . . . . 74.450000000000003 110.873 -179.914 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.44 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.2 m -116.01 -14.8 11.22 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.148 -0.478 . . . . 61.25 111.134 -179.905 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -82.29 -14.6 55.16 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.21 -0.45 . . . . 75.439999999999998 110.909 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.831 HG23 ' HA3' ' A' ' 16' ' ' GLY . 10.0 t -76.53 -55.39 1.63 Allowed Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.651 0.739 . . . . 71.319999999999993 111.108 179.875 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.586 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.4 Cg_endo -69.75 -19.83 35.64 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.712 2.274 . . . . 75.129999999999995 112.327 179.962 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.432 ' O ' HG12 ' A' ' 22' ' ' VAL . 41.6 t -102.3 -11.92 8.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.195 -0.457 . . . . 63.119999999999997 111.12 179.911 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 1.9 tp10 -52.13 -35.42 48.24 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.207 -0.451 . . . . 54.25 110.897 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 52.1 m-20 -115.37 -5.71 12.32 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.142 -0.481 . . . . 51.420000000000002 110.886 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 28.5 m80 . . . . . 0 C--N 1.329 -0.303 0 CA-C-N 116.174 -0.466 . . . . 74.0 110.888 -179.999 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 3.1 m . . . . . 0 C--O 1.231 0.096 0 CA-C-O 120.777 0.323 . . . . 74.439999999999998 111.107 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -62.66 -39.72 98.27 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.738 -0.744 . . . . 63.409999999999997 112.483 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . 0.569 ' HA ' HD23 ' A' ' 6' ' ' LEU . 7.6 t-20 -117.22 -5.44 11.34 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.858 0.361 . . . . 71.140000000000001 110.898 -179.872 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.4 HG12 ' O ' ' A' ' 4' ' ' VAL . 21.2 t -86.79 -11.36 11.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.146 -0.479 . . . . 74.129999999999995 111.145 179.909 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -117.02 37.43 3.35 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.742 -0.742 . . . . 62.25 112.521 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.569 HD23 ' HA ' ' A' ' 3' ' ' ASN . 1.9 mm? -88.48 -75.57 0.42 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.791 0.329 . . . . 72.150000000000006 110.942 -179.938 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.562 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.6 OUTLIER -69.05 -56.76 8.43 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.726 0.774 . . . . 73.129999999999995 110.916 -179.963 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.562 ' HD2' ' N ' ' A' ' 7' ' ' SER . 53.7 Cg_endo -69.76 -4.78 14.73 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.704 2.269 . . . . 62.240000000000002 112.359 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -111.23 -25.96 4.81 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.685 -0.769 . . . . 75.430000000000007 112.481 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 6.4 tp -80.15 -37.15 34.06 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.849 0.357 . . . . 73.409999999999997 110.939 -179.962 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -82.52 -19.22 39.1 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.173 -0.467 . . . . 43.520000000000003 110.874 -179.926 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 99.5 m -86.56 -23.19 25.92 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.124 -0.489 . . . . 63.340000000000003 111.123 -179.922 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.505 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -92.62 -34.83 13.84 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.194 -0.457 . . . . 73.140000000000001 111.11 179.895 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . 0.533 HD23 ' O ' ' A' ' 14' ' ' LEU . 1.0 OUTLIER -76.65 -11.8 59.91 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.203 -0.453 . . . . 43.32 110.933 179.987 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 98.9 m -99.14 -34.26 10.45 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.182 -0.463 . . . . 64.319999999999993 111.149 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.838 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -104.73 -7.77 38.46 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.731 -0.747 . . . . 74.329999999999998 112.537 179.921 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.509 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.5 p90 -29.81 -54.84 0.16 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.9 0.381 . . . . 75.540000000000006 110.887 -179.924 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.435 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 20.0 m -115.57 -14.95 11.48 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.175 -0.466 . . . . 74.120000000000005 111.135 -179.882 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 10.1 mp -82.11 -15.2 54.25 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.204 -0.453 . . . . 72.310000000000002 110.937 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.838 HG23 ' HA3' ' A' ' 16' ' ' GLY . 8.5 t -75.68 -55.29 2.04 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.6 0.714 . . . . 72.200000000000003 111.162 179.826 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.588 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.4 Cg_endo -69.79 -20.19 35.0 Favored 'Trans proline' 0 C--O 1.231 0.143 0 C-N-CA 122.669 2.246 . . . . 62.43 112.323 179.934 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.447 ' O ' HG12 ' A' ' 22' ' ' VAL . 47.4 t -100.41 -11.65 8.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.228 -0.442 . . . . 72.120000000000005 111.142 179.943 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -57.83 -21.05 40.44 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.14 -0.482 . . . . 70.129999999999995 110.884 -179.998 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -75.3 -6.4 49.68 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.144 -0.48 . . . . 64.140000000000001 110.867 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 116.183 -0.462 . . . . 75.219999999999999 110.865 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.23 0.062 0 CA-C-O 120.788 0.328 . . . . 75.099999999999994 111.107 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -55.86 -30.92 57.74 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.777 -0.725 . . . . 32.549999999999997 112.465 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -106.63 -5.45 18.64 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.825 0.345 . . . . 74.140000000000001 110.858 -179.872 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 20.8 t -94.47 -11.52 8.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.206 -0.452 . . . . 74.239999999999995 111.117 179.95 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -106.77 23.92 26.7 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.724 -0.75 . . . . 74.049999999999997 112.457 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 5.5 tt -85.84 -41.65 14.83 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.822 0.344 . . . . 75.129999999999995 110.957 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.516 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.0 OUTLIER -83.62 -58.57 0.39 Allowed Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.704 0.764 . . . . 72.549999999999997 110.858 -179.935 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.516 ' HD2' ' N ' ' A' ' 7' ' ' SER . 53.3 Cg_endo -69.77 -6.84 19.57 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.704 2.269 . . . . 73.409999999999997 112.351 -179.998 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -107.17 -27.42 5.34 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.696 -0.764 . . . . 65.420000000000002 112.513 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -78.71 -40.01 34.86 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.823 0.344 . . . . 64.209999999999994 110.908 -179.942 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -79.59 -19.22 49.84 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.194 -0.457 . . . . 63.520000000000003 110.875 -179.925 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 47.3 m -86.48 -23.31 26.02 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.117 -0.492 . . . . 73.0 111.148 -179.95 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.5 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -91.59 -35.5 14.21 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.203 -0.453 . . . . 70.209999999999994 111.094 179.877 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -75.91 -11.8 60.03 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.247 -0.433 . . . . 73.329999999999998 110.909 179.999 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 98.3 m -98.45 -35.57 10.23 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.22 -0.445 . . . . 73.219999999999999 111.146 179.936 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.808 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.95 -7.47 41.26 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.783 -0.722 . . . . 53.409999999999997 112.483 179.98 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.502 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.71 -54.05 0.15 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.877 0.37 . . . . 73.400000000000006 110.878 -179.832 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.444 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.5 m -116.01 -14.62 11.22 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.151 -0.477 . . . . 52.32 111.133 -179.922 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.413 HD13 ' HA ' ' A' ' 19' ' ' LEU . 4.0 mm? -82.26 -14.78 54.93 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.19 -0.459 . . . . 63.450000000000003 110.893 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.808 HG23 ' HA3' ' A' ' 16' ' ' GLY . 13.7 t -75.74 -55.32 2.01 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.625 0.726 . . . . 74.129999999999995 111.112 179.918 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.578 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.6 Cg_endo -69.71 -20.95 34.41 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.735 2.29 . . . . 73.25 112.324 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.433 ' O ' HG12 ' A' ' 22' ' ' VAL . 45.2 t -99.65 -11.78 8.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.2 -0.454 . . . . 63.140000000000001 111.145 179.94 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -58.14 -21.15 45.52 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.172 -0.467 . . . . 64.519999999999996 110.866 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 13.6 m-20 -102.95 -5.6 23.29 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.173 -0.467 . . . . 73.409999999999997 110.888 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.33 -0.28 0 CA-C-N 116.227 -0.442 . . . . 72.200000000000003 110.873 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.457 -0.077 0 CA-C-O 120.832 0.349 . . . . 70.140000000000001 111.13 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -57.68 -22.07 45.32 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.75 -0.738 . . . . 73.230000000000004 112.479 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 8.0 t-20 -119.6 -5.5 10.24 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.885 0.374 . . . . 73.530000000000001 110.856 -179.859 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.4 HG12 ' O ' ' A' ' 4' ' ' VAL . 21.1 t -94.31 -11.38 8.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.219 -0.446 . . . . 72.510000000000005 111.128 179.9 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -115.16 37.54 3.45 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.735 -0.745 . . . . 71.349999999999994 112.483 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 2.2 tt -81.16 -38.68 26.73 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.847 0.356 . . . . 75.200000000000003 110.946 -179.916 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.542 ' H ' ' HD2' ' A' ' 8' ' ' PRO . 0.0 OUTLIER -86.18 -59.35 0.3 Allowed Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.668 0.747 . . . . 33.130000000000003 110.882 -179.957 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.542 ' HD2' ' H ' ' A' ' 7' ' ' SER . 53.8 Cg_endo -69.73 -5.65 16.69 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.695 2.263 . . . . 70.310000000000002 112.348 179.962 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -109.17 -26.5 5.17 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.724 -0.751 . . . . 63.100000000000001 112.501 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 6.5 tt -78.62 -41.68 30.94 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.79 0.329 . . . . 73.450000000000003 110.902 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 2.2 t -77.96 -19.88 53.72 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.211 -0.45 . . . . 75.439999999999998 110.844 -179.91 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 91.8 m -86.74 -22.71 25.81 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.137 -0.483 . . . . 54.439999999999998 111.137 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.494 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -91.65 -34.75 14.56 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.224 -0.444 . . . . 51.229999999999997 111.124 179.835 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -76.44 -11.53 59.9 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.197 -0.456 . . . . 74.209999999999994 110.913 -179.967 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 96.7 m -99.01 -35.44 10.05 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.191 -0.459 . . . . 65.040000000000006 111.117 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.817 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.57 -7.63 42.02 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.714 -0.755 . . . . 54.439999999999998 112.479 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.512 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.57 -54.21 0.15 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.914 0.388 . . . . 73.239999999999995 110.843 -179.87 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.44 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 23.3 m -116.05 -14.75 11.19 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.168 -0.469 . . . . 74.109999999999999 111.159 -179.92 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -82.21 -14.46 55.53 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.229 -0.441 . . . . 61.450000000000003 110.901 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.817 HG23 ' HA3' ' A' ' 16' ' ' GLY . 14.9 t -75.71 -55.14 2.06 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.603 0.716 . . . . 54.43 111.097 179.839 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.592 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.7 Cg_endo -69.69 -21.18 34.17 Favored 'Trans proline' 0 C--O 1.231 0.15 0 C-N-CA 122.729 2.286 . . . . 71.349999999999994 112.329 179.961 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.435 ' O ' HG12 ' A' ' 22' ' ' VAL . 44.6 t -99.43 -11.88 8.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.224 -0.444 . . . . 72.129999999999995 111.104 179.965 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -56.98 -21.88 33.91 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.216 -0.447 . . . . 34.030000000000001 110.884 -179.956 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 39.0 m-20 -119.09 -5.8 10.48 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.18 -0.464 . . . . 61.229999999999997 110.868 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 3.4 t-160 . . . . . 0 C--N 1.33 -0.276 0 CA-C-N 116.193 -0.458 . . . . 74.430000000000007 110.85 -179.984 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 8.2 m . . . . . 0 N--CA 1.457 -0.09 0 CA-C-O 120.834 0.349 . . . . 71.25 111.132 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -69.26 -25.58 75.33 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.699 -0.762 . . . . 71.099999999999994 112.494 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 69.2 m-80 -117.63 -5.49 11.16 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.907 0.384 . . . . 65.109999999999999 110.904 -179.885 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 20.9 t -104.06 -11.39 9.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.154 -0.475 . . . . 35.25 111.133 179.894 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -120.09 40.01 2.31 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.74 -0.743 . . . . 74.120000000000005 112.474 179.975 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 44.6 tp -67.36 -36.13 80.76 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.84 0.353 . . . . 75.040000000000006 110.881 -179.912 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.524 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.3 OUTLIER -83.92 -58.44 0.38 Allowed Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.637 0.732 . . . . 61.420000000000002 110.856 -179.923 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.524 ' HD2' ' N ' ' A' ' 7' ' ' SER . 53.3 Cg_endo -69.75 -7.45 21.08 Favored 'Trans proline' 0 C--N 1.341 0.14 0 C-N-CA 122.736 2.291 . . . . 71.349999999999994 112.311 179.984 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -107.2 -26.26 5.79 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.723 -0.751 . . . . 65.319999999999993 112.449 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -78.44 -41.71 32.09 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.832 0.348 . . . . 51.43 110.954 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -77.54 -20.29 54.41 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.171 -0.468 . . . . 73.329999999999998 110.845 -179.917 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 86.1 m -86.67 -22.35 26.16 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.18 -0.464 . . . . 62.340000000000003 111.134 -179.951 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.492 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -91.76 -34.82 14.45 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.189 -0.459 . . . . 62.350000000000001 111.1 179.884 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -76.12 -11.97 60.03 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.182 -0.463 . . . . 74.439999999999998 110.883 -179.951 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 98.4 m -98.6 -35.33 10.24 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.229 -0.441 . . . . 73.5 111.138 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.823 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.87 -7.43 41.56 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.706 -0.759 . . . . 63.219999999999999 112.505 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.504 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.61 -54.28 0.15 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.957 0.408 . . . . 75.239999999999995 110.871 -179.874 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.443 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.4 m -116.01 -14.54 11.22 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.165 -0.471 . . . . 74.310000000000002 111.138 -179.886 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.424 ' HA ' HD13 ' A' ' 19' ' ' LEU . 4.0 mm? -82.45 -14.52 54.96 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.228 -0.442 . . . . 65.310000000000002 110.948 179.91 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.823 HG23 ' HA3' ' A' ' 16' ' ' GLY . 14.0 t -75.77 -55.13 2.04 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.623 0.725 . . . . 54.100000000000001 111.149 179.818 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.586 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.5 Cg_endo -69.81 -21.03 33.81 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.647 2.231 . . . . 72.439999999999998 112.375 179.934 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.433 ' O ' HG12 ' A' ' 22' ' ' VAL . 44.9 t -99.35 -11.77 8.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.187 -0.46 . . . . 65.140000000000001 111.119 179.88 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -57.97 -20.98 42.07 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.219 -0.446 . . . . 55.439999999999998 110.889 -179.976 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 40.3 t0 -75.31 -6.5 50.18 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.149 -0.478 . . . . 72.25 110.873 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 27.1 m80 . . . . . 0 C--N 1.329 -0.303 0 CA-C-N 116.205 -0.452 . . . . 64.099999999999994 110.81 -179.984 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.231 0.096 0 CA-C-O 120.844 0.355 . . . . 62.219999999999999 111.124 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -65.48 -31.12 79.23 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.739 -0.743 . . . . 71.010000000000005 112.483 180.0 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 8.2 m120 -119.8 -5.51 10.14 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.894 0.378 . . . . 75.329999999999998 110.917 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 21.1 t -97.27 -11.4 8.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.124 -0.489 . . . . 62.100000000000001 111.138 179.904 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -116.17 37.41 3.42 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.703 -0.76 . . . . 61.420000000000002 112.471 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 2.4 tt -67.12 -32.42 73.54 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.861 0.362 . . . . 71.430000000000007 110.922 -179.936 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.566 ' H ' ' HD2' ' A' ' 8' ' ' PRO . 0.0 OUTLIER -87.94 -59.5 0.26 Allowed Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.697 0.76 . . . . 75.010000000000005 110.868 -179.911 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.566 ' HD2' ' H ' ' A' ' 7' ' ' SER . 53.7 Cg_endo -69.75 -6.28 18.23 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.708 2.272 . . . . 71.209999999999994 112.337 179.963 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -108.72 -25.82 5.56 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.715 -0.755 . . . . 63.240000000000002 112.45 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.8 tt -79.13 -40.98 29.62 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.88 0.371 . . . . 71.310000000000002 110.955 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 30.0 t -78.7 -19.88 51.42 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.185 -0.461 . . . . 73.209999999999994 110.855 -179.919 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 92.3 m -86.77 -22.34 25.99 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.132 -0.486 . . . . 60.340000000000003 111.158 -179.974 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.495 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -91.88 -35.12 14.23 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.21 -0.45 . . . . 54.229999999999997 111.082 179.855 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -75.9 -12.14 60.1 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.236 -0.438 . . . . 74.129999999999995 110.898 -179.955 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 97.9 m -98.43 -35.3 10.32 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.196 -0.456 . . . . 52.130000000000003 111.153 179.96 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.829 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.99 -7.36 41.37 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.732 -0.747 . . . . 41.210000000000001 112.5 179.945 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.509 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.65 -54.2 0.15 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.915 0.388 . . . . 73.409999999999997 110.859 -179.87 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.44 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.2 m -116.15 -14.39 11.14 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.156 -0.475 . . . . 62.420000000000002 111.124 -179.912 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.402 ' HA ' HD13 ' A' ' 19' ' ' LEU . 4.0 mm? -82.56 -14.59 54.6 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.246 -0.434 . . . . 73.299999999999997 110.913 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.829 HG23 ' HA3' ' A' ' 16' ' ' GLY . 13.4 t -75.74 -55.26 2.02 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.631 0.729 . . . . 55.539999999999999 111.11 179.847 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.591 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.1 Cg_endo -69.78 -20.79 34.27 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.7 2.266 . . . . 60.149999999999999 112.316 179.989 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.439 ' O ' HG12 ' A' ' 22' ' ' VAL . 44.1 t -99.98 -11.7 8.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.231 -0.44 . . . . 63.240000000000002 111.133 179.889 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -56.87 -21.57 30.41 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.197 -0.456 . . . . 72.25 110.884 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 36.3 t0 -120.03 -5.63 10.02 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.142 -0.481 . . . . 75.430000000000007 110.884 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 55.6 t-80 . . . . . 0 C--N 1.329 -0.314 0 CA-C-N 116.211 -0.45 . . . . 70.099999999999994 110.897 -179.996 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.457 -0.091 0 CA-C-O 120.779 0.323 . . . . 72.150000000000006 111.121 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -59.26 -35.12 83.25 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.724 -0.75 . . . . 35.25 112.486 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 84.1 m-20 -103.97 -5.39 22.27 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.825 0.345 . . . . 45.439999999999998 110.889 -179.903 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 21.3 t -93.47 -11.36 9.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.206 -0.452 . . . . 71.310000000000002 111.112 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -101.37 29.76 11.83 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.773 -0.727 . . . . 72.299999999999997 112.478 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 1.9 tt -67.85 -29.15 68.21 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.813 0.34 . . . . 75.140000000000001 110.927 -179.89 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.574 ' H ' ' HD2' ' A' ' 8' ' ' PRO . 0.2 OUTLIER -89.6 -60.74 0.23 Allowed Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.66 0.743 . . . . 73.510000000000005 110.862 -179.983 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.574 ' HD2' ' H ' ' A' ' 7' ' ' SER . 53.3 Cg_endo -69.75 -6.62 19.04 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.649 2.233 . . . . 74.140000000000001 112.333 -179.976 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -108.0 -26.26 5.57 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.725 -0.75 . . . . 53.32 112.453 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -78.62 -41.81 30.57 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.848 0.356 . . . . 74.430000000000007 110.954 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 7.7 t -77.48 -20.53 54.22 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.157 -0.474 . . . . 70.040000000000006 110.874 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 98.0 m -86.65 -21.96 26.42 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.103 -0.498 . . . . 63.119999999999997 111.173 -179.918 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.488 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -92.06 -34.99 14.17 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.171 -0.468 . . . . 40.329999999999998 111.062 179.911 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -75.99 -11.72 60.01 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.214 -0.448 . . . . 65.409999999999997 110.892 -179.934 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 98.5 m -98.72 -35.38 10.18 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.164 -0.471 . . . . 64.420000000000002 111.162 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.815 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.94 -7.42 41.37 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.779 -0.724 . . . . 63.109999999999999 112.509 179.934 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.501 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.61 -54.27 0.15 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.913 0.387 . . . . 75.530000000000001 110.907 -179.869 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.445 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 20.6 m -115.91 -14.57 11.28 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.105 -0.498 . . . . 74.230000000000004 111.15 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.426 HD13 ' HA ' ' A' ' 19' ' ' LEU . 4.0 mm? -82.48 -14.33 55.2 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.211 -0.45 . . . . 65.420000000000002 110.933 179.952 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.815 HG23 ' HA3' ' A' ' 16' ' ' GLY . 14.3 t -75.98 -55.22 1.92 Allowed Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.669 0.747 . . . . 75.409999999999997 111.169 179.789 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.582 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.7 Cg_endo -69.74 -20.91 34.34 Favored 'Trans proline' 0 C--N 1.342 0.22 0 C-N-CA 122.631 2.221 . . . . 75.329999999999998 112.366 179.923 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.43 ' O ' HG12 ' A' ' 22' ' ' VAL . 46.4 t -99.23 -12.17 8.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.212 -0.449 . . . . 75.310000000000002 111.124 179.922 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -58.07 -20.87 42.78 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.178 -0.465 . . . . 73.219999999999999 110.897 -179.936 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 25.3 t70 -76.46 -5.59 48.07 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.163 -0.471 . . . . 71.439999999999998 110.907 179.939 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.33 -0.263 0 CA-C-N 116.169 -0.469 . . . . 73.030000000000001 110.872 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 1.3 m . . . . . 0 N--CA 1.458 -0.06 0 CA-C-O 120.821 0.343 . . . . 73.209999999999994 111.151 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -56.32 -41.37 87.17 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.733 -0.746 . . . . 62.049999999999997 112.493 179.944 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 59.6 t30 -89.96 -5.45 56.7 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.907 0.384 . . . . 73.209999999999994 110.939 -179.909 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 21.2 t -98.68 -11.35 8.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.152 -0.477 . . . . 72.049999999999997 111.109 179.93 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -104.91 19.72 40.36 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.753 -0.737 . . . . 60.329999999999998 112.496 -179.998 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.514 HD23 ' O ' ' A' ' 6' ' ' LEU . 5.2 tt -89.56 -5.1 57.53 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.822 0.344 . . . . 63.340000000000003 110.89 -179.896 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.659 ' H ' ' HD2' ' A' ' 8' ' ' PRO . 0.5 OUTLIER -120.35 -66.72 0.02 OUTLIER Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.695 0.759 . . . . 61.32 110.904 -179.955 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.659 ' HD2' ' H ' ' A' ' 7' ' ' SER . 53.4 Cg_endo -69.75 -7.3 20.69 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.683 2.255 . . . . 72.150000000000006 112.32 -179.993 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -121.32 -15.21 4.67 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.726 -0.75 . . . . 22.32 112.483 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.1 tp -80.07 -40.72 27.07 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.841 0.353 . . . . 70.5 110.952 -179.932 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -78.41 -20.1 51.86 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.141 -0.481 . . . . 65.329999999999998 110.881 -179.944 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 87.9 m -86.21 -22.54 26.86 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.145 -0.479 . . . . 51.420000000000002 111.17 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.492 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -91.86 -35.34 14.12 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.19 -0.459 . . . . 71.010000000000005 111.14 179.839 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -75.87 -12.02 60.08 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.187 -0.46 . . . . 72.040000000000006 110.914 -179.972 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 97.7 m -98.64 -35.34 10.23 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.165 -0.47 . . . . 73.239999999999995 111.157 179.932 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.844 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.81 -7.38 41.84 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.711 -0.757 . . . . 42.229999999999997 112.468 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.498 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.7 -54.08 0.15 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.913 0.387 . . . . 72.109999999999999 110.824 -179.849 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.449 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.0 m -116.31 -14.74 11.03 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.194 -0.457 . . . . 74.140000000000001 111.131 -179.869 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -82.39 -14.64 54.87 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.218 -0.446 . . . . 44.5 110.947 179.938 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.844 HG23 ' HA3' ' A' ' 16' ' ' GLY . 9.8 t -76.17 -55.31 1.81 Allowed Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.645 0.736 . . . . 71.519999999999996 111.138 179.848 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.586 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 54.1 Cg_endo -69.74 -20.23 35.2 Favored 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 122.715 2.277 . . . . 51.439999999999998 112.364 179.922 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.447 ' O ' HG12 ' A' ' 22' ' ' VAL . 45.1 t -100.67 -11.71 8.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.207 -0.451 . . . . 64.329999999999998 111.165 179.905 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -56.69 -21.7 29.62 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.18 -0.464 . . . . 71.420000000000002 110.878 -179.978 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 17.0 t70 -120.08 -5.93 9.99 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.17 -0.468 . . . . 70.109999999999999 110.845 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 1.3 t-80 . . . . . 0 C--N 1.329 -0.302 0 CA-C-N 116.174 -0.466 . . . . 62.549999999999997 110.815 -179.976 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.456 -0.135 0 CA-C-O 120.863 0.363 . . . . 71.230000000000004 111.143 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -62.19 -34.18 88.28 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.739 -0.743 . . . . 65.510000000000005 112.511 179.966 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 -112.48 -5.39 14.06 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.899 0.38 . . . . 74.549999999999997 110.908 -179.918 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 21.1 t -102.13 -11.36 8.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.168 -0.469 . . . . 60.329999999999998 111.114 179.913 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -100.61 22.11 41.15 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.705 -0.759 . . . . 44.420000000000002 112.489 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 3.9 tt -76.91 -5.2 47.54 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.834 0.349 . . . . 71.019999999999996 110.94 -179.921 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.662 ' H ' ' HD2' ' A' ' 8' ' ' PRO . 0.5 OUTLIER -120.41 -66.62 0.02 OUTLIER Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.618 0.723 . . . . 74.140000000000001 110.855 -179.939 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.662 ' HD2' ' H ' ' A' ' 7' ' ' SER . 53.7 Cg_endo -69.81 -7.25 20.6 Favored 'Trans proline' 0 N--CA 1.466 -0.115 0 C-N-CA 122.673 2.249 . . . . 54.409999999999997 112.357 179.979 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -121.34 -15.18 4.67 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.685 -0.769 . . . . 71.329999999999998 112.479 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.1 tt -80.0 -40.9 26.91 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.851 0.358 . . . . 54.200000000000003 110.896 -179.902 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -78.24 -20.15 52.29 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.177 -0.465 . . . . 72.150000000000006 110.859 -179.918 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 81.8 m -86.15 -22.55 26.97 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.128 -0.487 . . . . 71.439999999999998 111.162 -179.929 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.497 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -91.91 -35.38 14.06 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.188 -0.46 . . . . 73.200000000000003 111.077 179.882 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -75.87 -11.98 60.07 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.247 -0.433 . . . . 64.340000000000003 110.925 -179.964 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 97.6 m -98.58 -35.39 10.23 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.171 -0.468 . . . . 61.420000000000002 111.163 179.89 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.821 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.8 -7.44 41.73 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.704 -0.76 . . . . 70.519999999999996 112.449 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.497 ' HB3' ' O ' ' A' ' 13' ' ' ALA . 1.4 p90 -29.62 -54.23 0.15 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.907 0.384 . . . . 74.5 110.842 -179.846 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.448 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.1 m -116.05 -14.58 11.19 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.172 -0.467 . . . . 75.049999999999997 111.127 -179.864 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.413 ' HA ' HD13 ' A' ' 19' ' ' LEU . 4.0 mm? -82.46 -14.54 54.91 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.251 -0.431 . . . . 72.5 110.919 179.975 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.821 HG23 ' HA3' ' A' ' 16' ' ' GLY . 13.6 t -75.85 -55.16 1.99 Allowed Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.649 0.738 . . . . 72.239999999999995 111.117 179.834 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.586 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.5 Cg_endo -69.8 -20.82 34.15 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.652 2.235 . . . . 75.400000000000006 112.365 179.976 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.441 ' O ' HG12 ' A' ' 22' ' ' VAL . 44.3 t -99.88 -11.81 8.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.194 -0.457 . . . . 73.219999999999999 111.116 179.909 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -56.9 -21.55 30.55 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.2 -0.455 . . . . 75.5 110.842 -179.932 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 25.1 t0 -120.02 -5.77 10.02 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.163 -0.472 . . . . 64.409999999999997 110.859 179.982 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 19.4 t-160 . . . . . 0 C--N 1.329 -0.315 0 CA-C-N 116.234 -0.439 . . . . 74.510000000000005 110.849 -179.98 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 11.9 m . . . . . 0 C--O 1.231 0.112 0 CA-C-O 120.82 0.343 . . . . 64.239999999999995 111.131 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -68.01 -24.28 74.48 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.737 -0.744 . . . . 75.340000000000003 112.532 179.923 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 6.7 m120 -109.68 -5.42 15.64 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.863 0.363 . . . . 72.120000000000005 110.894 -179.92 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.4 ' O ' HG12 ' A' ' 4' ' ' VAL . 21.0 t -104.39 -11.37 9.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.176 -0.466 . . . . 61.409999999999997 111.111 179.942 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -98.09 22.17 42.24 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.757 -0.735 . . . . 50.420000000000002 112.49 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 4.6 mm? -81.53 -5.28 57.83 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.822 0.344 . . . . 71.099999999999994 110.933 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.659 ' H ' ' HD2' ' A' ' 8' ' ' PRO . 0.5 OUTLIER -120.35 -66.61 0.02 OUTLIER Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.64 0.733 . . . . 63.020000000000003 110.877 -179.955 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.659 ' HD2' ' H ' ' A' ' 7' ' ' SER . 53.8 Cg_endo -69.79 -7.26 20.6 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.702 2.268 . . . . 72.030000000000001 112.347 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -121.37 -15.21 4.65 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.696 -0.764 . . . . 35.310000000000002 112.462 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 5.6 tp -80.05 -40.75 27.08 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.792 0.329 . . . . 64.150000000000006 110.911 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.9 t -78.38 -20.12 51.92 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.23 -0.441 . . . . 71.340000000000003 110.836 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 64.1 m -86.24 -22.42 26.89 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.159 -0.473 . . . . 73.049999999999997 111.183 -179.956 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.495 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -92.01 -35.32 14.03 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.18 -0.464 . . . . 71.340000000000003 111.073 179.876 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -75.87 -12.06 60.09 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.235 -0.439 . . . . 71.209999999999994 110.913 -179.98 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 97.7 m -98.55 -35.46 10.22 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.226 -0.443 . . . . 60.25 111.124 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.824 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.78 -7.4 41.87 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.743 -0.741 . . . . 62.200000000000003 112.489 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.495 ' C ' ' O ' ' A' ' 16' ' ' GLY . 1.4 p90 -29.6 -54.23 0.15 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.985 0.421 . . . . 71.299999999999997 110.933 -179.906 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.449 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.4 m -116.08 -14.45 11.18 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.128 -0.487 . . . . 74.540000000000006 111.182 -179.951 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.445 HD13 ' HA ' ' A' ' 19' ' ' LEU . 4.0 mm? -82.51 -14.54 54.79 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.222 -0.445 . . . . 70.25 110.941 179.919 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.824 HG23 ' HA3' ' A' ' 16' ' ' GLY . 14.3 t -75.71 -55.16 2.06 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.595 0.712 . . . . 63.409999999999997 111.122 179.803 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.585 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.7 Cg_endo -69.8 -21.0 33.9 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.615 2.21 . . . . 72.430000000000007 112.37 179.987 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.444 ' O ' HG12 ' A' ' 22' ' ' VAL . 45.1 t -99.4 -11.74 8.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.208 -0.451 . . . . 73.439999999999998 111.097 179.911 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -57.94 -21.13 42.41 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.212 -0.449 . . . . 72.319999999999993 110.884 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 95.2 m-20 -103.17 -5.88 22.74 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.177 -0.465 . . . . 64.310000000000002 110.846 -179.989 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.33 -0.278 0 CA-C-N 116.233 -0.44 . . . . 73.409999999999997 110.887 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.457 -0.086 0 CA-C-O 120.856 0.36 . . . . 71.120000000000005 111.13 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -63.33 -29.09 73.47 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.735 -0.745 . . . . 55.439999999999998 112.482 -179.984 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 55.3 t30 -113.64 -5.49 13.38 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.853 0.359 . . . . 73.409999999999997 110.88 -179.893 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.402 ' O ' HG12 ' A' ' 4' ' ' VAL . 21.1 t -103.47 -11.33 9.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.163 -0.471 . . . . 64.209999999999994 111.131 179.896 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -110.37 23.81 19.57 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.716 -0.754 . . . . 65.340000000000003 112.476 179.942 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.425 HD23 ' O ' ' A' ' 6' ' ' LEU . 5.3 tt -83.52 -5.12 59.07 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.826 0.346 . . . . 51.310000000000002 110.923 -179.924 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.662 ' H ' ' HD2' ' A' ' 8' ' ' PRO . 0.5 OUTLIER -120.36 -66.68 0.02 OUTLIER Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.702 0.763 . . . . 72.219999999999999 110.882 -179.959 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.662 ' HD2' ' H ' ' A' ' 7' ' ' SER . 54.4 Cg_endo -69.72 -7.32 20.75 Favored 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 122.682 2.255 . . . . 61.539999999999999 112.327 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -121.33 -15.24 4.66 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.721 -0.752 . . . . 71.310000000000002 112.439 -179.948 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.7 tt -80.05 -40.72 27.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.832 0.349 . . . . 65.540000000000006 110.946 -179.903 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -78.32 -20.14 52.07 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.201 -0.454 . . . . 62.43 110.913 -179.979 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 86.0 m -86.22 -22.48 26.88 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.086 -0.507 . . . . 62.399999999999999 111.105 -179.907 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.498 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -91.97 -35.34 14.04 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.214 -0.448 . . . . 73.519999999999996 111.051 179.892 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -75.87 -12.06 60.09 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.244 -0.434 . . . . 73.239999999999995 110.912 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 97.8 m -98.6 -35.31 10.25 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.202 -0.454 . . . . 70.150000000000006 111.176 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.825 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.83 -7.45 41.64 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.778 -0.725 . . . . 60.130000000000003 112.477 179.979 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.498 ' HB3' ' O ' ' A' ' 13' ' ' ALA . 1.4 p90 -29.57 -54.31 0.15 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.953 0.406 . . . . 73.200000000000003 110.889 -179.891 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.448 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.4 m -116.04 -14.46 11.21 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.126 -0.488 . . . . 74.430000000000007 111.146 -179.938 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.446 HD13 ' HA ' ' A' ' 19' ' ' LEU . 4.0 mm? -82.45 -14.57 54.87 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.248 -0.433 . . . . 72.349999999999994 110.937 179.913 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.825 HG23 ' HA3' ' A' ' 16' ' ' GLY . 14.2 t -75.75 -55.14 2.05 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.629 0.728 . . . . 73.209999999999994 111.117 179.858 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.582 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.8 Cg_endo -69.78 -21.07 33.91 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.67 2.246 . . . . 64.519999999999996 112.346 179.951 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.445 ' O ' HG12 ' A' ' 22' ' ' VAL . 45.0 t -99.37 -11.75 8.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.234 -0.439 . . . . 72.099999999999994 111.151 179.905 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -57.95 -20.91 41.39 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.152 -0.476 . . . . 72.150000000000006 110.886 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -75.45 -6.31 49.45 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.126 -0.488 . . . . 73.409999999999997 110.886 179.971 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--N 1.329 -0.287 0 CA-C-N 116.187 -0.461 . . . . 75.209999999999994 110.83 179.983 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 48.6 m . . . . . 0 N--CA 1.458 -0.073 0 CA-C-O 120.796 0.331 . . . . 74.120000000000005 111.156 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -60.43 -32.74 78.53 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.73 -0.748 . . . . 53.0 112.486 179.95 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 16.8 m120 -105.1 -5.46 20.79 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.859 0.361 . . . . 71.140000000000001 110.844 -179.859 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.402 HG12 ' O ' ' A' ' 4' ' ' VAL . 21.0 t -97.17 -11.33 8.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.193 -0.458 . . . . 74.010000000000005 111.149 179.911 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -95.62 20.15 51.02 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.754 -0.736 . . . . 60.109999999999999 112.487 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -84.03 -5.75 59.29 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.791 0.329 . . . . 64.129999999999995 110.872 -179.9 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.661 ' H ' ' HD2' ' A' ' 8' ' ' PRO . 0.5 OUTLIER -120.4 -66.69 0.02 OUTLIER Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.647 0.737 . . . . 53.43 110.875 -179.955 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.661 ' HD2' ' H ' ' A' ' 7' ' ' SER . 54.3 Cg_endo -69.69 -7.28 20.62 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.676 2.251 . . . . 74.439999999999998 112.397 179.935 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -121.32 -15.27 4.65 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.749 -0.738 . . . . 71.329999999999998 112.48 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 5.2 tt -79.94 -40.89 27.15 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.838 0.352 . . . . 63.020000000000003 110.935 -179.929 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.7 t -78.28 -20.16 52.17 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.141 -0.481 . . . . 64.329999999999998 110.846 -179.899 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 85.6 m -86.19 -22.48 26.94 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.137 -0.483 . . . . 72.049999999999997 111.136 -179.929 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.497 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -91.92 -35.38 14.05 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.23 -0.441 . . . . 71.239999999999995 111.083 179.895 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -75.95 -11.95 60.06 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.185 -0.461 . . . . 73.129999999999995 110.882 -179.929 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 97.6 m -98.57 -35.45 10.22 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.213 -0.449 . . . . 71.299999999999997 111.155 179.901 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.825 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.75 -7.47 41.82 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.772 -0.727 . . . . 53.340000000000003 112.449 -179.979 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.497 ' HB3' ' O ' ' A' ' 13' ' ' ALA . 1.5 p90 -29.59 -54.25 0.15 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.961 0.41 . . . . 65.530000000000001 110.886 -179.855 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.448 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.3 m -116.07 -14.5 11.19 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.116 -0.493 . . . . 74.010000000000005 111.133 -179.896 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.446 HD13 ' HA ' ' A' ' 19' ' ' LEU . 4.0 mm? -82.47 -14.59 54.79 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.234 -0.439 . . . . 74.519999999999996 110.893 179.958 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.825 HG23 ' HA3' ' A' ' 16' ' ' GLY . 14.0 t -75.73 -55.13 2.06 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.605 0.717 . . . . 75.239999999999995 111.116 179.844 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.584 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.4 Cg_endo -69.8 -21.06 33.84 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.696 2.264 . . . . 74.409999999999997 112.304 -179.982 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.444 ' O ' HG12 ' A' ' 22' ' ' VAL . 44.7 t -99.41 -11.77 8.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.205 -0.452 . . . . 70.310000000000002 111.134 179.932 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -57.9 -20.96 40.92 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.178 -0.465 . . . . 75.219999999999999 110.933 179.964 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 81.7 m-20 -75.42 -6.36 49.65 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.129 -0.487 . . . . 73.120000000000005 110.852 179.969 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 26.8 t-80 . . . . . 0 C--N 1.329 -0.322 0 CA-C-N 116.187 -0.46 . . . . 72.120000000000005 110.871 179.983 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.231 0.085 0 CA-C-O 120.802 0.335 . . . . 64.540000000000006 111.108 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -63.11 -40.29 99.01 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.769 -0.729 . . . . 55.100000000000001 112.46 179.963 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 29.8 m120 -109.71 -5.39 15.63 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.832 0.349 . . . . 71.340000000000003 110.872 -179.84 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 21.1 t -101.97 -11.33 8.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.162 -0.472 . . . . 62.140000000000001 111.142 179.883 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -101.42 26.22 25.32 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.726 -0.75 . . . . 61.240000000000002 112.521 179.922 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -83.18 -5.26 59.06 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.768 0.318 . . . . 73.450000000000003 110.902 -179.943 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.661 ' H ' ' HD2' ' A' ' 8' ' ' PRO . 0.5 OUTLIER -120.32 -66.71 0.02 OUTLIER Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.7 0.762 . . . . 64.439999999999998 110.849 -179.948 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.661 ' HD2' ' H ' ' A' ' 7' ' ' SER . 54.1 Cg_endo -69.71 -7.29 20.67 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.747 2.298 . . . . 70.319999999999993 112.325 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -121.34 -15.23 4.66 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.735 -0.745 . . . . 23.210000000000001 112.479 179.988 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 2.1 tp -80.04 -40.76 27.07 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.821 0.344 . . . . 72.340000000000003 110.942 -179.937 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -78.37 -20.11 51.97 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.196 -0.456 . . . . 43.530000000000001 110.865 -179.955 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 40.0 m -86.22 -22.48 26.89 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.135 -0.484 . . . . 53.310000000000002 111.123 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.496 ' O ' ' HB3' ' A' ' 17' ' ' PHE . . . -91.95 -35.34 14.05 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.222 -0.444 . . . . 71.150000000000006 111.076 179.896 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -75.93 -11.98 60.06 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.201 -0.454 . . . . 62.509999999999998 110.931 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 97.6 m -98.53 -35.46 10.23 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.179 -0.464 . . . . 75.230000000000004 111.154 179.892 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.825 ' HA3' HG23 ' A' ' 20' ' ' VAL . . . -103.78 -7.43 41.79 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.773 -0.727 . . . . 71.420000000000002 112.485 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.496 ' HB3' ' O ' ' A' ' 13' ' ' ALA . 1.4 p90 -29.63 -54.27 0.15 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.852 0.358 . . . . 64.400000000000006 110.864 -179.893 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.449 ' N ' ' CG ' ' A' ' 17' ' ' PHE . 21.4 m -116.01 -14.48 11.22 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.171 -0.468 . . . . 51.219999999999999 111.144 -179.922 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.445 HD13 ' HA ' ' A' ' 19' ' ' LEU . 4.0 mm? -82.51 -14.54 54.81 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.225 -0.443 . . . . 53.439999999999998 110.953 179.94 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.825 HG23 ' HA3' ' A' ' 16' ' ' GLY . 14.1 t -75.79 -55.1 2.03 Favored Pre-proline 0 C--N 1.33 -0.251 0 CA-C-O 121.587 0.708 . . . . 60.130000000000003 111.118 179.838 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.585 ' HD2' ' N ' ' A' ' 20' ' ' VAL . 53.7 Cg_endo -69.79 -21.04 33.92 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.643 2.229 . . . . 61.43 112.336 179.978 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.443 ' O ' HG12 ' A' ' 22' ' ' VAL . 45.2 t -99.4 -11.74 8.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.223 -0.444 . . . . 52.219999999999999 111.137 179.917 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -57.91 -20.93 40.89 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.145 -0.48 . . . . 74.200000000000003 110.918 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 10.4 t70 -75.4 -6.38 49.71 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.15 -0.477 . . . . 74.430000000000007 110.861 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--N 1.329 -0.319 0 CA-C-N 116.181 -0.463 . . . . 75.25 110.884 -179.989 . . . . . . . . 1 1 . 1 stop_ save_